Multispecific antibodies having specificity for TNFα and il-17a, antibodies targeting il-17a, and methods of use thereof
Patent Information
- Application Number
- JP2024114926
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-01-31
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2040-01-31
AI Technical Summary
Current treatments for inflammatory and autoimmune diseases, such as rheumatoid arthritis, often fail to adequately respond to anti-TNFα therapy, and there is a need for improved therapeutic antibodies that can effectively neutralize both IL-17A and TNFα with enhanced affinity, efficacy, and safety profiles.
Development of multispecific antibodies that simultaneously inhibit IL-17A and TNFα, featuring improved properties such as higher affinity, selectivity, and stability, with optional binding to human serum albumin, to enhance therapeutic efficacy and safety.
The multispecific antibodies demonstrate potent neutralization of IL-17A and TNFα, offering improved clinical response rates and reduced immunogenicity, with enhanced biophysical properties for better developability and stability.
Abstract
Description
[Technical Field]
[0001] The present invention relates to an isolated multispecific antibody comprising a first domain that specifically binds to TNFα, a second domain that specifically binds to IL-17A, and optionally a third domain that specifically binds to human serum albumin. The present invention further relates to methods of using the antibody, pharmaceutical compositions comprising the antibody, methods of use thereof, and kits. The present invention also relates to nucleic acids comprising nucleotide sequences encoding the antibody, vectors comprising the nucleic acids, host cells comprising the nucleic acids or the vectors, and methods of producing the antibody.
[0002] The present invention further relates to an isolated antibody that specifically binds to human IL-17A, a multispecific molecule comprising said isolated antibody of the invention, pharmaceutical compositions, and methods of use thereof. The present invention further relates to kits comprising said antibodies, nucleic acids comprising a nucleotide sequence encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said nucleic acids or said vectors, and methods including methods of producing said antibodies. [Background technology]
[0003] TNFα is a homotrimeric pro-inflammatory cytokine released by and interacts with cells of the immune system. It is found as a soluble protein as well as a precursor called transmembrane TNFα, which is expressed as a type II polypeptide on the cell surface. Transmembrane TNFα is processed by metalloproteinases such as TNFα-converting enzyme (TACE) between residues Ala76 and Val77, releasing the 157-amino acid soluble form of TNFα. Soluble TNFα is a homotrimer of cleaved monomers of 17 kDa. Transmembrane TNFα also exists as a homotrimer of uncleaved monomers of 26 kDa. Both membrane and soluble TNFα are biologically active. TNFα can bind to two receptors, TNF receptor 1 (TNFR1) and 2 (TNFR2), with transmembrane TNFα acting primarily through TNFR2. TNFR1 is widely expressed in various cells, and its engagement triggers pro-inflammatory responses. TNFR2 expression is mostly restricted to immune cells, and its engagement promotes cell survival and proliferation (Bazzoni F, Beutler B, N Engl J Med (1996) 334(26):1717-25; Locksley RM, et al., Cell (2001) 104(4):487-501; Cabal-Hierro L, Lazo PS, Cell Signal (2012) 24(6):1297-305; Brenner D, et al., Nat Rev Immunol (2015) 15(6):362-74).
[0004] TNFα has been shown to be upregulated in many human diseases, including inflammatory and autoimmune diseases, including chronic conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and multiple sclerosis. Antibodies against TNFα have been proposed for the prevention and treatment of endotoxic shock (Beutler et al., Science, 234, 470-474, 1985). Bodmer et al. (Critical Care Medicine, 21, S441-S446, 1993) and Wherry et al. (Critical Care Medicine, 21, S436-S440, 1993) have discussed the therapeutic potential of anti-TNFα antibodies in the treatment of septic shock. The use of anti-TNFα antibodies in the treatment of septic shock has also been discussed by Kirschenbaum et al. (Critical Care Medicine, 26, 1625-1626, 1998). Collagen-induced arthritis can be effectively treated using anti-TNFα monoclonal antibodies (Williams et al. (Proc. Natl. Acad. Sci. USA 89, 9784-9788, 1992)). The use of anti-TNFα antibodies in the treatment of rheumatoid arthritis and Crohn's disease is discussed in Feldman et al. (Transplantation Proceedings, 30, 4126-4127, 1998), Adorini et al. (Trends in Immunology Today, 18, 209-211, 1997), and Feldman et al. (Advances in Immunology, 64, 283-350, 1997). Antibodies against TNFα previously used in such treatments are generally chimeric antibodies, such as those described in U.S. Patent No. 5,919,452.
[0005] Monoclonal antibodies against TNFα have been described in the prior art. Meager et al. (Hybridoma, 6, 305-311, 1987) describe a murine monoclonal antibody against recombinant TNFα. Fendly et al. (Hybridoma, 6, 359-370, 1987) describe the use of a murine monoclonal antibody against recombinant TNFα in defining neutralizing epitopes on TNFα. Furthermore, International Patent Application WO92 / 11383 discloses recombinant antibodies, including CDR-grafted antibodies specific for TNFα. Rankin et al. (British J. Rheumatology, 34, 334-342, 1995) describe the use of such CDR-grafted antibodies in the treatment of rheumatoid arthritis. U.S. Patent No. 5,919,452 discloses chimeric anti-TNFα antibodies and their use in treating conditions associated with the presence of TNFα. Further anti-TNFα antibodies are described in Stephens et al. (Immunology, 85, 668-674, 1995), GB-A-2 246570, GB-A-2 297145, U.S. Patent No. 8,673,310, U.S. Patent No. 2014 / 0193400, EP2390267B1, U.S. Patent No. 8,293,235, U.S. Patent No. 8,697,074, WO2009 / 155723A2, and WO2006 / 131013A2.
[0006] Currently approved anti-TNFα biologics include: (i) infliximab (Remicade®; Wiekowski M et al: “Infliximab (Remicade)”, Handbook of Therapeutic Antibodies, WILEY-VCH; Weinheim, 2007-01-01, pp. 885-904), a chimeric IgG anti-human monoclonal antibody; (ii) etanercept (Enbrel®), a TNFR2 dimeric fusion protein with IgG1 Fc; (iii) adalimumab (Humira®; Kupper H et al: “Adalimumab (Humira)”, Handbook of Therapeutic Antibodies, WILEY-VCH; Weinheim, 2007-01-01, pp. 697-732), a fully human monoclonal antibody (mAb); (iv) certolizumab (Cimzia®; Melmed GY et al: "Certolizumab pegol", Nature Reviews. Drug Discovery, Nature Publishing Group, GB, Vol. 7, No. 8, 2008-08-01, pp. 641-642; (v) golimumab (Simponi®; Mazumdar S et al: "Golimumab", mAbs, Landes Bioscience, US, Vol. 1, No. 5, 2009-09-01, pp. 422-431), a human IgG1K monoclonal antibody.
[0007] However, anti-TNFα treatment has been shown to have certain limitations. Not all patients achieve a sufficient clinical response or maintain a clinical response to anti-TNFα over the long term, necessitating switching to new therapies to control the disease. For example, in rheumatoid arthritis (RA) patients, approximately 40% of patients do not respond to anti-TNFα treatment, and only 20% of patients experience a significant reduction in disease activity. Therefore, there continues to be a significant unmet clinical need for treatments related to more effective suppression of the progression of disorders such as inflammatory and autoimmune disorders.
[0008] Activation of the complement biological pathway in patients after anti-TNFα treatment may possibly be one of the reasons why many patients do not respond or have only a partial response to anti-TNFα therapy.Recently emerging lines of evidence point to a role for IL-17A in the pathogenesis of inflammatory and autoimmune diseases, for example in rheumatoid arthritis.
[0009] The human and mouse interleukin-17 (IL-17) family consists of six cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25), and IL-17F, which play roles in acute and chronic inflammatory responses. The interleukin-17 receptor (IL-17R) family consists of five members: IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE.
[0010] Interleukin-17A (IL-17A or IL17A, synonymous with IL-17 or cytotoxic T-lymphocyte-associated antigen-8 (CTLA-8)) is a homodimeric proinflammatory cytokine. IL-17A is produced by memory CD4+ T cells (termed Th17), CD8+ T cells (Tc17), invariant NKT cells, gamma delta T cells, non-T, non-B lymphocytes (termed type 3 innate lymphocytes), and a subset of neutrophils. IL-17A and IL-17F form distinct subgroups within the IL-17 family. They share the greatest sequence homology and identity within the IL-17 family, although other members of the IL-17 family have significantly lower sequence identity to IL-17A (Starnes, T., et al., J Immunol. 167(8):4137-40 (2001); Aggarwal, S. and Gurney, AL, J. Leukoc Biol, 71(1): 1-8 (2002)). Both IL-17A and IL-17F signal through a heterodimeric receptor complex composed of IL-17RA and IL-17RC (Toy D., et al., J Immunol. 2006; Wright JF., et al., J Immunol. 2008; 181(4):2799-2805). IL-17A and IL-17F can form IL-17A / A or IL-17F / F disulfide-linked homodimers and IL-17A / F disulfide-linked heterodimers (Wright JF. et al., J Immunol. 2008; 181(4):2799-2805; Liang SC. et al., J Immunol. 2007; 179(11):7791-7799). IL-17A and IL-17F induce the expression of pro-inflammatory cytokines and antimicrobial peptides.
[0011] Human IL-17A (CTLA-8, Swiss Prot Q16552, also known as IL-17 or IL17; SEQ ID NO: 33) has been implicated in a variety of inflammatory conditions, such as autoimmune diseases, metabolic disorders, and cancer (Ouyang W., et al., Immunity. 2008; 28(4):454-467; Milner JD., Curr Opin Immunol. 2011; 23(6):784-788; Kuchroo VK., et al., Nat Med. 2012; 18(1):42-47; Ahmed M. and Gaffen SL., Cytokine Growth Factor Rev. 2010; 21(6):449-453; Trinchieri G., Annu Rev Immunol. 2012; 30:677-706; Gallimore AM, Godkin A., N Engl J Med. 2013; 368(3):282-284; Ye P., et al., J Exp Med. 2001; 194(4):519-527; Chung DR., et al., J Immunol. 2003; 170(4):1958-1963; Huang W., et al., J Infect Dis. 2004; 190(3):624-631; Ishigame H., et al., Immunity. 2009; 30(1):108-119; for review, see Gu C., et al., Cytokine. 2013 Nov 64(2)). IL-17A plays a role in the induction of other proinflammatory cytokines and chemokines, acute phase proteins, antimicrobial peptides, mucins, matrix metalloproteinases, and adhesion molecules for neutrophil recruitment. IL-17A also synergizes with other cytokines, including TNFα and IL-1β, to further induce chemokine expression (Chabaud M., et al., J. Immunol. 161(1):409-14 (1998)).
[0012] Pathological production of IL-17A causes excessive inflammation and tissue damage (for review, see Gu et al., Cytokine. 2013 November; 64(2)). High levels of IL-17A have been found in patients with multiple sclerosis (MS), psoriasis, asthma, Crohn's disease, and rheumatoid arthritis. Treatment of animals with IL-17A-neutralizing antibodies reduces the incidence and severity of autoimmune encephalomyelitis (Komiyama, Y. et al, J. Immunol. 177 (2006) 566-573). Furthermore, IL-17A neutralizing antibodies reduce the severity and incidence of collagen-induced arthritis in a murine rheumatoid arthritis model, and high levels of IL-17A can be detected in the synovial fluid of inflamed joints from patients with rheumatoid arthritis (Ziolkowska, M. et al, J. Immunol. 164 (2000) 2832-2838; Kotake, S. et al, J. Clin. Invest. 103 (1999) 1345-1352; Hellings PW et al, Am. J. Resp. Cell Mol. Biol. 28 (2003) 42-50).
[0013] A large body of experimental evidence in humans and animal models has supported the development of IL-17A-targeted therapies. Several anti-IL-17 antibodies have been developed, including AIN457 (secukinumab; see U.S. Patent No. 7,807,155 and WO2006 / 013107), LY2439821 (ixekizumab; see U.S. Patent Nos. 7,838,638 and 8,110,191, and WO2007 / 070750), SCH900117 (Merck), and RG4943 (Roche). Examples of anti-IL-17A antibodies are described in WO2006 / 013107, WO2006 / 054059, WO2007 / 070750, WO2007 / 149032, WO2008 / 001063, WO2008 / 021156, WO2010 / 034443, WO2010 / 102251, and WO2012 / 0187. 67, WO2014 / 161570, WO2014 / 001368, WO2014 / 122613, WO2015 / 070697, WO2015 / 137843, WO2016 / 048188, WO2016 / 113557, WO2016 / 138842, and WO2017 / 068472.
[0014] Several clinical trials using various molecules that block IL-17A signaling have been conducted or are currently underway. Biologics targeting IL-17A or its receptors and their efficacy are being evaluated in the setting of inflammatory or autoimmune diseases such as rheumatoid arthritis, ankylosing spondyloarthropathy, Crohn's disease, psoriasis, multiple sclerosis, and ozone-induced neutrophilia.
[0015] For example, secukinumab (U.S. Patent No. 7,807,155 and WO2006 / 013107), a fully human IgG1κ anti-IL-17A monoclonal antibody, is currently approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis (for review, see Wang et al., Eur J Rheumatol 2017 (4) 272-7). In phase III trials (FUTURE I and FUTURE II) evaluating the long-term efficacy and safety of secukinumab in subjects with psoriatic arthritis, secukinumab was significantly more effective than placebo in improving the signs and symptoms of psoriatic arthritis (Mease PJ. et al. N Engl J Med 2015; 373: 1329-39; McInnes IB. et al. The Lancet; 386:1137-46).
[0016] Ixekizumab, a humanized anti-IL-17A monoclonal antibody (U.S. Patent Nos. 7,838,638 and 8,110,191 and WO 2007 / 070750), was tested in a 24-week Phase III trial (SPIRIT-P1) in biologic-naive patients with active psoriatic arthritis (Mease PJ. Et al., Ann Rheum Dis. 2017 Jan;76(1):79-87). In biologic-naive patients with active psoriatic arthritis, ixekizumab treatment demonstrated improvements in disease activity and physical function, as well as inhibition of progression of structural damage. Ixekizumab has also been shown to be effective in treating patients with moderate to severe plaque psoriasis (Griffiths CEM, et al., The Lancet;386:541-51).
[0017] Brodalumab, a fully human IL-17 receptor (IL-17RA) monoclonal antibody (see U.S. Patent No. 7,767,206), has proven effective in treating psoriasis (Papp KA. et al. N Engl J Med 2012; 366: 1181-9). It also demonstrated significant and durable responses in patients with psoriatic arthritis in a placebo-controlled phase II trial (Mease PJ. et al., N Engl J Med 2014; 370: 2295-306). However, treatment with brodalumab has been associated with significant adverse events, including upper respiratory tract infections, fatigue, diarrhea, and reported suicidal thoughts and behaviors (for review, see Wang et al., Eur J Rheumatol 2017 (4) 272-7).
[0018] Therefore, IL-17A is a promising target for the treatment of inflammatory and autoimmune diseases. Although many anti-IL-17A antibodies have been identified to date, there remains a need for improved therapeutic antibodies that can effectively reduce or eliminate IL-17A activity in inflammatory responses and autoimmune diseases, while at the same time possessing an improved safety profile and being suitable for development. In addition to favorable affinity, efficacy, and immunogenicity, therapeutic antibodies should also possess improved biophysical properties, improved developability, high-yield productivity, and protein stability. A treatment that simultaneously blocks both the TNFα and IL-17A biological pathways could significantly improve response rates and address unmet needs in the treatment of disorders mediated by TNFα and IL-17A. Several biological therapeutics that specifically bind to IL-17 and TNFα have been proposed. WO 2010 / 102251 (Abbvie Inc.) discloses a bispecific tetravalent antibody that binds to both TNFα and IL-17. WO 2013 / 063110 (Abbvie Inc.) discloses a multivalent DVD-Ig binding protein capable of binding to TNF and IL-17. WO 2014 / 044758 (Covagen ACJ) discloses a fusion construct capable of inhibiting glycosylated IL-17A and binding to TNFα. WO 2014 / 137961 (Eli Lilly and Company) and WO 2017 / 132457 (Janssen Biotech) disclose anti-TNF and anti-IL-17A bispecific antibodies. WO 2017 / 102830 (UCB Biopharma) discloses a multispecific antibody capable of inhibiting TNFα, IL-17A, and IL-17F, specifically comprising a binding domain specific for human TNFα and a binding domain specific for human IL-17A and human IL-17F. Xu et al., Oncotarget, 8 (2017) 81860-81872 generated an IgG-like bispecific antibody (bsAb) in which the two arms of the IgG-like molecule are directed against TNFα and IL-17A, respectively.Interestingly, WO2015 / 014979 (Roche, see also Fischer et al., Arthritis & Rheumatology 67 (2015) 51-62) discloses bispecific tetravalent IL-17AxTNF antibody constructs that are either bivalent ("2+2" constructs) or monovalent ("2+2" constructs) for each of the two antigens. According to WO2015 / 014979, bivalent constructs are preferred over the monovalent alternatives. Summary of the Invention [Problem to be solved by the invention]
[0019] However, there remains a need for improved anti-inflammatory drugs that can effectively neutralize the activity of both IL-17A and TNFα for the treatment of disorders such as inflammatory and autoimmune diseases, e.g., rheumatoid arthritis, for which the majority of patients still do not adequately respond to treatment. There remains a need for the development of improved therapeutic antibodies that effectively neutralize the activity of both IL-17A and TNFα, have beneficial affinity and efficacy, and an improved safety profile, e.g., less immunogenicity. Furthermore, therapeutic antibodies should have improved biophysical properties that lead to better developability, high-yield productivity, and excellent antibody stability. [Means for solving the problem]
[0020] It is an object of the present invention to provide agents for improved treatment of inflammatory and autoimmune disorders.
[0021] The antibodies of the present invention provide new treatment options for patients with unmet medical needs. The present invention provides novel multispecific antibodies, which are capable of simultaneously inhibiting IL-17A and TNFα, and which have further improved properties beneficial for therapeutic use, such as higher affinity, improved efficacy, selectivity, safety, e.g., low immunogenicity, and improved biophysical properties, e.g., developability and stability.
[0022] In one aspect, the present disclosure relates to an isolated multispecific antibody comprising a first domain that specifically binds IL-17A, a second domain that specifically binds TNFα, and optionally a third domain that specifically binds human serum albumin.
[0023] In one aspect, the present disclosure relates to a pharmaceutical composition comprising a multispecific antibody of the invention and a pharmaceutically acceptable carrier.
[0024] In a further aspect, the present disclosure provides a multispecific antibody of the invention or a pharmaceutical composition of the invention for use as a medicament.
[0025] In a further aspect, the present disclosure provides a multispecific antibody of the invention or a pharmaceutical composition of the invention for use in the treatment of a disorder mediated by IL-17A and / or TNFα or a disorder that can be treated by inhibiting Gro-α secretion, in particular in the treatment of an inflammatory condition or an autoimmune disease.
[0026] In one aspect, the present disclosure provides the use of a multispecific antibody of the invention or a pharmaceutical composition of the invention for use in the treatment of a disorder mediated by IL-17A and / or TNFα or a disorder that can be treated by inhibiting Gro-α secretion, in particular for the treatment of an inflammatory condition or an autoimmune disease.
[0027] In one aspect, the present disclosure provides the use of a multispecific antibody of the invention or a pharmaceutical composition of the invention in the manufacture of a medicament for the treatment of a disorder mediated by IL-17A and / or TNFα or a disorder that can be treated by inhibiting Gro-α secretion, in particular for the treatment of an inflammatory condition or an autoimmune disease.
[0028] In yet another aspect, the present disclosure provides a method for treating a disorder mediated by IL-17A and / or TNFα, said method comprising administering to a subject in need thereof an effective amount of a multispecific antibody of the invention or a pharmaceutical composition of the invention.
[0029] In one aspect, the present disclosure provides a kit comprising a multispecific antibody of the invention or a pharmaceutical composition of the invention.
[0030] In a further aspect, the disclosure provides a nucleic acid comprising a nucleotide sequence encoding a multispecific antibody of the invention. In a further aspect, the disclosure provides a vector comprising said nucleic acid. In a further aspect, the disclosure provides a host cell comprising said nucleic acid or said vector.
[0031] In yet another aspect, the present disclosure provides a method for producing a multispecific antibody of the invention or a binding domain thereof or a fragment thereof, said method comprising the step of culturing a host cell comprising a nucleic acid or vector encoding a multispecific antibody of the invention or a binding domain thereof or a fragment thereof.
[0032] The aspects, advantageous features, and preferred embodiments of the present disclosure summarized in the following items, each alone or in combination, further contribute to solving the object of the present invention:
[0033] 1. An isolated multispecific antibody comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα.
[0034] 2. The multispecific antibody according to item 1, wherein the antibody comprises only one domain that specifically binds to IL-17A and / or only one domain that specifically binds to TNFα.
[0035] 3. The multispecific antibody of item 1 or 2, wherein the antibody is capable of neutralizing the biological activity of human TNFα and human IL-17A.
[0036] 4. The multispecific antibody of any one of the preceding items, wherein the antibody selectively binds to human IL-17A over human IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F as measured by ELISA.
[0037] 5. The multispecific antibody according to any one of the preceding items, further comprising a third domain having specificity for an antigen other than IL-17A or TNFα.
[0038] 6. The multispecific antibody according to item 5, wherein the antibody comprises a third domain that specifically binds to human serum albumin (HSA), preferably wherein the antibody comprises only one domain that specifically binds to human serum albumin.
[0039] 7. A multispecific antibody according to any one of the preceding items, wherein the domains are capable of simultaneously binding to their respective antigens or receptors.
[0040] 8. The multispecific antibody according to any one of the preceding paragraphs, wherein the first domain and the second domain, and optionally the third domain, are independently selected from the group consisting of Fab, Fv, scFv, dsFv, scAb, STAB, single domain antibodies (sdAb or dAb), single domain heavy chain antibodies, and single domain light chain antibodies, VHH, VNAR, single domain antibodies based on shark VNAR structures, and binding domains based on alternative scaffolds, including but not limited to ankyrin-based domains, finomers, avimers, anticalins, fibronectin, and binding sites engineered into antibody constant regions (e.g. F-star's Modular Antibody Technology™), preferably selected from the group consisting of Fab, Fv, and scFv, more preferably wherein the first domain and / or the second domain and / or the third domain is an Fv or scFv.
[0041] 9. The multispecific antibody according to any one of the preceding items, wherein the multispecific antibody is selected from the group consisting of a single-chain diabody (scDb), a tandem scDb (Tandab), a linear dimeric scDb (LD-scDb), a cyclic dimeric scDb (CD-scDb), a bispecific T cell engager (BiTE; tandem di-scFv), a tandem tri-scFv, a tribody (Fab-(scFv)2) or a bibody (Fab-(scFv)1), a Fab, a Fab-Fv2, a Morrison (IgG CH3-scFv fusion (Morrison L) or an IgG CL-scFv fusions (Morrison H)), triabodies, scDb-scFv, bispecific Fab2, diminibody, tetrabody, scFv-Fc-scFv fusions, scFv-HSA-scFv fusions, didiabodies, DVD-Ig, COVD, IgG-scFab, scFab-dsscFv, Fv2-Fc, IgG-scFv fusions, e.g., bsAb (scFv linked to the C-terminus of the light chain), Bs1Ab (scFv linked to the N-terminus of the light chain), Bs2Ab (scFv linked to the N-terminus of the heavy chain), Bs3Ab (scFv linked to the C-terminus of the heavy chain), Ts1Ab (scFv linked to the N-terminus of both the heavy and light chains), scFv), Ts2Ab (dsscFv linked to the C-terminus of the heavy chain), bispecific antibodies based on heterodimeric Fc domains, such as Knob-into-Hole antibodies (KiH); Fv, scFv, scDb, tandem-di-scFv, tandem tri-scFv, Fab-(scFv)2, Fab-(scFv)1, Fab, Fab-Fv2, COVD, MATCH and duobodies, preferably tribodies or scDb-scFv, fused to the N-terminus and / or C-terminus of either chain of a heterodimeric Fc domain or any other heterodimerization domain.
[0042] 10. The multispecific antibody of any one of the preceding items, wherein the antibody does not comprise an immunoglobulin Fc region polypeptide, and optionally does not comprise a CH1 and / or CL region.
[0043] 11. The multispecific antibody of any one of the preceding items, wherein the antibody is a tribody.
[0044] 12. The multispecific antibody of item 11, wherein the first domain, the second domain, and the third domain are independently selected from the group consisting of Fab and scFv, and preferably the second domain is Fab and the first and third domains are scFv.
[0045] 13. The multispecific antibody of item 9, wherein the antibody is an scDb-scFv, preferably wherein the scFv portion is fused C-terminally to an scDb, more preferably wherein the first domain and the second domain form an scDb and the third domain is an scFv.
[0046] 14. The multispecific antibody according to item 13, wherein the antibody has the formula: VLA-L1-VHC-L2-VLC-L3-VHA-L4-VLB-L5-VHB, or VLB-L1-VHA-L2-VLA-L3-VHB-L4-VLC-L5-VHC or is VLC-L1-VHB-L2-VLB-L3-VHC-L4-VLA-L5-VHA or VLA-L1-VHB-L2-VLB-L3-VHA-L4-VLC-L5-VHC, Preferably, VLB-L1-VHA-L2-VLA-L3-VHB-L4-VLC-L5-VHC, or VLA-L1-VHB-L2-VLB-L3-VHA-L4-VLC-L5-VHC, More preferably, it is represented by VLB-L1-VHA-L2-VLA-L3-VHB-L4-VLC-L5-VHC, wherein VLA and VHA are the light chain variable region and heavy chain variable region of the first domain, respectively; VLB and VHB are the light chain variable region and heavy chain variable region of the second domain, respectively; VLC and VHC are the light chain variable region and heavy chain variable region of the third domain, respectively; and wherein L1, L2, L3, L4, and L5 are polypeptide linkers.
[0047] 15. The multispecific antibody described in item 14, wherein L1 and L3 are as set forth in SEQ ID NO: 132.
[0048] 16. The multispecific antibody according to any one of items 14 to 15, wherein L2, L4, and L5 are set forth in SEQ ID NO: 23.
[0049] 17. The multispecific antibody of any one of the preceding items, wherein the antibody has the following properties:
[0050] (a) has the ability to neutralize IL-17A with a potency (relative potency) of greater than 2, e.g., greater than 5, greater than 10, greater than 15, greater than 20, greater than 25, greater than 30, greater than 35, greater than 40, greater than 45, preferably greater than 50, relative to the potency of secukinumab as determined by measuring Gro-α secretion in an HT-29 assay, wherein said relative potency is the IC of secukinumab as measured by the HT-29 assay. 50 values (ng / mL) and IC of the multispecific antibodies measured by HT-29 assay 50 the ratio of the α-glutamic acid concentration (ng / mL) to the α-glutamic acid concentration (ng
[0051] (b) have the ability to neutralize TNFα with a potency (relative potency) of at least 1, e.g., greater than 1, greater than 1.5, greater than 2, greater than 2.5, greater than 3, greater than 3.5, preferably greater than 4, more preferably greater than 4.5, compared to the potency of the scDb of SEQ ID NO: 149 (A13) as determined by measuring Gro-α secretion in an HT-29 assay, wherein said relative potency is the IC of said scDb of SEQ ID NO: 149 (A13) as measured by an HT-29 assay. 50 values (nM) and IC of said multispecific antibodies measured by HT-29 assay 50 is the ratio of the value (nM) to the
[0052] (c) optionally, having the ability to block the interaction of IL-17A and IL-17RA with a potency (relative potency) of greater than 2, e.g., greater than 3, greater than 4, greater than 5, greater than 6, greater than 7, greater than 8, greater than 9, preferably greater than 10, compared to the potency of secukinumab as determined by ELISA assay, wherein said relative potency is the IC of secukinumab measured by ELISA. 50 values (ng / mL) and IC of the multispecific antibodies measured by ELISA 50 the ratio of the α-glutamic acid concentration (ng / mL) to the α-glutamic acid concentration (ng
[0053] (d) optionally, having the ability to neutralize TNFα with a potency (relative potency) of at least 0.4, such as at least 0.5, preferably at least 1, compared to the potency of the scDb of SEQ ID NO: 149 (A13) as determined in the L929 assay, wherein said relative potency is the IC of said scDb of SEQ ID NO: 149 as measured by the L929 assay. 50 values (nM) and IC of said multispecific antibodies measured by L929 assay 50 and / or
[0054] (e) a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, preferably less than 0.5 nM, as measured by surface plasmon resonance D ) and binds to human IL-17A, and optionally has a K of less than 5 nM, e.g., less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, preferably less than 0.5 nM, as measured by surface plasmon resonance. D and binds to cynomolgus monkey IL-17A; and
[0055] (f) a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, preferably less than 0.5 nM, more preferably less than 25 nM, as measured by surface plasmon resonance D ) and binds to human TNFα; and
[0056] (g) optionally, a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, preferably less than 2 nM, as measured by surface plasmon resonance; D ) binds to human serum albumin with a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, preferably less than 2 nM, as measured by surface plasmon resonance. D ) and binds to cynomolgus monkey serum albumin.
[0057] 18. The multispecific antibody of any one of the preceding items, wherein the antibody has the following properties: (a) a melting temperature (Tm) in phosphate-citrate buffer, pH 6.4, 150 mM NaCl, as determined by differential scanning fluorimetry, of at least 55°C, preferably at least 58°C, and more preferably at least 60°C; (b) the multispecific antibody has a loss of monomer content of less than 5%, e.g., less than 4%, less than 3%, less than 2%, preferably 1% or less, after five consecutive freeze-thaw cycles when at a starting concentration of 10 mg / ml in phosphate-buffered saline (PBS), pH 7.4; (c) the multispecific antibody has a loss of less than 10%, preferably less than 5%, of monomer content after storage at 4°C for at least 2 weeks, particularly at least 4 weeks, when the multispecific antibody is at a starting concentration of 10 mg / ml in phosphate-buffered saline (PBS), pH 7.4; and / or (d) the multispecific antibody has a loss of less than 20%, preferably less than 15%, of monomer content after storage at 37°C for at least 2 weeks, particularly at least 4 weeks, when the multispecific antibody is at a starting concentration of 10 mg / ml in phosphate buffered saline (PBS), pH 7.4.
[0058] 19. The multispecific antibody according to any one of the preceding items, wherein each domain comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: (a) the VH comprises three complementarity determining regions HCDR1, HCDR2, and HCDR3, in that order; and (b) the multispecific antibody, wherein the VL comprises three complementarity determining regions LCDR1, LCDR2, and LCDR3, in that order.
[0059] 20. The multispecific antibody according to any one of the preceding items, wherein the first domain that specifically binds to IL-17A comprises a set of CDRs (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3), and the set of CDRs has no more than 10 amino acid substitutions from a set of CDRs ((i) HCDR1' is set forth in SEQ ID NO: 1; HCDR2' is set forth in SEQ ID NO: 2; HCDR3' is set forth in SEQ ID NO: 3; LCDR1' is set forth in SEQ ID NO: 12; LCDR2' is set forth in SEQ ID NO: 13; LCDR3' is set forth in SEQ ID NO: 14, or (ii) HCDR1' is set forth in SEQ ID NO: 39; HCDR2' is set forth in SEQ ID NO: 40; HCDR3' is set forth in SEQ ID NO: 41; LCDR1' is set forth in SEQ ID NO: 50; LCDR2' is set forth in SEQ ID NO: 51; LCDR3' is set forth in SEQ ID NO: 52).
[0060] 21. The multispecific antibody according to item 20, (i) (a) the HCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 1, 4, and 7; (b) the HCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 2, 5, and 8; (c) the HCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 3, 6, and 9; (d) the LCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 12, 15, and 18; (e) the LCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 13, 16, and 19; and (f) the LCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 14, 17, and 20; or (ii) (a) the HCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45; (b) the HCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46; (c) the HCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 41, 44, and 47; (d) the LCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 50, 53, and 56; (e) the LCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 51, 54, and 57; and (f) The multispecific antibody, wherein the LCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58.
[0061] 22. The multispecific antibody of item 21, comprising (i) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively, or (ii)(i) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively.
[0062] 23. The multispecific antibody according to any one of the preceding items, wherein the first domain that specifically binds to IL-17A comprises a heavy chain variable region VHA, wherein the VHA is VH3 or VH4, preferably VH3.
[0063] 24. The multispecific antibody according to any one of the preceding items, wherein the first domain that specifically binds to IL-17A comprises a light chain variable region VLA, wherein the VLA comprises Vκ frameworks FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 FR1-FR3, and a framework FR4, wherein the framework FR4 is a Vκ FR4, particularly a Vκ1 FR4, a Vκ3 FR4, and a Vλ FR4, particularly a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 selected from any of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 set forth in SEQ ID NO: 26 or 27, more preferably a Vλ FR4 set forth in SEQ ID NO: 27.
[0064] 25. The multispecific antibody according to any one of items 23 to 24, wherein the VHA is (i) comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 10, and / or said VLA comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 21, or (ii) the multispecific antibody, wherein said VLA comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 48, and / or said VLA comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 59.
[0065] 26. The multispecific antibody according to item 25, wherein the VHA is (i) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 11, and / or said VLA comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 21 and 22, or (ii) the multispecific antibody, wherein said VLA comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 48 and 49, and / or said VLA comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 59 and 60.
[0066] 27. The multispecific antibody of item 26, comprising (i) the VHA sequence of SEQ ID NO: 10 and / or the VLA sequence of SEQ ID NO: 21, or (ii) the VHA sequence of SEQ ID NO: 48 and / or the VLA sequence of SEQ ID NO: 59.
[0067] 28. The multispecific antibody according to any one of the preceding items, wherein the second domain specifically binding to TNFα comprises a set of CDRs (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3), wherein the set of CDRs has no more than 10 amino acid substitutions from a set of CDRs (wherein HCDR1' is set forth in SEQ ID NO: 63; HCDR2' is set forth in SEQ ID NO: 64; HCDR3' is set forth in SEQ ID NO: 65; LCDR1' is set forth in SEQ ID NO: 76; LCDR2' is set forth in SEQ ID NO: 77; and LCDR3' is set forth in SEQ ID NO: 78).
[0068] 29. (a) the HCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 63, 66, and 69; (b) the HCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 64, 67, and 70; (c) the HCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 65, 68, and 71; (d) the LCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 76, 79, and 82; (e) the LCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 77, 80, and 83; and (f) The multispecific antibody of item 28, wherein the LCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 78, 81, and 84.
[0069] 30. The multispecific antibody of item 29, comprising HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 63, 64, and 65, respectively, and LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 76, 77, and 78, respectively.
[0070] 31. The multispecific antibody according to any one of the preceding items, wherein the second domain that specifically binds to TNFα comprises a heavy chain variable region VHB, wherein the VHB is VH3 or VH4, preferably VH3.
[0071] 32. The multispecific antibody according to any one of the preceding items, wherein the second domain that specifically binds to TNFα comprises a light chain variable region VLB, and the VLB comprises Vκ frameworks FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 FR1-FR3, and a framework FR4, wherein the framework FR4 comprises a Vκ FR4, particularly a Vκ1 FR4, a Vκ3 FR4, and a Vλ FR4, particularly a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 set forth in any of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 set forth in SEQ ID NO: 26 or 27, more preferably a Vλ FR4 set forth in SEQ ID NO: 27.
[0072] 33. The multispecific antibody according to any one of items 31 to 32, wherein the VHB comprises an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 73, 74, and 75, preferably at least 90% identical to SEQ ID NO: 72; and / or the VLB comprises an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 85, 86, 87, 88, and 89, preferably at least 90% identical to SEQ ID NO: 85.
[0073] 34. The multispecific antibody described in item 33, wherein the VHB comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 73, 74, and 75, and / or the VLB comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 85, 86, 87, 88, and 89.
[0074] 35. (i) the VHB sequence of SEQ ID NO: 72 and / or the VLB sequence of SEQ ID NO: 85; or (ii) the VHB sequence of SEQ ID NO: 75 and / or the VLB sequence of SEQ ID NO: 88; or (iii) The multispecific antibody of item 34, comprising a VHB sequence of SEQ ID NO: 75 and / or a VLB sequence of SEQ ID NO: 89.
[0075] 36. The multispecific antibody according to any one of items 6 to 35, wherein the third domain that specifically binds to HSA comprises a set of CDRs (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3), wherein the set of CDRs is a set of CDRs [wherein: (a) HCDR1' is set forth in SEQ ID NO:90; HCDR2' is set forth in SEQ ID NO:91; HCDR3' is set forth in SEQ ID NO:92; LCDR1' is set forth in SEQ ID NO:100; LCDR2' is set forth in SEQ ID NO:101; and LCDR3' is set forth in SEQ ID NO:102; or (b) HCDR1' is set forth in SEQ ID NO: 111; HCDR2' is set forth in SEQ ID NO: 112; HCDR3' is set forth in SEQ ID NO: 113; LCDR1' is set forth in SEQ ID NO: 120; LCDR2' is set forth in SEQ ID NO: 121; and LCDR3' is set forth in SEQ ID NO: 122.
[0076] 37. The multispecific antibody according to item 36, (a) the HCDR1 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 90, 93, and 96; the HCDR2 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 91, 94, and 97; the HCDR3 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 92, 95, and 98; the LCDR1 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 100, 103, and 106; the LCDR2 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 101, 104, and 107; and the LCDR3 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 102, 105, and 108; or (b) the multispecific antibody, wherein the HCDR1 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 111, 114, and 117; the HCDR2 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 112, 115, and 118; the HCDR3 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 113, 116, and 119; the LCDR1 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 121, 124, and 127; the LCDR2 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 122, 125, and 128; and the LCDR3 is set forth in the amino acid sequence selected from any one of SEQ ID NOs: 123, 126, and 129.
[0077] 38. The multispecific antibody according to item 37, comprising: (a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 90, 91, and 92, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 100, 101, and 102, respectively; or (b) The HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 111, 112, and 113, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 121, 122, and 123, respectively.
[0078] 39. The multispecific antibody according to any one of items 6 to 38, wherein the third domain that specifically binds to HSA comprises a heavy chain variable region VHC, and the VHC is VH3 or VH4, preferably VH3.
[0079] 40. The multispecific antibody according to any one of Items 6 to 39, wherein the third domain that specifically binds to HSA comprises a light chain variable region VLC, wherein the VLC comprises Vκ framework FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 FR1-FR3, and a framework FR4, wherein the framework FR4 comprises a Vκ FR4, particularly a Vκ1 FR4, a Vκ3 FR4, and a Vλ FR4, particularly a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 of SEQ ID NO: 26 or 27, more preferably a Vλ FR4 of SEQ ID NO: 27.
[0080] 41. The multispecific antibody according to any one of items 39 to 40, wherein the VHC comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 99; and / or the VLC comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 109.
[0081] 42. The multispecific antibody of item 41, comprising a VHC sequence of SEQ ID NO: 99 and / or a VLC sequence of SEQ ID NO: 109.
[0082] 43. The multispecific antibody according to any one of items 39 to 40, wherein the VHC comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 110; and / or the VLC comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 120.
[0083] 44. The multispecific antibody of item 43, comprising the VHC sequence of SEQ ID NO: 110 and / or the VLC sequence of SEQ ID NO: 120.
[0084] 45. The multispecific antibody of any one of the preceding items, wherein the antibody is humanized.
[0085] 46. The multispecific antibody according to any one of the preceding items, wherein the antibody comprises an amino acid sequence having at least 80% identity, preferably at least 90% identity, to a sequence selected from any of SEQ ID NOs: 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, and 148, preferably 143, and the CDRs have the sequences of items 22, 30, and 38(a).
[0086] 47. The multispecific antibody of any one of the preceding items, wherein the antibody comprises an amino acid sequence selected from any of SEQ ID NOs: 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, and 148, preferably 143.
[0087] 48. A pharmaceutical composition comprising a multispecific antibody according to any one of the preceding items and a pharmaceutically acceptable carrier.
[0088] 49. The multispecific antibody according to any one of items 1 to 47, or the pharmaceutical composition according to item 48, for use as a medicament.
[0089] 50. The multispecific antibody according to any one of items 1 to 47 or the pharmaceutical composition according to item 48 for use in the treatment of a disorder mediated by L-17A and / or TNFα or a disorder that can be treated by inhibiting Gro-α secretion.
[0090] 51. A multispecific antibody according to any one of items 1 to 47 or a pharmaceutical composition according to item 48 for use in treating an inflammatory condition or an autoimmune disease.
[0091] 52. A multispecific antibody according to any one of items 1 to 47, or a pharmaceutical composition according to item 48, for use in treating the following diseases: cancer, arthritis, rheumatoid arthritis, osteoarthritis of the elbow, reactive arthritis, psoriasis, chronic obstructive pulmonary disease, systemic lupus erythematosus (SLE), lupus nephritis, autoimmune inflammatory bowel disease, asthma, multiple sclerosis, cystic fibrosis, bone loss, airway hyperresponsiveness, demyelinating disorders, skin hyperresponsiveness, acute transplant rejection, allograft rejection, graft-versus-host disease, systemic sclerosis, urinary tract inflammatory diseases, cardiovascular diseases, vasculitis, periodic fever, glucose metabolism disorders, lung diseases, periodontitis, hepatic interstitial keratitis, allergies, inflammatory pain, spondyloarthropathy, sepsis, septic or endotoxic shock, meningitis, surgical trauma, autoimmune blood diseases, Alzheimer's disease, sarcoidosis, liver cirrhosis, hepatitis, glomerulonephritis, or dyslipidemia.
[0092] 53. Use of a multispecific antibody according to any one of items 1 to 47 or a pharmaceutical composition according to item 48 in the manufacture of a medicament for use in the treatment of a disorder mediated by L-17A and / or TNFα or a disorder that can be treated by inhibiting Gro-α secretion.
[0093] 54. Use of a multispecific antibody according to any one of items 1 to 47 or a pharmaceutical composition according to item 48 in the manufacture of a medicament for use in the treatment of an inflammatory condition or an autoimmune disease.
[0094] 55. Use of a multispecific antibody according to any one of items 1 to 47 or a pharmaceutical composition according to item 48 in the manufacture of a medicament for use in the treatment of the following diseases: cancer, arthritis, rheumatoid arthritis, osteoarthritis of the elbow, reactive arthritis, psoriasis, chronic obstructive pulmonary disease, systemic lupus erythematosus (SLE), lupus nephritis, autoimmune inflammatory bowel disease, asthma, multiple sclerosis, cystic fibrosis, bone loss, airway hyperresponsiveness, demyelinating disorders, and skin hyperresponsiveness. , acute transplant rejection, allograft rejection, graft-versus-host disease, systemic sclerosis, urinary inflammatory disease, cardiovascular disease, vasculitis, periodic fever, glucose metabolism disorders, pulmonary disease, periodontitis, hepatic interstitial keratitis, allergy, inflammatory pain, spondyloarthropathy, sepsis, septic or endotoxic shock, meningitis, surgical trauma, autoimmune blood disorders, Alzheimer's disease, sarcoidosis, liver cirrhosis, hepatitis, glomerulonephritis, or dyslipidemia.
[0095] 56. A method for treating a disorder mediated by IL-17A and / or TNFα, comprising administering an effective amount of a multispecific antibody according to any one of items 1 to 47 or a pharmaceutical composition according to item 48, such that the condition is alleviated.
[0096] 57. The method of item 56, wherein the disorder mediated by IL-17A and / or TNFα is an inflammatory condition or an autoimmune disease.
[0097] 58. The method of item 56, wherein the disorder mediated by IL-17A and / or TNFα is cancer, arthritis, rheumatoid arthritis, osteoarthritis of the elbow, reactive arthritis, psoriasis, chronic obstructive pulmonary disease, systemic lupus erythematosus (SLE), lupus nephritis, autoimmune inflammatory bowel disease, asthma, multiple sclerosis, cystic fibrosis, bone loss, airway hyperresponsiveness, demyelinating disorders, skin hyperresponsiveness, acute transplant rejection, allograft rejection, graft-versus-host disease, systemic sclerosis, urinary inflammatory disease, cardiovascular disease, vasculitis, periodic fever, glucose metabolism disorders, lung disease, periodontitis, hepatic interstitial keratitis, allergy, inflammatory pain, spondyloarthropathy, sepsis, septic or endotoxic shock, meningitis, surgical trauma, autoimmune blood disease, Alzheimer's disease, sarcoidosis, liver cirrhosis, hepatitis, glomerulonephritis, or dyslipidemia.
[0098] 59. A nucleic acid encoding the multispecific antibody or fragment thereof according to any one of items 1 to 47.
[0099] 60. A vector comprising the nucleic acid described in item 59.
[0100] 61. A host cell comprising the nucleic acid according to item 59 or the vector according to item 60.
[0101] 62. A method for producing the multispecific antibody according to any one of items 1 to 47, comprising the step of culturing a host cell containing a nucleic acid or vector encoding the multispecific antibody or fragment thereof according to any one of items 1 to 47.
[0102] 63. A kit comprising the multispecific antibody according to any one of items 1 to 47 or the pharmaceutical composition according to item 48.
[0103] Another object of the present invention is to provide anti-IL-17A antibodies with improved affinity, potency, and improved biophysical properties, such as improved solubility, developability, and stability.
[0104] The anti-IL-17A antibodies of the present invention have improved properties beneficial for therapeutic use, such as higher affinity, improved potency, selectivity, improved biophysical properties such as solubility, developability, and stability.
[0105] Thus, in one aspect, the present disclosure provides an isolated antibody having binding specificity for human IL-17A, in particular, which comprises a set of CDRs (HCDR1, HCDR2, HCDR3, LDCR1, LDCR2, and LDCR3), wherein the set of CDRs has 10 or fewer, preferably zero, amino acid substitutions from a set of CDRs (wherein HCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 1, 4, and 7; HCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 2, 5, and 8; HCDR3' is an amino acid sequence selected from any one of SEQ ID NOs: 3, 6, and 9; LCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 12, 15, and 18; LCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 13, 16, and 19; and LCDR3' has an amino acid sequence selected from any one of SEQ ID NOs: 14, 17, and 20). In one aspect, the present disclosure relates to a multispecific molecule comprising an isolated antibody of the present disclosure.
[0106] In another aspect, the present disclosure provides an isolated antibody having binding specificity for human IL-17A, in particular, which comprises a set of CDRs (HCDR1, HCDR2, HCDR3, LDCR1, LDCR2, and LDCR3), wherein the set of CDRs has 10 or fewer, preferably zero, amino acid substitutions from a set of CDRs (wherein HCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45; HCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46; HCDR3' is an amino acid sequence selected from any one of SEQ ID NOs: 41, 44, and 47; LCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 50, 53, and 56; LCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 51, 54, and 57; and LCDR3' has an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58). In one aspect, the present disclosure relates to a multispecific molecule comprising an isolated antibody of the present disclosure.
[0107] In one aspect, the present disclosure relates to a pharmaceutical composition comprising an isolated antibody of the disclosure, or a multispecific molecule comprising an isolated antibody of the disclosure, and a pharmaceutically acceptable carrier.
[0108] In another aspect, the present disclosure relates to an antibody of the present disclosure, or a multispecific molecule comprising said isolated antibody, or a pharmaceutical composition of the present disclosure, for use as a medicament.
[0109] In one aspect, the disclosure relates to an antibody of the disclosure, or a multispecific molecule comprising said isolated antibody, or a pharmaceutical composition for use in treating a disorder mediated by IL-17A or a disorder that can be treated by inhibiting GRO-α secretion.
[0110] In one aspect, the disclosure relates to the use of an antibody of the disclosure, or a multispecific molecule comprising said isolated antibody, or a pharmaceutical composition of the disclosure in the manufacture of a medicament for use in the treatment of a disorder mediated by IL-17A or a disorder that can be treated by inhibiting GRO-α secretion.
[0111] In another aspect, the present disclosure relates to a method of treating an IL-17A-mediated disorder, the method comprising administering to a subject in need thereof an effective amount of an antibody of the present disclosure, or a multispecific molecule of the present disclosure, or a pharmaceutical composition of the present disclosure. In yet another aspect, the present disclosure relates to a nucleic acid encoding an antibody of the present disclosure. In a further aspect, the present disclosure relates to a vector comprising the nucleic acid. In a further aspect, the present disclosure relates to a host cell comprising the nucleic acid or the vector.
[0112] In another aspect, the present disclosure relates to a method of producing an antibody of the present disclosure, the method comprising culturing a host cell containing a nucleic acid or vector encoding an antibody of the present disclosure.
[0113] Each alone or in combination, the aspects, advantageous features, and preferred embodiments of the present disclosure summarized in the following items further contribute to solving the objects of the present invention.
[0114] 1. An antibody having binding specificity to human IL-17A, comprising a set of CDRs (HCDR1, HCDR2, HCDR3, LDCR1, LDCR2, and LDCR3), wherein the set of CDRs is a set of CDRs [wherein: (i) HCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 1, 4, and 7; HCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 2, 5, and 8; HCDR3' is an amino acid sequence selected from any one of SEQ ID NOs: 3, 6, and 9; LCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 12, 15, and 18; LCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 13, 16, and 19; LCDR3' has an amino acid sequence selected from any one of SEQ ID NOs: 14, 17, and 20; or (ii) HCDR1′ is an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45; HCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46; HCDR3' is an amino acid sequence selected from any one of SEQ ID NOs: 41, 44, and 47; LCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 50, 53, and 56; LCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 51, 54, and 57; LCDR3' has an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58], wherein the antibody has 10 or fewer amino acid substitutions from the sequence shown.
[0115] 2. The antibody of item 1, comprising a set of CDRs (HCDR1, HCDR2, HCDR3, LDCR1, LDCR2, and LDCR3), wherein the set of CDRs is a set of CDRs [wherein: (i) HCDR1′ is set forth in SEQ ID NO: 1; HCDR2' is set forth in SEQ ID NO:2, HCDR3' is set forth in SEQ ID NO:3, LCDR1' is set forth in SEQ ID NO: 12; LCDR2' is set forth in SEQ ID NO: 13; LCDR3' is set forth in SEQ ID NO: 14; or (ii) HCDR1′ is set forth in SEQ ID NO: 39; HCDR2' is set forth in SEQ ID NO: 40, HCDR3' is set forth in SEQ ID NO: 41, LCDR1' is set forth in SEQ ID NO: 50; LCDR2' is set forth in SEQ ID NO: 51; The antibody described above, wherein LCDR3' is set forth in SEQ ID NO: 52], has 10 or fewer amino acid substitutions from the sequence indicated above.
[0116] 3. The antibody of item 1 or 2, comprising a heavy chain variable region (VH) and a light chain variable region (VL), (c) the VH comprises three complementarity determining regions HCDR1, HCDR2, and HCDR3, in order; and (d) The above antibody, wherein the VL comprises three complementarity determining regions LCDR1, LCDR2, and LCDR3, in that order.
[0117] 4. (i) (g) the HCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 1, 4, and 7; (h) the HCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 2, 5, and 8; (i) the HCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 3, 6, and 9; (j) the LCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 12, 15, and 18; (k) the LCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 13, 16, and 19; and (l) the LCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 14, 17, and 20; or (ii) (a) the HCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45; (b) the HCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46; (c) the HCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 41, 44, and 47; (d) the LCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 50, 53, and 56; (e) the LCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 51, 54, and 57; and (f) The antibody of item 3, wherein the LCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58.
[0118] 5. The antibody of item 4, comprising: (i) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively; or (ii) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively.
[0119] 6. The antibody of any one of items 3 to 5, wherein the VH is VH3 or VH4, preferably VH3.
[0120] 7. The antibody of any one of Items 3 to 6, wherein the VL comprises Vκ framework FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1 to FR3, preferably Vκ1 FR1 to FR3, and framework FR4, wherein the framework FR4 comprises a Vκ FR4, particularly a Vκ1 FR4, a Vκ3 FR4, and a Vλ FR4, particularly a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 set forth in any of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 set forth in SEQ ID NO: 26 or 27, more preferably a Vλ FR4 set forth in SEQ ID NO: 27.
[0121] 8. The antibody of any one of items 3 to 7, wherein (i) the VH comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 10, and / or the VL comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 21; or (ii) the VH comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 48, and / or the VL comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 59.
[0122] 9. The antibody of item 8, wherein (i) the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 11, and / or the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 21 and 22; or (ii) the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 48 and 49, and / or the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 59 and 60.
[0123] 10. The antibody of item 9, comprising (i) the VH sequence of SEQ ID NO: 10 and / or the VL sequence of SEQ ID NO: 21; or (ii) the VH sequence of SEQ ID NO: 48 and / or the VL sequence of SEQ ID NO: 59.
[0124] 11. The antibody of item 9, comprising: (i) the VH sequence of SEQ ID NO: 11 and / or the VL sequence of SEQ ID NO: 49; or (ii) the VH sequence of SEQ ID NO: 11 and / or the VL sequence of SEQ ID NO: 60.
[0125] 12. The antibody of any one of the preceding items, wherein the antibody has binding specificity for cynomolgus IL-17A.
[0126] 13. The antibody of any one of the preceding items, which selectively binds to human IL-17A over human IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F as measured by ELISA.
[0127] 14. Binding to IL-17A (a) inhibiting or blocking the binding of IL-17A to its receptor (IL-17RA); (b) an antibody according to any one of the preceding items, which reduces or neutralizes IL-17A activity.
[0128] 15. The antibody of item 14, wherein the antibody is capable of inhibiting GRO-α secretion when assessed in vitro in an HT-29 assay.
[0129] 16. The antibody of any of the preceding items, (h) has the ability to block the interaction of IL-17A and IL-17RA with a potency (relative potency) of greater than 5, preferably greater than 10, more preferably greater than 15, and even more preferably greater than 20 compared to the potency of secukinumab, as determined by ELISA assay, wherein said relative potency is the IC50 of secukinumab measured by ELISA. 50 values (ng / mL) and IC of antibodies of the invention in scFv format measured by ELISA 50 and / or the ratio of the α-glutamyltransferase (αg / mL) to the α-glutamyltransferase (αg / mL) value (ng / mL); and / or (i) has the ability to neutralize IL-17A with a potency (relative potency) of greater than 50, preferably greater than 100, and more preferably greater than 150, relative to the potency of secukinumab, as determined by measuring Gro-α secretion in an HT-29 assay, wherein said relative potency is the IC50 of secukinumab measured by the HT-29 assay. 50 values (ng / mL) and IC of antibodies of the invention in scFv format measured by HT-29 assay 50 and / or the ratio of the α-glutamyltransferase (αg / mL) to the α-glutamyltransferase (αg / mL) value (ng / mL); and / or (j) The above antibody, which is capable of inhibiting the activity of 1 ng of human IL-17A by 50% at a concentration of 1 ng / mL or less, preferably 0.5 ng / mL or less, and more preferably 0.2 ng / mL or less, wherein the inhibitory activity is determined by measuring GRO-α secretion induced by human IL-17A in an HT-29 assay in the presence of 50 pg / mL of TNFα.
[0130] 17. The antibody of any of the preceding items, (a) human IL-17A has a dissociation constant (K) of less than 5 nM, particularly less than 1 nM, less than 0.5 nM, less than 0.2 nM, even more particularly less than 100 pM, and even more particularly less than 50 pM, as measured by surface plasmon resonance, particularly in a direct setting by surface plasmon resonance; D ), and (b) optionally, a K of less than 10 nM, particularly less than 7 nM, less than 5 nM, less than 2 nM, less than 1 nM, more particularly less than 0.5 nM for cynomolgus IL-17A, when measured by surface plasmon resonance, particularly when measured by surface plasmon resonance in a capture setting; D The antibody described above, which binds to
[0131] 18. The antibody has a dissociation constant (K) of less than 0.5 nM, less than 0.2 nM, less than 100 pM, particularly less than 50 pM for human IL-17A, as measured by surface plasmon resonance, particularly as measured by surface plasmon resonance in a direct setting. D ) the antibody of item 17 that binds to
[0132] 19. The antibody of any of the preceding items, (e) when in scFv format, particularly when the antibody is in phosphate-citrate buffer, pH 6.4, 150 mM NaCl, the melting temperature (Tm) as determined by differential scanning fluorimetry is at least 60°C, particularly at least 62°C, at least 65°C, and more particularly at least 70°C; (f) when in scFv format, the antibody of the invention loses less than 5%, particularly less than 3%, and even more particularly less than 1% of its monomer content after five successive freeze-thaw cycles when the antibody is at a starting concentration of 10 mg / ml, particularly when the antibody is in phosphate buffered saline (PBS), pH 7.4; (g) when in scFv format, the antibody of the invention loses no more than 5%, particularly less than 4%, less than 3%, less than 2%, more particularly less than 1%, of its monomer content after storage at 4°C for at least 2 weeks, particularly at least 4 weeks, when the antibody is at a starting concentration of 10 mg / ml, particularly when the antibody is in phosphate buffered saline (PBS), pH 7.4; and / or (h) The antibody of the invention, which loses less than 5% of its monomer content after storage at 37°C for at least 2 weeks, particularly at least 4 weeks, when the antibody is at a starting concentration of 10 mg / ml.
[0133] 20. The antibody of any of the preceding items, wherein the antibody is selected from the group consisting of monoclonal antibodies, chimeric antibodies, Fabs, Fvs, scFvs, dsFvs, scAbs, STABs, single domain antibodies (sdAbs or dAbs), single domain heavy chain antibodies, and single domain light chain antibodies, VHHs, VNARs, single domain antibodies based on shark VNAR structures, and binding domains based on alternative scaffolds including, but not limited to, ankyrin-based domains, finomers, avimers, anticalins, fibronectin, and binding sites engineered into the constant region of the antibody (e.g., F-star's Modular Antibody Technology™), preferably scFVs.
[0134] 21. The antibody of item 20, wherein the scFv has (i) an amino acid sequence selected from the group consisting of SEQ ID NO: 24 and SEQ ID NO: 25, preferably the scFv has the amino acid sequence of SEQ ID NO: 24; or (ii) an amino acid sequence selected from the group consisting of SEQ ID NO: 61 and SEQ ID NO: 62, preferably the scFv has the amino acid sequence of SEQ ID NO: 61.
[0135] 22. The isolated antibody of item 20, wherein the antibody is an IgG selected from the group consisting of IgG1, IgG2, IgG3, and IgG4, preferably the antibody is IgG1 or IgG4.
[0136] 23. The isolated antibody of any of the preceding items, wherein the antibody is humanized.
[0137] 24. The antibody of any one of items 1 to 23, which is a multispecific molecule.
[0138] 25. The antibody of item 24, which is a single-chain diabody (scDb), a tandem scDb (Tandab), a linear dimeric scDb (LD-scDb), a cyclic dimeric scDb (CD-scDb), a bispecific T cell engager (BiTE; tandem di-scFv), a tandem tri-scFv, a tribody (Fab-(scFv)2) or a bibody (Fab-(scFv)1), a Fab, a Fab-Fv2, a Morrison (IgG CH3-scFv fusion (Morrison L) or an IgG CL-scFv fusions (Morrison H)), triabodies, scDb-scFv, bispecific Fab2, diminibody, tetrabody, scFv-Fc-scFv fusions, scFv-HSA-scFv fusions, didiabodies, DVD-Ig, COVD, IgG-scFab, scFab-dsscFv, Fv2-Fc, IgG-scFv fusions, such as bsAb (scFv linked to the C-terminus of the light chain), Bs1Ab (scFv linked to the N-terminus of the light chain), Bs2Ab (scFv linked to the N-terminus of the heavy chain), Bs3Ab (scFv linked to the C-terminus of the heavy chain), Ts1Ab ( the above antibodies selected from the group consisting of Fv, scFv, scDb, tandem-di-scFv, tandem tri-scFv, Fab-(scFv)2, Fab-(scFv)1, Fab, Fab-Fv2, COVD, MATCH, and duobodies fused to the N-terminus and / or C-terminus of a heterodimeric Fc domain or any other heterodimerization domain.
[0139] 26. A pharmaceutical composition comprising the antibody of any one of items 1 to 25 and a pharmaceutically acceptable carrier.
[0140] 27. The antibody of any one of items 1 to 25 or the pharmaceutical composition of item 26 for use as a medicament.
[0141] 28. The antibody of any one of items 1 to 25 or the pharmaceutical composition of item 26 for use in treating a disorder mediated by IL-17A or a disorder that can be treated by inhibiting GRO-α secretion.
[0142] 29. The antibody of any one of items 1 to 25 or the pharmaceutical composition of item 26 for use in treating an inflammatory condition or an autoimmune disease.
[0143] 30. The antibody of any one of items 1 to 25 or the pharmaceutical composition of item 26 for use in treating the following diseases: cancer, arthritis, rheumatoid arthritis, osteoarthritis of the elbow, reactive arthritis, psoriasis, chronic obstructive pulmonary disease, systemic lupus erythematosus (SLE), lupus nephritis, autoimmune inflammatory bowel disease, asthma, multiple sclerosis, cystic fibrosis, bone loss, airway hyperresponsiveness, demyelinating disorders, skin hyperresponsiveness, acute transplant rejection, allograft rejection, graft-versus-host disease, systemic sclerosis, urinary tract inflammatory disease, cardiovascular disease, vasculitis, periodic fever, glucose metabolism disorders, pulmonary disease, periodontitis, hepatic interstitial keratitis, allergy, inflammatory pain, spondyloarthropathy, sepsis, septic or endotoxic shock, meningitis, surgical trauma, autoimmune blood disease, Alzheimer's disease, sarcoidosis, liver cirrhosis, hepatitis, glomerulonephritis, or dyslipidemia.
[0144] 31. Use of the antibody of any one of items 1 to 25 or the pharmaceutical composition of item 26 in the manufacture of a medicament for use in the treatment of a disorder mediated by IL-17A or a disorder that can be treated by inhibiting Gro-α secretion.
[0145] 32. Use of the antibody of any one of items 1 to 25 or the pharmaceutical composition of item 26 in the manufacture of a medicament for use in treating an inflammatory condition or an autoimmune disease.
[0146] 33. Use of the antibody of any one of items 1 to 25 or the pharmaceutical composition of item 26 in the manufacture of a medicament for use in the treatment of the following diseases: cancer, arthritis, rheumatoid arthritis, osteoarthritis of the elbow, reactive arthritis, psoriasis, chronic obstructive pulmonary disease, systemic lupus erythematosus (SLE), lupus nephritis, autoimmune inflammatory bowel disease, asthma, multiple sclerosis, cystic fibrosis, bone loss, airway hyperresponsiveness, demyelinating disorders, skin hyperresponsiveness, acute transplant rejection, allograft rejection, graft-versus-host disease, systemic sclerosis, urinary tract inflammatory disease, cardiovascular disease, vasculitis, periodic fever, glucose metabolism disorders, lung disease, periodontitis, hepatic interstitial keratitis, allergy, inflammatory pain, spondyloarthropathy, sepsis, septic or endotoxic shock, meningitis, surgical trauma, autoimmune blood disease, Alzheimer's disease, sarcoidosis, liver cirrhosis, hepatitis, glomerulonephritis, or dyslipidemia.
[0147] 34. A method for treating a disorder mediated by IL-17A, comprising administering an effective amount of the antibody of any one of items 1 to 25 or the pharmaceutical composition of item 26 so that the condition is alleviated.
[0148] 35. The method of item 34, wherein the disorder mediated by IL-17A is an inflammatory condition or an autoimmune disease.
[0149] 36. The method of Item 34, wherein the disorder mediated by IL-17A is cancer, arthritis, rheumatoid arthritis, osteoarthritis of the elbow, reactive arthritis, psoriasis, chronic obstructive pulmonary disease, systemic lupus erythematosus (SLE), lupus nephritis, autoimmune inflammatory bowel disease, asthma, multiple sclerosis, cystic fibrosis, bone loss, airway hyperresponsiveness, demyelinating disorders, skin hyperresponsiveness, acute transplant rejection, allograft rejection, graft-versus-host disease, systemic sclerosis, urinary inflammatory disease, cardiovascular disease, vasculitis, periodic fever, glucose metabolism disorders, pulmonary disease, periodontitis, hepatic interstitial keratitis, allergy, inflammatory pain, spondyloarthropathy, sepsis, septic or endotoxic shock, meningitis, surgical trauma, autoimmune blood disease, Alzheimer's disease, sarcoidosis, cirrhosis, hepatitis, glomerulonephritis, or dyslipidemia.
[0150] 37. A nucleic acid encoding the antibody of items 1 to 25.
[0151] 38. A vector comprising the nucleic acid of Item 37.
[0152] 39. A host cell containing the nucleic acid of item 37 or the vector of item 38.
[0153] 40. A method for producing an antibody according to any one of items 1 to 25, comprising culturing a host cell containing a nucleic acid or vector encoding the antibody according to any one of items 1 to 25.
[0154] 41. A kit comprising the antibody of any one of items 1 to 25 or the pharmaceutical composition of item 26.
[0155] The present disclosure contemplates all combinations of any one or more of the foregoing aspects and / or embodiments, as well as combinations with any one or more of the embodiments described in the detailed description and examples.
[0156] Other features, objects, and advantages of the compositions and methods herein will become apparent from the description and drawings, and from the claims. [Brief explanation of the drawings]
[0157] [Figure 1] This demonstrates that labeled IL-17A is suitable for use in the selection process. Bioactivity of labeled IL-17A in the HT-29 assay. Three-fold serial dilutions of labeled and unlabeled IL-17A were tested in parallel for their potential to induce GRO-α secretion in HT-29 cells. The EC50 values for labeled (IL-17A-RPE) and unlabeled (IL-17A) IL-17A are 82.8 ng / ml and 55 ng / ml, respectively. [Figure 2] The potency of 27-07-G02 rabbit IgG (A) and 27-31-CO4 IgG (B) to neutralize IL-17A in an HT-29 assay is shown. [Figure 3]The potency of 27-07-G02 rabbit IgG (A) and 27-31-CO4 IgG (B) to inhibit the interaction between IL-17A and IL-17RA is shown. [Figure 4] The potency of humanized cFvs A1 and A2 (A), and PRO571 and PRO592 (B) to neutralize IL-17A in an HT-29 assay is shown. [Figure 5] The potency (ELISA) of anti-IL-17A scFvs A1 and A2 (A), and PRO571 and PRO592 (B) for inhibiting the interaction of human IL-17A with IL-17RA is shown. [Figure 6-I] The target specificity of scFv A1 (A), and scFvs PRO571 and PRO592 (B) is shown. The possibility of IL-17B-IL-17F inhibiting the interaction of biotinylated IL-17A with scFv was analyzed by competitive ELISA. The dose-dependent effects of IL-17A and IL-17B-IL-17F are shown. [Figure 6-II] The target specificity of scFv A1 (A), and scFvs PRO571 and PRO592 (B) is shown. The possibility of IL-17B-IL-17F inhibiting the interaction of biotinylated IL-17A with scFv was analyzed by competitive ELISA. The dose-dependent effects of IL-17A and IL-17B-IL-17F are shown. [Figure 7] Thermal unfolding curves from DSF measurements of scFv A1 and A2 (A), and scFv PRO571 and PRO592 (B) are shown. The resulting Tm values were determined by fitting the data to the Boltzmann equation to obtain the midpoint of the transition. [Figure 8A] Storage stability studies of scFvA1 (A) and scFv PRO571 and PRO592 (B) were conducted at concentrations >10 mg / mL for 4 weeks at three temperatures (37°C, 4°C, and -80°C). Monomer content over time at various storage temperatures is shown on the left, and protein concentration over time at various storage temperatures (4°C (left) and 37°C (right)) is shown on the right. Monomer content was determined by integration of SE-HPLC peak areas, and protein concentration was calculated by UV280 measurements. [Figure 8B] Storage stability studies of scFvA1 (A) and scFv PRO571 and PRO592 (B) were conducted at concentrations >10 mg / mL for 4 weeks at three temperatures (37°C, 4°C, and -80°C). Monomer content over time at various storage temperatures is shown on the left, and protein concentration over time at various storage temperatures (4°C (left) and 37°C (right)) is shown on the right. Monomer content was determined by integration of SE-HPLC peak areas, and protein concentration was calculated by UV280 measurements. [Figure 9] Shown is a trace of the monomer content of scFv A1 (A), and scFvs PRO571 and PRO592 (B) over five repeated freeze and thaw cycles. [Figure 10] Trispecific formats are shown. A, Three domain permutation variants of the Fab-(scFv)2 molecule were designed. ScFv fusions at positions CL and CH1 of the tribody format are considered equivalent, resulting in three variants of this format. B, Three scDb-scFv domain permutation variants were designed. Domain specificities are indicated at the bottom. The Gly-Ser linker connecting the variable domains and the interdomain disulfide bond is shown as a gray key. [Figure 11] A typical process for lead compound production is shown. A, Overlay of SE-HPLC traces for the final A3–A5 (left graph) and A6–A8 (right graph) samples. The peaks at retention times 7–8 min correspond to the apparent molecular weights of the monomers of the respective molecules. Peaks at retention times greater than 10 min are buffer- and salt-related artifacts. B, SDS-PAGE analysis of A3–A8 under non-reducing (left) and reducing (right) buffer conditions. Molecular weight standards were added to the center lane. Under non-reducing conditions, the bands correspond to the predicted molecular weights of approximately 100 kDa for A3–A5 and approximately 75 kDa for A6–A8, respectively. As expected, for the heterodimeric Fab-(scFv)2 antibody format, the (A3–A5) bands shift to approximately 50 kDa under reducing conditions, while the A6–A8 bands with molecular weights of approximately 75 kDa are still observable under reducing conditions. [Figure 12]Figure 12 shows the TNFα neutralizing potency in the L929 assay. The absorbance measured using the Cell Counting Kit-8 is expressed as a function of the trispecific molecule A3-A8 concentration (in nM). A13 (parent bispecific, HSA binder and TNFα blocking agent) was used as a reference. [Figure 13] Figure 1 shows a comparison of the potency to neutralize human TNFα and cynomolgus TNFα. The absorbance measured using the Cell Counting Kit-8 in the presence of human TNFα or cynomolgus TNFα is shown as a function of A5 and A7 concentrations. [Figure 14] Figure 1 shows simultaneous inhibition of TNF-α and IL-17A in the presence of HSA in an HT-29 assay. In vitro simultaneous inhibition of TNFα and IL-17A by six trispecific molecules A3–A8 was analyzed in the presence of 1 mg / ml HSA using an HT-29 cell-based assay. Secukinumab (IL-17A inhibitor) and A13 (parent bispecific, HSA-binding, and TNFα inhibitor) were used as references. The resulting GRO-α secretion data are expressed as a function of molecule concentration in nM (A, C, and E) and ng / ml (B, D, and F). "No TNFα" indicates GRO-α secretion with the addition of IL-17A alone, corresponding to the maximal effect of TNFα blockade. "No IL17a" indicates GRO-α secretion with the addition of TNFα alone, corresponding to the maximal effect of IL-17A blockade. "No IL17a, no TNFa" indicates background GRO-α secretion in the absence of added IL-17A and TNFα, and corresponds to the maximal effect of simultaneous blockade of TNFα and IL-17A. [Figure 15] Neutralization of IL-17A binding to IL-17RA in a competitive ELISA is shown. The absorbance measured by the competitive ELISA to assess IL-17A binding to IL-17RA is expressed as a function of increasing concentrations of six trispecific molecules (A3–A8). Secukinumab (an IL-17A inhibitor) was used as a reference. [Figure 16]Simultaneous binding of human TNFα, human IL-17A, and HSA by SPR is shown. Six possible sequences of injections of different analytes (human TNFα, human IL-17A, and HSA) were performed on the MAAS-1 SPR instrument, and the resulting sensorgrams are shown. The trispecific molecule was immobilized on the sensor chip (A3, Ch1B on channel 1B; A4, Ch2B on channel 2B; A5, Ch3B on channel 3B; A6, Ch4B on channel 4B; A7, Ch5B on channel 5B; A8, Ch6B on channel 6B), and the antigen was injected sequentially. [Figure 17] Storage stability studies were performed at 37° C., 4° C., and −80° C. for 4 weeks at a protein concentration of 10 mg / mL. The change in % monomer content and % monomer loss over time was recorded on d0, d2, d7, d14, d21, and d28. [Figure 18] Shown is an overlay of SE-HPLC traces of d0 (black, shaded) and d28 (gray) stability samples of A5 (left), A7 (center), and A8 (right). [Figure 19] Pharmacokinetic profile of A7 in cynomolgus monkeys after intravenous (n=3) and subcutaneous (n=3) administration and ADA analysis. [Figure 20] Schematic structures of Morrison L constructs A14 and A15 are shown. [Figure 21] Average size of soluble complexes determined by dynamic light scattering for scDb-scFv A7 is shown. [Figure 22] The average size of the soluble complexes as determined by dynamic light scattering in A14 is shown. [Figure 23] The average size of the soluble complexes as determined by dynamic light scattering in A15 is shown. [Figure 24] Protein concentration recovery of soluble complexes of scDb-scFv A7 is shown. [Figure 25] The recovery of protein concentration of the soluble complex of A14 is shown. [Figure 26] The recovery of protein concentration of the soluble complex of A15 is shown. DETAILED DESCRIPTION OF THE INVENTION
[0158] The present disclosure is based on the discovery of multispecific antibody molecules that specifically bind to IL-17A and TNFα and have improved affinity, potency, and selectivity. Furthermore, the multispecific antibodies of the present disclosure have an improved safety profile, as the inventors have demonstrated that the antibodies do not form immune complexes with TNFα and are therefore potentially less immunogenic. The bivalent binding of other multispecifics (e.g., Covagen, Abbvie, etc.) increases the likelihood of immune complex formation, which can lead to immunogenicity or other adverse effects. In contrast, the monovalent bi- and trispecific constructs of the present disclosure are less likely to form such complexes and are therefore less likely to result in anti-drug antibodies and immune-related adverse effects. Furthermore, the multispecific antibodies of the present disclosure have improved biophysical properties, such as amenability and productivity in large quantities with relatively few impurities, as well as excellent stability.
[0159] The present disclosure further provides antibodies that specifically bind to human IL-17A protein, as well as pharmaceutical compositions, methods of making, and methods of using such antibodies and pharmaceutical compositions.
[0160] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0161] The terms "comprising" and "including" are used herein in their open, non-limiting sense unless expressly stated otherwise. Thus, with respect to such latter embodiments, the term "comprising" includes the narrower term "consisting of."
[0162] The terms "a," "an," and "the" and similar references in the context of describing the present invention (particularly in the context of the claims below) should be construed to encompass both the singular and the plural unless otherwise stated herein or clearly contradicted by context. For example, the term "cell" includes a plurality of cells, including mixtures thereof. When the plural is used for compounds, salts, etc., this is construed to mean a single compound, salt, etc.
[0163] Multispecific antibodies of the present disclosure In one aspect, the present disclosure provides an isolated multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα.
[0164] The term "TNFα" or "TNF-α" or "tumor necrosis factor" specifically refers to human TNFα. TNFα is found as a precursor called transmembrane TNFα, which is expressed as a soluble protein and as a type II polypeptide on the cell surface. Transmembrane TNFα is processed by metalloproteinases such as TNFα-converting enzyme (TACE) between residues Ala76 and Val77, releasing a soluble form of TNFα of 157 amino acid residues. Soluble TNFα is a homotrimer of 17 kDa cleaved monomers. Transmembrane TNFα also exists as a homotrimer of 26 kD uncleaved monomers. As used herein, the term "TNFα" encompasses both soluble and transmembrane forms. The term "TNFα" specifically refers to human transmembrane TNFα, having UniProt ID number P01375, reproduced herein as SEQ ID NO: 134. The term "TNFα" refers in particular to the soluble transmembrane form of TNFα having UniProt ID number P01375, reproduced herein as SEQ ID NO: 135.
[0165] Suitably, the antibodies of the present disclosure are isolated antibodies. As used herein, the term "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigen specificities (e.g., an isolated antibody that specifically binds only to IL-17A and TNFα is substantially free of antibodies that specifically bind to antigens other than IL-17A and TNFα). However, an isolated antibody that specifically binds to IL-17A and TNFα may have cross-reactivity to other antigens, such as IL-17A and TNFα molecules from other species. Furthermore, an isolated antibody may be substantially free of other cellular material and / or chemicals.
[0166] Suitably, the antibodies of the present disclosure are monoclonal antibodies. As used herein, the term "monoclonal antibody" or "monoclonal antibody composition" refers to antibodies having substantially identical or derived amino acid sequences from the same genetic source. Monoclonal antibody compositions exhibit binding specificity and affinity for a particular epitope, or binding specificity and affinity for a particular epitope.
[0167] Antibodies of the present disclosure include, but are not limited to, chimeric antibodies and humanized antibodies.
[0168] The term "chimeric antibody" refers to an antibody molecule in which (a) the constant region or a portion thereof has been modified, substituted, or exchanged, such that the antigen-binding site (variable region) is linked to the constant region of a different or modified class, effector function, and / or species, or to that of an entirely different molecule, such as an enzyme, toxin, hormone, growth factor, drug, etc., that confers new properties to the chimeric antibody; or (b) the variable region or a portion thereof has been modified, substituted, or exchanged for a variable region with a different or modified antigen specificity. For example, a murine antibody can be modified by replacing its constant region with that from a human immunoglobulin. The substitution with a human constant region allows the chimeric antibody to retain its specificity for recognizing an antigen while reducing its antigenicity in humans compared to the original murine antibody.
[0169] As used herein, a "humanized" antibody is an antibody that retains the reactivity of a non-human antibody while being less immunogenic in humans. This can be achieved, for example, by retaining the non-human CDRs and replacing the remainder of the antibody with their human counterparts (i.e., the constant and variable region framework portions). Additional framework region modifications can be made within the human framework sequences as well as within CDR sequences derived from the germline of another mammalian species. The humanized antibodies of the present disclosure may include amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro, or by somatic mutation in vivo, or by conservative substitutions to facilitate stability or manufacturing). See, e.g., Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855, 1984; Morrison and Oi, Adv. Immunol., 44:65-92, 1988; Verhoeyen et al., Science, 239:1534-1536, 1988; Padlan, Molec. Immun., 28:489-498, 1991; and Padlan, Molec. Immun., 31:169-217, 1994. Other examples of human engineering techniques include, but are not limited to, the Xoma technology disclosed in U.S. Patent No. 5,766,886.
[0170] As used herein, the term "recombinant humanized antibody" includes all humanized antibodies of the present disclosure that are prepared, expressed, created, or isolated by recombinant means, such as antibodies isolated from an animal (e.g., a rabbit), antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant combinatorial human antibody library, or antibodies prepared, expressed, created, or isolated by any other means, including splicing human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions (if present) derived from human germline immunoglobulin sequences. However, such antibodies are subject to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) such that the amino acid sequences of the VH (antibody heavy chain variable region) and VL (antibody light chain variable region) of the recombinant antibody, while derived from and related to human germline VH and VL sequences, are sequences that may not naturally occur within the human antibody germline.
[0171] Suitably, the antibodies or binding domains thereof of the disclosure are humanised. Suitably, the antibodies or binding domains thereof of the disclosure are humanised and comprise CDRs of rabbit origin.
[0172] The term "multispecific antibody" as used herein refers to an antibody that binds to two or more different epitopes on at least two or more different targets (e.g., IL-17A and TNFα) or two or more different epitopes on the same target. The term "multispecific antibody" of the present disclosure has two or more binding domains, for example, two or three binding domains. The term "multispecific antibody" includes bispecific, trispecific, tetraspecific, pentaspecific, and hexaspecific antibodies. The term "bispecific antibody" as used herein refers to an antibody that binds, for example, to two different targets (e.g., IL-17A and TNFα) or to two different epitopes on the same target. The term "trispecific antibody" as used herein refers to an antibody that binds, for example, to three different targets (e.g., IL-17A, TNFα, and HSA) or to three different epitopes on the same target.
[0173] The term "multivalent antibody" refers to a single binding molecule with multiple valencies, where "valency" is described as the number of antigen-binding moieties that bind to the same epitope on the target molecule. "Valency" refers to the presence of a specific number of antigen-specific binding domains within the molecule. Thus, the terms "monovalent," "bivalent," "tetravalent," and "hexavalent" refer to the presence of one, two, four, and six antigen-specific binding domains within the molecule, respectively. As used herein, the term "monovalent antibody" refers to an antibody having a single antigen-binding moiety that binds to a single epitope on a target molecule, such as IL-17A or TNFα. As used herein, the term "bivalent antibody" refers to an antibody having two antigen-binding moieties, each of which binds to the same epitope.
[0174] The multispecific antibodies of the disclosure can be monovalent or multivalent, e.g., bivalent, trivalent, or tetravalent, preferably monovalent, for binding to IL-17A.
[0175] The multispecific antibodies of the present disclosure can be monovalent or multivalent, e.g., bivalent, trivalent, or tetravalent, preferably monovalent, for binding to TNFα. Because TNFα forms trimers, they are potentially trivalent and can form three-dimensional immune complexes with antibodies having several domains that specifically bind to TNFα, such as bivalent, trivalent, or multivalent antibodies for binding to TNFα. To illustrate, a study of the size of immune complexes formed between TNFα and infliximab (a chimeric TNFα IgG antibody) and etanercept (a TNFR2 dimeric fusion protein with IgG1 Fc) at different antigen / antibody ratios showed that each antibody produced immune complexes with a unique size profile (Kim MS, et al., J Mol Biol. 2007;374:1374-1388). Therefore, potential high immunogenicity is one of the concerns for therapeutic antibodies targeting TNFα. Therefore, in a preferred embodiment, the multispecific antibodies of the present disclosure are monovalent for binding to TNFα.
[0176] Suitably, a multispecific antibody of the present disclosure comprises only one domain that specifically binds to IL-17A and / or only one domain that specifically binds to TNFα. In a preferred embodiment, a multispecific antibody of the present disclosure comprises only one domain that specifically binds to TNFα. Suitably, a multispecific antibody of the present disclosure comprises only one domain that specifically binds to IL-17A and only one domain that specifically binds to TNFα. In certain embodiments, a multispecific antibody of the present disclosure consists of a first domain that specifically binds to IL-17A, a second domain that specifically binds to TNFα, and, optionally, a polypeptide linker between the two domains. In certain embodiments, the optional polypeptide linker is present and consists of a polypeptide having 4 to 25 amino acid residues.
[0177] Suitably, the multispecific antibodies of the present disclosure are advantageously capable of neutralizing the biological activity of human TNFα and human IL-17A. It will be understood that the term "neutralizing" as used herein refers to a reduction in biological signaling activity, which may be partial or complete. Suitable assays for determining neutralization are known in the art, and some such assays are provided in the Examples herein.
[0178] In one embodiment, an antibody or first domain thereof of the present disclosure selectively binds to human IL-17A over human IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F, particularly as measured by ELISA. As used herein, the term "selectively binds" is intended to mean that the antibody, composition, formulation, etc. does not significantly bind to IL-17B / C / D / E / F, but binds to IL-17A. Selective binding can be achieved by high affinity (or low K D ) and low to medium IC 50 characterized by a low affinity (or high K D ) with medium to high IC 50 This is distinguished from non-specific binding, which typically occurs when an antibody is 10 -7 K less than M D Suitably, the antibody or first domain thereof of the present disclosure binds to human IL-17B, IL-17C, IL-17D, IL-17E, IL-17F with a higher affinity or a lower K as measured by SPR. D Suitably, the antibody or first domain thereof of the disclosure binds to human IL-17A at an IC value of 100 or less against IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F as measured by ELISA. 50 IC against IL-17A 50 at least 100 times greater, e.g., at least 200 times greater, at least 300 times greater, or at least 400 times greater than 50In one embodiment, an antibody or first domain thereof of the disclosure binds to human IL-17A but does not bind to human IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F, particularly as measured by SPR and / or ELISA.
[0179] In a further embodiment, the multispecific antibody of the present disclosure further comprises a third domain having specificity for an antigen different from IL-17A and TNFα. Suitably, the multispecific antibody of the present disclosure is a trispecific antibody. As used herein, "trispecific antibody" refers to an antibody molecule having three antigen-binding domains, for example, one binding domain that binds to human TNFα, another binding domain that binds to human IL-17A, and yet another binding domain that binds to an antigen that can extend the half-life of the antibody molecule, such as human serum albumin.
[0180] In particular, the multispecific antibodies of the present disclosure further comprise a third domain that specifically binds to human serum albumin (HSA).
[0181] The present inventors have surprisingly found that the addition of a third domain that specifically binds human serum albumin to a multispecific antibody of the present disclosure comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα has the following beneficial effects: (i) increasing the serum half-life of a multispecific antibody of the disclosure comprising at least one domain that specifically binds to human serum albumin; and (ii) The addition of a human serum albumin binding domain to the multispecific antibodies of the disclosure is compatible with the function of other binding domains, for example, the neutralizing activity of the Il-17A and TNFα binding domains.
[0182] The term "HSA" specifically refers to human serum albumin, UniProt ID number P02768. Human serum albumin (HSA) is a 66.4 kDa abundant protein (50% of total protein) in human serum, composed of 585 amino acids (Sugio, Protein Eng, Vol. 12, 1999, 439-446). The multifunctional HSA protein is related to its structure, which allows it to bind and transport many metabolites, such as fatty acids, metal ions, bilirubin, and some drugs (Fanali, Molecular Aspects of Medicine, Vol. 33, 2012, 209-290). The serum HSA concentration is approximately 3.5-5 g / dL. Albumin-binding antibodies can be used, for example, to extend the in vivo serum half-life of drugs or proteins bound thereto.
[0183] Suitably, in one embodiment, the multispecific antibody of the present disclosure comprises a first domain that specifically binds to IL-17A, a second domain that specifically binds to TNFα, and a third domain that specifically binds to human serum albumin. The multispecific antibody of the present disclosure can be monovalent or multivalent, e.g., bivalent, trivalent, or tetravalent, preferably monovalent, for binding to human serum albumin. Suitably, the multispecific antibody of the present disclosure comprises only one domain that specifically binds to IL-17A, only one domain that specifically binds to TNFα, and only one domain that specifically binds to human serum albumin. In certain embodiments, the multispecific antibody of the present disclosure comprises a first domain that specifically binds to IL-17A, a second domain that specifically binds to TNFα, a third domain that specifically binds to human serum albumin, and, optionally, a polypeptide linker between the two domains. In certain embodiments, the optional polypeptide linker is present and comprises a polypeptide having 4 to 25 amino acid residues.
[0184] Advantageously, a multispecific antibody of the present disclosure comprises a first domain that specifically binds to IL-17A, a second domain that specifically binds to TNFα, and optionally a third domain that specifically binds to human serum albumin, wherein said domains are capable of simultaneously binding to each of these antigens or receptors.
[0185] The domains of the multispecific antibodies of the present disclosure, such as the first domain, the second domain, and the third domain, are independently selected from the group consisting of Fab, Fv, scFv, dsFv, scAb, STAB, single domain antibodies (sdAb or dAb), single domain heavy chain antibodies, and single domain light chain antibodies, VHH, VNAR, single domain antibodies based on shark VNAR structures, and binding domains based on alternative scaffolds, including but not limited to ankyrin-based domains, phinomers, avimers, anticalins, fibronectin, and binding sites incorporated into antibody constant regions (e.g., -star's Modular Antibody Technology®), preferably from the group consisting of Fab, Fv, and scFv, and more preferably wherein the first domain and / or the second domain and / or the third domain is an Fv or scFv.
[0186] The multispecific antibodies of the present disclosure may be in any suitable format. In one embodiment, the multispecific antibodies of the present disclosure are single-chain diabodies (scDbs), tandem scDbs (Tandabs), linear dimeric scDbs (LD-scDbs), cyclic dimeric scDbs (CD-scDbs), bispecific T cell engagers (BiTEs; tandem di-scFvs), tandem tri-scFvs, tribodies (Fab-(scFv)2) or bibodies (Fab-(scFv)1), Fab, Fab-Fv2, Morrison (IgG CH3-scFv fusions (Morrison L) or IgG CL-scFv fusions (Morrison H)), triabodies, scDb-scFv, bispecific Fab2, diminibody, tetrabody, scFv-Fc-scFv fusions, scFv-HSA-scFv fusions, didiabodies, DVD-Ig, COVD, IgG-scFab, scFab-dsscFv, Fv2-Fc, IgG-scFv fusions, e.g., bsAb (scFv linked to the C-terminus of the light chain), Bs1Ab (scFv linked to the N-terminus of the light chain), Bs2Ab (scFv linked to the N-terminus of the heavy chain), Bs3Ab (scFv linked to the C-terminus of the heavy chain), Ts1Ab (scFv linked to the N-terminus of both the heavy and light chains), and a format selected from the group consisting of Fv, scFv, scDb, tandem-di-scFv, tandem tri-scFv, Fab-(scFv)2, Fab-(scFv)1, Fab, Fab-Fv2, COVD, MATCH and duobody fused to the N-terminus and / or C-terminus of either the heterodimeric Fc domain or any other heterodimerization domain, preferably a tribody or scDb-scFv.
[0187] The term "diabody" refers to an antibody fragment having two antigen-binding sites, which fragments comprise a VH connected to a VL in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with complementary domains on another chain, creating two antigen-binding sites. Diabodies can be bivalent or bispecific. Diabodies are described in more detail in, for example, EP 404097, WO 93 / 01161, Hudson et al., Nat. Med. 9:129-134 (2003), and Holliger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003). Bispecific scDbs, particularly bispecific monomeric scDbs, particularly comprise two variable heavy chain domains (VH) or fragments thereof and two variable light chain domains (VL) or fragments thereof, connected by linkers L1, L2, and L3, as follows: VHA-L1-VLB-L2-VHB-L3-VLA, VHA-L1-VHB-L2-VLB-L3-VLA, VLA-L1-VLB-L2-VHB-L3-VHA, VLA-L1-VLB-L2-VHB-L3-VHA, VLA-L1-V The VLA and VHA domains are linked in the following order: HB-L2-VLB-L3-VHA, VHB-L1-VLA-L2-VHA-L3-VLB, VHB-L1-VHA-L2-VLA-L3-VLB, VLB-L1-VLA-L2-VHA-L3-VHB, or VLB-L1-VHA-L2-VLA-L3-VHB, where the VLA and VHA domains together form an antigen-binding site for a first antigen, and the VLB and VHB domains together form an antigen-binding site for a second antigen. Linker L1 is preferably a peptide of 2 to 10 amino acids, more preferably 3 to 7 amino acids, and most preferably 5 amino acids. Linker L3 is preferably a peptide of 1 to 10 amino acids, more preferably 2 to 7 amino acids, and most preferably 5 amino acids. Intermediate linker L2 is preferably a peptide of 10 to 40 amino acids, more preferably 15 to 30 amino acids, and most preferably 20 to 25 amino acids.
[0188] In one embodiment, a multispecific antibody of the present disclosure comprises an immunoglobulin Fc region polypeptide. The term "Fc region" is used herein to define the C-terminal region of an immunoglobulin heavy chain, including native-sequence Fc regions and variant Fc regions. Suitable native-sequence Fc regions include human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4. "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. Preferred FcRs are native-sequence human FcRs. Further, preferred FcRs are those that bind IgG antibodies (gamma receptors), including receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors; FcγRII receptors include FcγRIIA ("activating receptor") and FcγRIIB ("inhibiting receptor"), which have similar amino acid sequences that differ primarily in their cytoplasmic domains. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. The inhibitory receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain (see M. Daeron, Annu. Rev. Immunol. 5:203-234 (1997)). FcRs have been reviewed by Ravetch and Kinet, Annu. Rev. Immunol. 9:457-92 (1991); Capet et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those identified in the future, are encompassed herein by the term "FcR." The term "Fc receptor" or "FcR" also includes the neonatal receptor FcRn, which is involved in the transport of maternal IgG to the fetus. Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24: 249 (1994).Methods for measuring binding to FcRn are known (see, for example, Ghetie and Ward, Immunol. Today 18: (12): 592-8 (1997); Ghetie et al., Nature Biotechnology 15 (7): 637-40 (1997); Hinton et al., J. Biol. Chem. TJI (8): 6213-6 (2004); WO2004 / 92219 (Hinton et al)). In vivo binding to FcRn and serum half-life of human FcRn high-affinity binding polypeptides can be assayed, for example, in transgenic mice or transfected human cell lines expressing human FcRn, or in primates administered polypeptides with variant Fc regions. WO2004 / 42072 (Presta) describes antibody variants with improved or diminished binding to FcRs. See, e.g., Shields et al., J. Biol. Chem. 9(2): 6591-6604 (2001).
[0189] To increase the number of specificities / functionalities at the same or smaller molecular weight, it is advantageous to use antibodies containing antibody fragments such as Fv, Fab, Fab', and F(ab')2 fragments, as well as other antibody fragments. These smaller molecules retain the antigen-binding activity of whole antibodies and can also exhibit improved tissue penetration and pharmacokinetic properties compared to whole immunoglobulin molecules. While such fragments appear to offer many advantages over whole immunoglobulins, they lack the Fc domain, which confers a longer half-life in vivo, resulting in a faster clearance rate from serum (Medasan et al., 1997, J. Immunol. 158:2211-2217). Smaller molecular weight molecules may penetrate target tissues (such as solid tumors) more efficiently, potentially improving efficacy at the same or lower doses. Suitably, the antibodies of the present disclosure do not include immunoglobulin Fc region polypeptides and, optionally, do not include CH1 and CL regions, particularly when the multispecific antibody includes a third domain that specifically binds human serum albumin.
[0190] Suitably, the antibody of the present disclosure may be in a tribody format (Fab-(scFv)2). Suitably, the first domain and / or the second domain and / or the third domain are Fab or scFv domains. In particular, the multispecific antibody of the present disclosure has one Fab domain and two scFv domains, in particular, an scFv domain fused to the carboxy terminus of each chain of the Fab domain. The inventors have tested the optimal relative positions of the individual binding domains in a trispecific format in terms of pharmacodynamic and biophysical properties and have surprisingly found that when the multispecific antibody of the present disclosure is in a tribody format, it has advantageous properties when the second domain that specifically binds to TNFα is a Fab domain and the first and third domains that specifically bind to IL-17A and HSA, respectively, are scFv domains fused to the Fab domains.
[0191] Preferably, the antibodies of the present disclosure are in the scDb-scFv format. The term "scDb-scFv" refers to an antibody format in which a single-chain Fv (scFv) fragment is fused to a single-chain diabody (scDb) via a flexible Gly-Ser linker. Suitably, the first domain and / or the second domain and / or the third domain are Fv or scFv domains. In particular, when the multispecific antibody of the present disclosure is in the scDb-scFv format, it has one scFv domain fused at the C-terminus to an scDb comprising the other two domains. When the multispecific antibody of the present disclosure is in the scDb-Fv format, it can be represented by the following formula:
[0192] VLA-L1-VHC-L2-VLC-L3-VHA-L4-VLB-L5-VHB, or VLB-L1-VHA-L2-VLA-L3-VHB-L4-VLC-L5-VHC, or VLC-L1-VHB-L2-VLB-L3-VHC-L4-VLA-L5-VHA, or VLA-L1-VHB-L2-VLB-L3-VHA-L4-VLC-L5-VHC, Preferably, VLB-L1-VHA-L2-VLA-L3-VHB-L4-VLC-L5-VHC, or VLA-L1-VHB-L2-VLB-L3-VHA-L4-VLC-L5-VHC, More preferably, VLB-L1-VHA-L2-VLA-L3-VHB-L4-VLC-L5-VHC,
[0193] where VLA and VHA are the light chain variable region and heavy chain variable region, respectively, of the first domain (specifically binds to IL-17A); VLB and VHB are the light chain variable region and heavy chain variable region, respectively, of the second domain (specifically binds to TNFα); VLC and VHC are the light chain variable region and heavy chain variable region, respectively, of the third domain (specifically binds to HSA), and L1, L2, L3, L4, and L5 are polypeptide linkers.
[0194] In the context of the present disclosure, the term "polypeptide linker" refers to a linker consisting of a chain of amino acid residues linked by peptide bonds connecting two domains, each attached to one end of the linker. The polypeptide linker must be long enough to link two molecules so that they assume the correct conformation relative to each other and thus retain the desired activity. In certain embodiments, the polypeptide linker has a continuous chain of 2 to 30 amino acid residues (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid residues). Furthermore, the amino acid residues selected for inclusion in the polypeptide linker must exhibit properties that do not significantly interfere with the activity of the polypeptide. Thus, the linker peptide as a whole must not exhibit charges that are inconsistent with the activity of the polypeptide, that interfere with internal folding, or that form bonds or other interactions with the amino acid residues of one or more of the monomers that would significantly impede the binding of the monomer domains. In certain embodiments, the polypeptide linker is an unstructured polypeptide. Useful linkers include glycine-serine or GS linkers. "Gly-Ser" or "GS" linkers are polymers of tandem glycine and serine (e.g., (Gly-Ser)n, (GSGGS)n(GGGGS)n, and (GGGS)n, where n is an integer of at least 1), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers such as the tether of Shaker potassium channels, and various other flexible linkers as will be appreciated by those skilled in the art. Glycine-serine polymers are preferred because both amino acids in the glycine-serine polymer are relatively unstructured and therefore may be able to function as a neutral tether between components. Second, serine is hydrophilic, so it can solubilize what may be globular glycine chains. Third, similar chains have proven effective in joining subunits of recombinant proteins such as single-chain antibodies.
[0195] Suitably, said L1 and L3 of the present disclosure are as set out in SEQ ID NO: 132. Suitably, said L2, L4 and L5 of the present disclosure are as set out in SEQ ID NO: 23.
[0196] The present inventors have tested the optimal relative positions of the individual binding domains in a trispecific format from the standpoint of pharmacodynamic and biophysical properties, and have surprisingly found that, in the case of a multispecific antibody of the present disclosure, in the scDb-scFv format, the first and second domains that specifically bind to IL-17A and TNFα, respectively, form an scDb, and the third domain that specifically binds to HSA is an scFv.
[0197] The multispecific antibodies of the present disclosure have the following advantageous properties: (a) has the ability to neutralize IL-17A with a potency (relative potency) of greater than 2, e.g., greater than 5, greater than 10, greater than 15, greater than 20, greater than 25, greater than 30, greater than 35, greater than 40, greater than 45, preferably greater than 50, compared to the potency of secukinumab as determined by measuring Gro-α secretion in an HT-29 assay, wherein said relative potency is the IC of secukinumab as determined by the HT-29 assay. 50 values (ng / mL) and IC of the multispecific antibodies as determined by HT-29 assay 50 is the ratio of the α-glutamyltransferase (αg / mL) to the α-glutamyltransferase (αg / mL) value (ng / mL); and
[0198] (b) have the ability to neutralize TNFα with a potency (relative potency) of at least 1, e.g., greater than 1, greater than 1.5, greater than 2, greater than 2.5, greater than 3, greater than 3.5, preferably greater than 4, more preferably greater than 4.5, compared to the potency of the scDb of SEQ ID NO: 149 (A13) as determined by measuring Gro-α secretion in an HT-29 assay, wherein said relative potency is the IC of said scDb of SEQ ID NO: 149 (A13) as determined by an HT-29 assay. 50 values (nM) and IC of said multispecific antibodies as determined by HT-29 assay 50is the ratio of the value (nM) to the
[0199] (c) optionally, having the ability to block the interaction of IL-17A and IL-17RA with a potency (relative potency) of greater than 2, e.g., greater than 3, greater than 4, greater than 5, greater than 6, greater than 7, greater than 8, greater than 9, preferably greater than 10, compared to the potency of secukinumab as determined by ELISA assay, wherein said relative potency is the IC of secukinumab as determined by ELISA. 50 values (ng / mL) and IC of the multispecific antibodies as determined by ELISA. 50 is the ratio of the α-glutamyltransferase (αg / mL) to the α-glutamyltransferase (αg / mL) value (ng / mL); and
[0200] (d) optionally, having the ability to neutralize TNFα with a potency (relative potency) of at least 0.4, such as at least 0.5, preferably at least 1, compared to the potency of the scDb of SEQ ID NO: 149 (A13) as determined in the L929 assay, wherein said relative potency is the IC of said scDb of SEQ ID NO: 149 as measured by the L929 assay. 50 values (nM) and IC of said multispecific antibodies measured by L929 assay 50 and / or
[0201] (e) a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, preferably less than 0.5 nM, as measured by surface plasmon resonance D ) and binds to human IL-17A, and optionally has a K of less than 5 nM, e.g., less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, preferably less than 0.5 nM, as measured by surface plasmon resonance. D and binds to cynomolgus monkey IL-17A;
[0202] (f) a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, preferably less than 0.5 nM, more preferably less than 25 nM, as measured by surface plasmon resonance D ) and binds to human TNFα; and
[0203] (g) optionally, a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, preferably less than 2 nM, as measured by surface plasmon resonance; D ) binds to human serum albumin with a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, preferably less than 2 nM, as measured by surface plasmon resonance. D ) and binds to cynomolgus monkey serum albumin.
[0204] The term "affinity" as used herein refers to the strength of the interaction between an antibody and an antigen at a single antigenic site. Within each antigenic site, the variable regions of the antibody "arms" interact with the antigen at multiple sites through weak non-covalent forces. The more interactions, the stronger the affinity.
[0205] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity," "binds," "binds to," or "bound to" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of molecule X for partner Y is generally determined by the dissociation constant (K D ) Affinity can be measured by common methods known in the art, including those described herein. Low affinity antibodies generally bind antigens slowly and tend to dissociate easily, while high affinity antibodies generally bind antigens quickly and tend to remain bound longer. Various methods for measuring binding affinity are known in the art, any of which can be used for the purposes of the present disclosure. Specific illustrative and exemplary embodiments for measuring binding affinity, i.e., binding strength, are described below.
[0206] As used herein, "k" assoc ", "ka" or "k on" is intended to refer to the association rate of a particular antibody-antigen interaction, while "k" as used herein is dis ", "kd" or "k off The term "K" is intended to refer to the off-rate of a particular antibody-antigen interaction. D The term "K" is intended to refer to the dissociation constant, which is obtained from the ratio of kd to ka (i.e., kd / ka) and is expressed as a molar concentration (M). D " or "K D The "K value" or "KD" or "KD value" is, in one embodiment, measured by using a surface plasmon resonance assay with a MAAS-1 SPR instrument (SierraSensors), as described in the Examples. The binding affinity of an antibody can be measured, for example, by measuring the dissociation constant (K D ) can be determined by the K D where weaker affinity is represented by a higher K D is expressed by
[0207] Thus, in suitable embodiments, the antibodies of the present disclosure have a dissociation constant (K) of 1 pM to 10 nM, 1 pM to 7 nM, 1 pM to 5 nM, 1 pM to 4 nM, 1 pM to 3 nM, 1 pM to 2.5 nM, 1 pM to 2 nM, 1 pM to 1.5 nM, 1 pM to 1 nM, preferably 1 pM to 0.5 nM, as measured by surface plasmon resonance. D In suitable embodiments, the antibodies of the disclosure bind to human IL-17A with a dissociation constant (K) of 1 to 500 pM as measured by surface plasmon resonance. D In suitable embodiments, the antibodies of the disclosure bind to human IL-17A with a dissociation constant (K) of less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, and preferably less than 0.5 nM, as measured by surface plasmon resonance. D ) binds to human IL-17A. Suitably, the antibodies of the disclosure bind to human IL-17A with a dissociation constant (K D Suitably, the antibodies of the disclosure bind to human IL-17A with a dissociation constant (K) of less than 0.5 nM. DIn further embodiments, the antibodies of the disclosure bind to human IL-17A with a K of less than 10 nM, e.g., less than 7 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, preferably less than 0.5 nM, as measured by surface plasmon resonance (SPR). D Binds to cynomolgus monkey IL-17A.
[0208] Suitably, the antibodies of the disclosure have a dissociation constant (K) of 1 pM to 10 nM, 1 pM to 7 nM, 1 pM to 5 nM, 1 pM to 4 nM, 1 pM to 3 nM, 1 pM to 2.5 nM, 1 pM to 2 nM, 1 pM to 1.5 nM, 1 pM to 1 nM, preferably 1 pM to 0.5 nM, more preferably 1 pM to 0.25 nM, as measured by surface plasmon resonance (SPR). D In a suitable embodiment, the antibodies of the present disclosure bind to human TNFα with a dissociation constant (K) of 1 to 500 pM, preferably 1 to 250 pM, as measured by surface plasmon resonance. D In suitable embodiments, the antibodies of the disclosure bind to human TNFα with a dissociation constant (K) of less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, preferably less than 0.5 nM, and more preferably less than 0.25 nM, as measured by surface plasmon resonance. D ) binds to human TNFα. Suitably, the antibodies of the disclosure bind to human TNFα with a dissociation constant (K D ) binds to human TNFα. Suitably, the antibodies of the disclosure bind to human TNFα with a dissociation constant (K D ) binds to human TNFα.
[0209] In suitable embodiments, the antibodies of the disclosure have a dissociation constant (K) of 1 pM to 10 nM, 1 pM to 7 nM, 1 pM to 5 nM, 1 pM to 4 nM, 1 pM to 3 nM, preferably 1 pM to 2 nM, as measured by surface plasmon resonance. D ) binds to human serum albumin. In suitable embodiments, the antibodies of the disclosure have a dissociation constant (K) of 1 to 2000 pM as measured by surface plasmon resonance. DIn suitable embodiments, the antibodies of the disclosure bind to human serum albumin with a dissociation constant (K) of less than 5 nM, less than 4 nM, less than 3 nM, and preferably less than 2 nM, as measured by surface plasmon resonance. D ) binds to human serum albumin. Suitably, the antibodies of the disclosure bind to human serum albumin with a dissociation constant (K) of less than 2 nM. D In further embodiments, the antibodies of the disclosure bind to human serum albumin with a K of less than 10 nM, e.g., less than 7 nM, less than 5 nM, less than 4 nM, less than 3 nM, preferably less than 2 nM, as measured by surface plasmon resonance (SPR). D It binds to cynomolgus monkey serum albumin.
[0210] Suitably, the antibodies of the present disclosure have beneficial biophysical properties. (a) has a melting temperature (Tm) in phosphate-citrate buffer, pH 6.4, 150 mM NaCl, of at least 55°C, preferably at least 58°C, and more preferably at least 60°C, as determined by differential scanning fluorimetry; (b) the multispecific antibody has a loss of monomer content of less than 5%, e.g., less than 4%, less than 3%, less than 2%, preferably 1% or less, after five consecutive freeze-thaw cycles when at a starting concentration of 10 mg / ml in phosphate-buffered saline (PBS), pH 7.4; (c) the multispecific antibody has a loss of less than 10%, preferably less than 5%, of monomer content after storage at 4°C for at least 2 weeks, particularly at least 4 weeks, when the multispecific antibody is at a starting concentration of 10 mg / ml in phosphate-buffered saline (PBS), pH 7.4; and / or (d) the multispecific antibody has a loss of less than 20%, preferably less than 15%, of monomer content after storage at 37°C for at least 2 weeks, particularly at least 4 weeks, when the multispecific antibody is at a starting concentration of 10 mg / ml in phosphate buffered saline (PBS), pH 7.4.
[0211] Melting temperatures (Tm) are determined by differential scanning fluorimetry (DSF) as previously described (Egan, et al., MAbs, 9(1) (2017), 68-84; Niesen, et al., Nature Protocols, 2(9) (2007) 2212-2221). The midpoint of the thermal unfolding transition is determined by differential scanning fluorimetry (DSF) using the fluorescent dye SYPRO® Orange (see Wong & Raleigh, Protein Science 25 (2016) 1834-1840). Samples in pH 6.4 phosphate-citrate buffer are prepared at a final protein concentration of 50 μg / mL and a final concentration of 5× SYPRO® Orange in a total volume of 100 μl. 25 microliters of the prepared sample are added to a white-walled AB gene PCR plate in triplicate. The assay is performed in a qPCR instrument used as a thermal cycler, and fluorescence emission is detected using a custom dye calibration routine in the software. The PCR plate containing the test samples is subjected to a temperature ramp from 25°C to 96°C in 1°C increments, with a 30-second pause after each temperature increase. The total assay time is approximately 2 hours. Tm is calculated using the GraphPad Prism software using the mathematical second derivative method to calculate the inflection point of the curve. The reported Tm is the average of triplicate measurements.
[0212] Monomer content loss is determined by SE-HPLC. SE-HPLC is a separation technique based on a solid stationary phase and a liquid mobile phase, as outlined in USP Chapter 621. This method utilizes a hydrophobic stationary phase and an aqueous mobile phase to separate molecules based on size and shape. Molecular separation occurs between the void volume (V0) and total permeable volume (VT) of a specific column. SE-HPLC measurements are performed on a Chromaster HPLC system (Hitachi High-Technologies Corporation) equipped with automatic sample injection and a UV detector set at a detection wavelength of 280 nm. The instrument is controlled by EZChrom Elite software (Agilent Technologies, version 3.3.2 SP2), which also supports the analysis of the resulting chromatograms. Protein samples are clarified by centrifugation and maintained at 6°C in an autosampler before injection. For the analysis of scFv samples, a Shodex KW403-4F column (Showa Denko K.K., #F6989202) is used with a standardized buffered saline mobile phase (50 mM sodium phosphate pH 6.5, 300 mM sodium chloride) at a recommended flow rate of 0.35 mL / min. The target sample load per injection was 5 µg. Samples are detected with a UV detector at a wavelength of 280 nm, and data are recorded with an appropriate software suite. The resulting chromatograms are analyzed in the V0-VT range to exclude large matrix-related peaks with elution times greater than 10 min.
[0213] Exemplary Domains That Specifically Bind IL-17A The multispecific antibodies of the present disclosure comprise a first domain that specifically binds to IL-17A, wherein said domain comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein (a) said VH comprises, in order, three complementarity determining regions: HCDR1, HCDR2, and HCDR3, and (b) said VL comprises, in order, three complementarity determining regions: LCDR1, LCDR2, and LCDR3.
[0214] Suitable domains that specifically bind to IL-17A for use in the multispecific antibodies of the present disclosure include, but are not limited to: a humanized monoclonal antibody or binding domain thereof as presented in the section "Anti-IL-17A Antibodies of the Present Disclosure" below, the sequence of which is set forth in Table 1; AIN457 (also known as secukinumab and disclosed in U.S. Pat. No. 7,807,155 and WO2006 / 013107, which are incorporated by reference in their entireties) or an antigen-binding fragment thereof; LY2439821 (also known as ixekizumab; disclosed in U.S. Patent Nos. 7,838,638 and 8,110,191, and WO 2007 / 070750, which are incorporated by reference in their entireties) or an antigen-binding fragment thereof; SCH900117 or its antigen-binding fragment (Merck); RG4943 or its antigen-binding fragment (Roche); Anti-IL-17A antibodies or antigen-binding fragments thereof are disclosed in WO2006 / 013107, WO2006 / 054059, WO2007 / 070750, WO2007 / 149032, WO2008 / 001063, WO2008 / 021156, WO2010 / 034443, WO2010 / 102251, WO2012 / 018767, WO2014 / 161570, WO2014 / 001368, WO2014 / 122613, WO2015 / 070697, WO2015 / 137843, WO2016 / 048188, WO2016 / 113557, WO2016 / 138842, WO2017 / 068472, which are incorporated herein by reference in their entireties.
[0215] Preferred domains that specifically bind to IL-17A for use in the multispecific antibodies of the present disclosure include, but are not limited to, the humanized monoclonal antibodies or binding domains thereof provided below, the sequences of which are set forth in Table 1.
[0216] Accordingly, in one embodiment, the present disclosure provides a first domain that specifically binds to human IL-17A and a second domain that specifically binds to TNFα, wherein said first domain comprises a set of CDRs (HCDR1, HCDR2, HCDR3, LDCR1, LDCR2, and LDCR3), wherein said set of CDRs is selected from a set of CDRs [wherein (i) HCDR1′ is a sequence selected from any one of SEQ ID NOs: 1, 4, and 7, preferably SEQ ID NO: 1; HCDR2′ is an amino acid sequence selected from any one of SEQ ID NOs: 2, 5, and 8, preferably SEQ ID NO: 2; HCDR3′ is an amino acid sequence selected from any one of SEQ ID NOs: 3, 6, and 9, preferably SEQ ID NO: 3; LCDR1′ is an amino acid sequence selected from any one of SEQ ID NOs: 12, 15, and 18, preferably SEQ ID NO: 12; LCDR2′ is an amino acid sequence selected from SEQ ID NOs: 13, 16, and 19, preferably SEQ ID NO: 13; and LCDR3' has an amino acid sequence selected from any one of SEQ ID NOs: 14, 17, and 20, preferably SEQ ID NO: 14; or (ii) wherein HCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45, preferably SEQ ID NO: 39; HCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46, preferably SEQ ID NO: 40; HCDR3' has an amino acid sequence selected from any one of SEQ ID NOs: 41, 44, and 47, preferably SEQ ID NO: 40; LCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 50, 53, and 56, preferably SEQ ID NO: 50; and LCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 51, 54, and 57, preferably SEQ ID NO: 51;and LCDR3' has an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58, preferably SEQ ID NO: 52, with 10 or fewer amino acid substitutions, for example, 9 or fewer amino acid substitutions, 8 or fewer amino acid substitutions, 7 or fewer amino acid substitutions, 6 or fewer amino acid substitutions, 5 or fewer amino acid substitutions, 4 or fewer amino acid substitutions, 3 or fewer amino acid substitutions, 2 or fewer amino acid substitutions, 1 or 0 amino acid substitutions, preferably 0 amino acid substitutions;
[0217] In particular, the present disclosure provides multispecific antibodies comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said first domain comprises a VH CDR having the amino acid sequence of any one of the VH CDRs listed in Table 1. In particular, said domain comprises (or alternatively consists of) one, two, three, or more VH CDRs having the amino acid sequence of any of the VH CDRs set forth in Table 1.
[0218] Suitably, the first domain that specifically binds to IL-17A comprises a heavy chain variable region (VH), wherein said VH comprises, in order: (i) three complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein said HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 1, 4 and 7, said HCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 2, 5 and 8, and said HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 3, 6 and 9. In particular, the present disclosure provides antibodies that have binding specificity for human IL-17A and that comprise the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively; or (ii) three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein said HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45, said HCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46, and said HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 41, 44, and 47. In particular, the present disclosure provides antibodies that have binding specificity for human IL-17A and that comprise the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively.
[0219] The present disclosure also provides a multispecific antibody comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, wherein the first domain comprises a VL CDR having the amino acid sequence of any one of the VL CDRs listed in Table 1. In particular, the first domain that specifically binds to IL-17A comprises (or consists of) one, two, three, or more VL CDRs having the amino acid sequence of any of the VL CDRs listed in Table 1.
[0220] Suitably, the first domain that specifically binds to IL-17A comprises a light chain variable region (VL), wherein the VL comprises, in order: (i) three complementarity determining regions LDCR1, LDCR2 and LDCR3, wherein the LDCR1 has an amino acid sequence selected from any one of SEQ ID NOs: 12, 15 and 18, the LCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 13, 16 and 19, and the LCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 14, 17 and 20. In particular, the present disclosure provides antibodies having binding specificity for human IL-17A and comprising the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively; or (ii) three complementarity determining regions, LCDR1, LCDR2, and LCDR3, wherein the LCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 50, 53, and 56, the LCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 51, 54, and 57, and the LDCR3 has an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58. In particular, the present disclosure provides antibodies having binding specificity for human IL-17A and comprising the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively.
[0221] Suitably, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said first domain comprises a heavy chain variable region (VH) and a light chain variable region (VL); (i) where (a) the VH comprises, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein the HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 1, 4, and 7, the HCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 2, 5, and 8, and the HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 3, 6, and 9; and (b) the VL comprises, in order, three complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein the LCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 12, 15, and 18, the LCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 13, 16, and 19, and the LCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 14, 17, and 20; or (ii) where (a) the VH comprises, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein the HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45, the HCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46, and the HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 41, 44, and 47; and (b) The VL comprises, in order, three complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein the LCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 50, 53, and 56, the LCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 51, 54, and 57, and the LCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58.
[0222] In particular, the present disclosure provides multispecific antibodies comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, wherein the first domain comprises (i)(a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and (b) the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively, or (ii)(a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and (b) the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively.
[0223] Other domains of the present disclosure that specifically bind to IL-17A have been mutated but comprise amino acids in their CDR regions that have at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the CDR regions set forth in the sequences in Table 1. Suitably, other domains of the present disclosure that specifically bind to IL-17A comprise mutated amino acid sequences in which no more than 1, 2, 3, 4, 5, or 10 amino acids in the CDR regions have been mutated by amino acid deletion, insertion, or substitution when compared to the CDR regions set forth in the sequences in Table 1. The mutations, e.g., substitutions, can be made at any residue within the set of CDRs and may be within CDR1, CDR2, and / or CDR3.
[0224] The term "amino acid" refers to naturally occurring amino acids, synthetic amino acids, and amino acid analogs and amino acid mimetics that function similarly to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those that are later modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. This term applies to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of the corresponding naturally occurring amino acid, as well as to natural and non-natural amino acid polymers. Unless otherwise specified, a particular polypeptide sequence also implicitly encompasses conservatively modified variants thereof.
[0225] The techniques necessary to make mutations, e.g., substitutions, within CDRs, antibody VH or VL domains, and antibody amino acid sequences are generally available in the art. Mutations, e.g., substitutions, are used to generate variant sequences that may or may not be predicted to have minimal or beneficial effects on activity, and may or may not be tested for the ability to bind to and / or neutralize IL-17A or TNFα or human serum albumin, and / or other desirable properties. Because suitable mutations, e.g., substitutions, within CDRs do not result in loss of function, antibodies or binding domains thereof of the present disclosure comprising such mutated amino acid sequences retain the ability to bind to and / or neutralize IL-17A or TNFα or human serum albumin. For example, they may retain the same quantitative binding and / or neutralizing ability as the unaltered domain of the present disclosure, as measured, for example, by the assays described herein. Suitably, domains of the present disclosure of antigen-binding fragments comprising such mutated amino acid sequences may have improved ability to bind to and / or neutralize IL-17A or TNFα or human serum albumin. Suitably, a first domain of the present disclosure which specifically binds to IL-17A and comprises such a mutated amino acid sequence has the ability to neutralise IL-17A with a potency (relative potency) of greater than 2, for example greater than 5, greater than 10, greater than 15, greater than 20, greater than 25, greater than 30, greater than 35, greater than 40, greater than 45, preferably greater than 50, compared to the potency of secukinumab as determined by measuring Gro-α secretion in an HT-29 assay, wherein said relative potency is the IC50 of secukinumab as determined by an HT-29 assay. 50 values (ng / mL) and IC of the multispecific antibodies as determined by HT-29 assay 50 The ratio is the value (ng / mL).
[0226] Furthermore, suitable mutations, e.g., substitutions, within the CDRs do not result in loss of solubility, stability, and high-yield productivity of the multispecific antibodies of the present disclosure, such that multispecific antibodies of the present disclosure or binding domains thereof comprising such altered amino acid sequences retain their biophysical properties. For example, they may retain the same high-yield productivity and / or stability as the unaltered multispecific antibodies of the present disclosure, as measured, for example, by the assays described herein. Suitably, multispecific antibodies of the present disclosure or binding domains thereof comprising such altered amino acid sequences may have improved biophysical properties.
[0227] The terms "identical" or "identity," in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that are the same. "Percent (%) sequence identity" and "homology," with respect to nucleic acid, peptide, polypeptide, or antibody sequences, are defined as the percentage of nucleotides or amino acid residues in a candidate sequence that are identical with amino acid residues in a particular peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering conservative substitutions as part of the sequence identity. Alignment to determine percent amino acid sequence identity can be accomplished in a variety of ways that are within the skill of those in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or ALIGN software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
[0228] In sequence comparison, one sequence typically serves as a reference sequence and is compared to test sequences. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated as needed, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identity of the test sequence relative to the reference sequence based on the program parameters.
[0229] Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described, respectively, in Altschul et al., Nuc. Acids Res. 25:3389-3402, 1977, and Altschul et al., J. Mol. Biol. 215:403-410, 1990. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
[0230] The percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17, 1988) incorporated into the ALIGN program (version 2.0), using a PAM120 weighting table, a gap length penalty of 12, and a gap penalty of 4. Additionally, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. 48:444-453, 1970) algorithm incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossom62 matrix or a PAM250 matrix, and gap weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6.
[0231] Suitably, the first domain that specifically binds to IL-17A of the multispecific antibody of the present disclosure comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: (i) (a) the VH comprises three complementarity determining regions HCDR1, HCDR2, and HCDR3, in order; the HCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 1, 4, and 7, preferably SEQ ID NO: 1; the HCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 2, 5, and 8, preferably SEQ ID NO: 2; the HCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 3, 6, and 9, preferably SEQ ID NO: 3; and / or (b) the VL comprises three complementarity-determining regions LCDR1, LCDR2, and LCDR3, in order; the LCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 12, 15, and 18, preferably SEQ ID NO: 12; the LCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 13, 16, and 19, preferably SEQ ID NO: 13; the LCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 14, 17, and 20, preferably SEQ ID NO: 14; or
[0232] (ii) (a) the VH comprises three complementarity determining regions HCDR1, HCDR2, and HCDR3, in order; the HCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 39, 42, and 45, preferably SEQ ID NO: 39; the HCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 40, 43, and 46, preferably SEQ ID NO: 40; the HCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 41, 44, and 47, preferably SEQ ID NO: 41; and / or (b) the VL comprises three complementarity-determining regions LCDR1, LCDR2, and LCDR3, in order; the LCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 50, 53, and 56, preferably SEQ ID NO: 50; the LCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 51, 54, and 57, preferably SEQ ID NO: 51; The LCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 52, 55, and 58, preferably SEQ ID NO: 52.
[0233] Suitably, the first domain that specifically binds to IL-17A comprises: (i) HCDR1, HCDR2, and HCDR3 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the sequences of SEQ ID NOs: 1, 2, and 3, respectively, and / or LCDR1 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the sequences of SEQ ID NOs: 12, 13, and 14, respectively; LCDR2 and LCDR3; or (ii) HCDR1, HCDR2, and HCDR3 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the sequences of SEQ ID NOs: 39, 40, and 41, respectively, and / or LCDR1, LCDR2, and LCDR3 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the sequences of SEQ ID NOs: 50, 51, and 52, respectively.
[0234] In a further embodiment, the first domain that specifically binds to IL-17A comprises a heavy chain variable region VHA and a light chain variable region VLA.
[0235] In the context of the present disclosure, the terms "VH" (variable heavy chain or heavy chain variable region), "VL" (variable light chain or light chain variable region), "Vκ," and "Vλ" refer to a family of antibody heavy and light chain sequences grouped according to sequence identity and homology. Methods for determining sequence homology and grouping sequences by homology, for example by using homology search matrices such as BLOSUM (Henikoff, S. & Henikoff, JG, Proc. Natl. Acad. Sci. USA 89 (1992) 10915-10919), are well known to those skilled in the art. For VH, Vκ, and Vλ, different subfamilies can be identified, as shown, for example, in Knappik et al., J. Mol. Biol. 296 (2000) 57-86, which group VH into VH1A, VH1B, and VH2 to VH6, Vκ into Vκ1 to Vκ4, and Vλ into Vλ1 to Vλ3. In vivo, antibody Vκ, Vλ, and VH chains are the result of random rearrangement of germline κ chain V and J segments, germline λ chain V and J segments, and heavy chain V, D, and J segments, respectively. The subfamily to which a particular antibody variable chain belongs is determined by the corresponding V segment, specifically the framework regions FR1 to FR3. Thus, in the present application, any VH sequence characterized by a particular set of framework regions HFR1 to HFR3 only can be combined with any HFR4 sequence, for example, an HFR4 sequence taken from one of the heavy chain germline J segments or an HFR4 sequence taken from a rearranged VH sequence.
[0236] Suitably, the first domain of the multispecific antibody of the present disclosure that specifically binds to IL-17A comprises a heavy chain variable region VHA, wherein said VHA is VH1A, VH1B, VH3, or VH4. In one embodiment, the first domain of the present disclosure that specifically binds to IL-17A comprises a heavy chain variable region VHA, wherein said VHA is VH4. In a preferred embodiment, the first domain of the present disclosure that specifically binds to IL-17A comprises a heavy chain variable region VHA, wherein said VHA is VH3.
[0237] Suitably, the first domain of the multispecific antibody of the present disclosure that specifically binds to IL-17A comprises a light chain variable region VLA, wherein said VLA comprises Vκ framework FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 framework FR1-FR3, and framework FR4, wherein said framework FR4 is selected from Vκ FR4, particularly Vκ1 FR4, Vκ3 FR4, and Vλ FR4. Suitable Vλ FR4s are those set forth in SEQ ID NOs: 26 to 32. In one embodiment, the first domain that specifically binds to IL-17A comprises a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any of SEQ ID NOs: 26 to 32, preferably SEQ ID NO: 26 or SEQ ID NO: 27, more preferably SEQ ID NO: 27. Suitably, the first domain that specifically binds to IL-17A comprises a Vλ FR4 comprising an amino acid sequence selected from any of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 set forth in SEQ ID NO: 26 or 27, more preferably a Vλ FR4 set forth in SEQ ID NO: 27.
[0238] Accordingly, in one embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, wherein said first domain comprises: (i)(a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively; or (i)(b) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively; (ii) a VH3 or VH4 domain, preferably a VH3 domain; and (iii) A VL domain comprising a VL framework comprising Vκ frameworks FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 FR1-FR3, and framework FR4, wherein the framework FR4 is selected from Vκ FR4, particularly Vκ1 FR4, Vκ3 FR4, and Vλ FR4, particularly a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any one of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 set forth in an amino acid sequence selected from any one of SEQ ID NOs: 26 to 32, and more preferably a Vλ FR4 set forth in SEQ ID NO: 27.
[0239] Suitably, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said first domain comprises a VH as set forth in Table 1. Suitably, the present disclosure also provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said first domain comprises (or alternatively consists of) a VH amino acid sequence as set forth in Table 1, wherein about 20 or fewer amino acids, preferably 10 or fewer amino acids, in the framework sequence (e.g., a sequence that is not a CDR) have been mutated (wherein the mutations are additions, substitutions, or deletions, as various non-limiting examples). Other domains of the present disclosure that specifically bind IL-17A have been mutated but have amino acids in the VH region that have at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the VH region set forth in the sequence set forth in Table 1.
[0240] Suitably, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said first domain comprises a VL domain set forth in Table 1. Suitably, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said first domain comprises (or alternatively consists of) a VL amino acid sequence set forth in Table 1, and wherein no more than about 20 amino acids, preferably no more than about 10 amino acids, have been mutated in the framework sequence (e.g., a sequence that is not a CDR) (wherein the mutations are additions, substitutions, or deletions, as various non-limiting examples). Other domains of the present disclosure that specifically bind IL-17A include mutated amino acids in the VL region that have at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the VL region set forth in the sequence set forth in Table 1.
[0241] In one embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, wherein said first domain comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to amino acid sequence SEQ ID NO: 10 or SEQ ID NO: 11, preferably SEQ ID NO: 10, and in particular said domain comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively. In a further embodiment, the first domain that specifically binds to IL-17A comprises a heavy chain variable region comprising an amino acid sequence that is at least 90% identical to amino acid sequence SEQ ID NO: 11, and said heavy chain variable region comprises Q14K, G16E, and G56A (AHo numbering).
[0242] In another embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, wherein said first domain comprises a heavy chain variable region comprising an amino acid sequence at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to amino acid sequence SEQ ID NO: 48 or SEQ ID NO: 49, preferably SEQ ID NO: 48, and in particular, said domain comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively. In a further embodiment, the present disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein said antibody comprises a heavy chain variable region comprising an amino acid sequence at least 90% identical to amino acid sequence SEQ ID NO: 49, and said heavy chain variable region comprises R20T and Q141P (AHo numbering).
[0243] In another embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said first domain comprises (i) a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:21 or SEQ ID NO:22, preferably SEQ ID NO:21; particularly wherein said antibody is or (ii) a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 59 or SEQ ID NO: 60, preferably SEQ ID NO: 59, particularly wherein the antibody comprises the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NO: 50, 51, and 52, respectively.
[0244] In another embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said first domain comprises a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence SEQ ID NO: 22, and wherein said light chain variable region comprises A51P (AHo numbering).
[0245] In a further embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said first domain comprises: (i) a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 10; and (ii) a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 21. or (ii) a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:48, and a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:59.
[0246] Preferably, the first domain that specifically binds to IL-17A of the multispecific antibody of the present disclosure comprises: (i) a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 10; and (ii) a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 21. comprise a light chain variable region comprising amino acid sequences that are at least 90% identical, wherein the antibody comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and / or the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively; particularly, wherein the antibody comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively. , LDCR2, and LDCR3 sequences; or (ii) a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:48; and an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:59. and a light chain variable region comprising the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and / or the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively; particularly the antibody comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively.
[0247] In certain embodiments, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, wherein said first domain comprises (i) a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 11; and / or a VL comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 21 and 22, or (ii) a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 48 and 19; and / or a VL comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 59 and 60.
[0248] In certain embodiments, the first domain that specifically binds to IL-17A comprises (i) the VH sequence of SEQ ID NO: 10 and the VL sequence of SEQ ID NO: 21, or (ii) the VH sequence of SEQ ID NO: 48 and the VL sequence of SEQ ID NO: 59. In yet another specific embodiment, the first domain that specifically binds to IL-17A comprises (i) the VH sequence of SEQ ID NO: 11 and the VL sequence of SEQ ID NO: 22, or (ii) the VH sequence of SEQ ID NO: 49 and the VL sequence of SEQ ID NO: 60.
[0249] In one embodiment, the domain that specifically binds to human IL-17A is a domain set forth in Table 1. In one embodiment, the domain that specifically binds to human IL-17A comprises an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to (i) an amino acid sequence selected from the group consisting of SEQ ID NOs: 24 and 25, preferably SEQ ID NO: 24, or (ii) an amino acid sequence selected from the group consisting of SEQ ID NOs: 61 and 62, preferably SEQ ID NO: 61. In one embodiment, the domain that specifically binds to human IL-17A is set forth in (i) SEQ ID NO: 24 or SEQ ID NO: 25, preferably SEQ ID NO: 24, or (ii) SEQ ID NO: 61 or SEQ ID NO: 62, preferably SEQ ID NO: 61.
[0250] Other domains of the present disclosure that have binding specificity for human IL-17A include domains in which the amino acids or nucleic acids encoding the amino acids have been mutated, but which have at least 60, 70, 80, 90, or 95% identity to the sequences set forth in Table 1. In one embodiment, this includes variant amino acid sequences in which no more than 1, 2, 3, 4, or 5 amino acids have been mutated in the variable regions when compared to the variable regions set forth in the sequences set forth in Table 1, while retaining substantially the same activity. The term "substantially the same activity" as used herein refers to an activity that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 100%, or at least 110%, or at least 120%, or at least 130%, or at least 140%, or at least 150%, or at least 160%, or at least 170%, or at least 180%, or at least 190%, such as up to 200%, of the activity determined for a parent antibody, e.g., a multispecific antibody of the disclosure, in particular a multispecific antibody of the disclosure comprising a first domain that specifically binds human IL-17A as described in Table 1, and / or a second domain that specifically binds human TNFα as described in Table 1.
[0251] In yet another embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said first domain comprises an amino acid sequence homologous to a sequence set forth in Table 1, and wherein said first domain binds to human IL-17A and retains desirable functional properties of the domains set forth in Table 1.
[0252] In one embodiment, a domain of the present disclosure that specifically binds to IL-17A has a heavy chain variable region comprising HCDR1, HCDR2, and HCDR3 sequences, and a light chain variable region comprising LDCR1, LDCR2, and LDCR3 sequences, wherein one or more of these CDR sequences have a particular amino acid sequence based on the domains described herein or conservative modifications thereof, and said domain retains the desired functional properties of the antibodies of the present disclosure.
[0253] The term "conservatively modified variants" or "conservative variants" applies to both amino acid and nucleic acid sequences. With respect to a particular nucleic acid sequence, conservatively modified variants refer to nucleic acids that encode identical or essentially identical amino acid sequences, or that do not encode essentially identical amino acid sequences. Due to the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For example, the codons GCA, GCC, GCG, and GCU all encode the amino acid alanine. Thus, at every position where alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variants are "silent variants," which are one species of conservatively modified variant. Every nucleic acid sequence herein that encodes a polypeptide also describes every possible silent variant of the nucleic acid. Those of skill in the art will recognize that each codon in a nucleic acid (except AUG, which is usually the only codon for methionine, and TGG, which is usually the only codon for tryptophan) can be modified to produce a functionally identical molecule. Thus, each silent variant of a nucleic acid that encodes a polypeptide is implicit in each described sequence.
[0254] In the case of polypeptide sequences, "conservatively modified variants" or "conservative variants" include individual substitutions, deletions, or additions to a polypeptide sequence that result in the replacement of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants (i.e., having one or more "conservative modifications") are in addition to, and do not exclude, polymorphic variants, interspecies homologs, and alleles of the present disclosure. The following eight groups contain amino acids that are conservatively substituted for one another: 1) alanine (A), glycine (G); 2) aspartic acid (D), glutamic acid (E); 3) asparagine (N), glutamine (Q); 4) arginine (R), lysine (K); 5) isoleucine (I), leucine (L), methionine (M), valine (V); 6) phenylalanine (F), tyrosine (Y), tryptophan (W); 7) serine (S), threonine (T); and 8) cysteine (C), methionine (M) (see, e.g., Creighton, Proteins (1984)). In one embodiment, the term "conservative sequence modifications" is used to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence.
[0255] Accordingly, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said first domain comprises (or consists of):
[0256] (i) A heavy chain variable region (VH) comprising, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the amino acid sequence SEQ ID NO: 1 or a conservative variant thereof; HCDR2 has the amino acid sequence SEQ ID NO: 2 or a conservative variant thereof; and HCDR3 has the amino acid sequence selected from any one of SEQ ID NO: 3 or a conservative variant thereof; and a light chain variable region (VL) comprising, in order, three complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein said LCDR1 has the amino acid sequence SEQ ID NO: 12 or a conservative variant thereof; said LCDR2 has the amino acid sequence SEQ ID NO: 13 or a conservative variant thereof; and said LCDR3 has the amino acid sequence SEQ ID NO: 14 or a conservative variant thereof; or (ii) A heavy chain variable region (VH) comprising, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein HCDR1 is the amino acid sequence SEQ ID NO: 39 or a conservative variant thereof; HCDR2 is the amino acid sequence SEQ ID NO: 40 or a conservative variant thereof; and HCDR3 is the amino acid sequence selected from any one of SEQ ID NO: 41 or a conservative variant thereof; and a light chain variable region (VL) comprising, in order, three complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein said LCDR1 has the amino acid sequence SEQ ID NO: 50 or a conservative variant thereof; said LCDR2 has the amino acid sequence SEQ ID NO: 51 or a conservative variant thereof; and said LCDR3 has the amino acid sequence SEQ ID NO: 52 or a conservative variant thereof; wherein the antibody specifically binds to and / or neutralizes human IL-17A.
[0257] Anti-IL-17A antibodies of the present disclosure The present disclosure is based on the discovery of antibody molecules that specifically bind to human IL-17A and have improved affinity, potency, and selectivity. Furthermore, the antibodies of the present disclosure have improved biophysical properties, such as improved solubility, developability, high productivity with relatively few impurities (>98%, specifically >99% monomer as detected by SE-HPLC), and stability.
[0258] In one aspect, the present disclosure provides an isolated antibody having binding specificity for human IL-17A and comprising a set of CDRs (HCDR1, HCDR2, HCDR3, LDCR1, LDCR2, and LDCR3), wherein the set of CDRs is a set of CDRs [wherein: (i) HCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 1, 4, and 7, preferably SEQ ID NO: 1; HCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 2, 5, and 8, preferably SEQ ID NO: 2; HCDR3' is an amino acid sequence selected from any one of SEQ ID NOs: 3, 6, and 9, preferably SEQ ID NO: 3; LCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 12, 15, and 18, preferably SEQ ID NO: 12; LCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 13, 16, and 19, preferably SEQ ID NO: 13; LCDR3' has an amino acid sequence selected from any one of SEQ ID NOs: 14, 17, and 20, preferably SEQ ID NO: 14; or (ii) HCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45, preferably SEQ ID NO: 39; HCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46, preferably SEQ ID NO: 40; HCDR3' is an amino acid sequence selected from any one of SEQ ID NOs: 41, 44, and 47, preferably SEQ ID NO: 40; LCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 50, 53, and 56, preferably SEQ ID NO: 50; LCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 51, 54 and LCDR3' has an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58, preferably SEQ ID NO: 52; ..., with 10 or fewer amino acid substitutions, for example, 9 or fewer amino acid substitutions, 8 or fewer amino acid substitutions, 7 or fewer amino acid substitutions, 6 or fewer amino acid substitutions, 5 or fewer amino acid substitutions, 4 or fewer amino acid substitutions, 3 or fewer amino acid substitutions, 2 or fewer amino acid substitutions, 1 or 0 amino acid substitutions, preferably 0 amino acid substitutions.
[0259] The term "IL-17A" or "IL17A" specifically refers to human IL-17A having UniProt ID number Q16552, reproduced herein as SEQ ID NO: 33. The term "cynomolgus IL-17A" or "cynomolgus monkey IL-17A" refers to cynomolgus monkey (Macaca fascicularis) IL-17A having UniProt ID number G1QUS7.
[0260] The term "IL-17B" refers in particular to human IL-17B having UniProt ID number Q9UHF5, reproduced herein as SEQ ID NO: 34. The term "IL-17C" refers in particular to human IL-17C having UniProt ID number Q9P0M4, reproduced herein as SEQ ID NO: 35. The term "IL-17D" refers in particular to human IL-17D having UniProt ID number Q8TAD2, reproduced herein as SEQ ID NO: 36. The term "IL-17E" refers in particular to human IL-17E having UniProt ID number Q9H293, reproduced herein as SEQ ID NO: 37. The term "IL-17F" refers in particular to human IL-17F having UniProt ID number Q96PD4, reproduced herein as SEQ ID NO: 38.
[0261] The term "epitope" refers to a localized region of an antigen to which an antibody can specifically bind. An epitope can be, for example, contiguous amino acids of a polypeptide, or an epitope can be, for example, comprised of two or more non-contiguous regions of two or more polypeptides.
[0262] As used herein, the term "antibody" and the like includes whole antibodies; any antigen-binding fragment (i.e., "antigen-binding portion") of a whole antibody or single chain thereof; and molecules comprising antibody CDRs, VH regions, or VL regions (including, but not limited to, multispecific antibodies). A naturally occurring "whole antibody" is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain is composed of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is composed of three domains, CH1, CH2, and CH3. Each light chain is composed of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is composed of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability called complementarity-determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant regions of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
[0263] As used herein, the term "isotype" refers to the antibody class provided by the heavy chain constant region genes (e.g., IgM, IgE, IgD, IgA, IgY, and IgG, such as IgG1 or IgG4). Isotype also includes modified versions of one of these classes, in which changes have been made to modify Fc function, for example to enhance or reduce effector function or binding to an Fc receptor. Suitably, the antibody of the disclosure is an IgG selected from the group consisting of IgG1, IgG2, IgG3, and IgG4. More suitably, the antibody of the disclosure is an IgG1 or IgG4.
[0264] As used herein, the terms "antigen-binding fragment," "antigen-binding portion," and the like refer to one or more fragments of an intact whole antibody that retain the ability to specifically bind to a given antigen (e.g., IL-17A). Examples of binding fragments encompassed by the term "antigen-binding portion" of an antibody include a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; a F(ab)2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CH1 domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; and a single-domain antibody (dAb) fragment consisting of the VH domain (Ward et al., 1989 Nature ). 341:544-546); including isolated complementarity determining regions (CDRs), dsFv, scAb, STAB, single domain antibodies (sdAb or dAb), single domain heavy chain antibodies, and single domain light chain antibodies, VHH, VNAR, single domain antibodies based on shark VNAR structures, and binding domains based on alternative scaffolds including, but not limited to, ankyrin-based domains, phinomers, avimers, anticalins, fibronectin, and binding sites engineered into the constant region of an antibody (e.g., F-star's Modular Antibody Technology™).
[0265] The term "complementarity determining region" ("CDR") refers to an amino acid sequence having boundaries determined using any of several well-known schemes, e.g., the Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 ("Chothia" numbering scheme), ImMunoGenTics (IMGT) numbering (Lefranc, M.-P., The Immunologist, 7, 132-136 (1999); Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003) ("IMGT" numbering scheme), and Honegger & Pluckthun, J. Mol. Biol. 309 (2001) 657-670 ("AHo" numbering). For example, in the classical format, in Kabat, the CDR amino acid residues of the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3), and the CDR amino acid residues of the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). In Chothia, the CDR amino acids of the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3), and the amino acid residues of the VL are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3).Combining the Kabat and Chothia CDR definitions, the CDRs are composed of amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3) in human VH, and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) in human VL. In IMGT, the CDR amino acid residues in VH are numbered approximately 26-35 (HCDR1), 51-57 (HCDR2), and 93-102 (HCDR3), and the CDR amino acid residues in VL are numbered approximately 27-32 (LCDR1), 50-52 (LCDR2), and 89-97 (LCDR3) ("Kabat" numbering). In IMGT, antibody CDRs can be determined using the program IMGT / DomainGapAlign.
[0266] In the context of the present invention, unless otherwise specified, the numbering system proposed by Honegger & Plückthun ("AHo") is used (Honegger & Plückthun, J. Mol. Biol. 309 (2001) 657-670).Furthermore, the following residues are defined as CDRs according to the AHo numbering scheme: LCDR1 (also referred to as CDR-L1): L24-L42; LCDR2 (also referred to as CDR-L2): L58-L72; LCDR3 (also referred to as CDR-L3): L107-L138; HCDR1 (also referred to as CDR-H1): H27-H42; HCDR2 (also referred to as CDR-H2): H57-H76; HCDR3 (also referred to as CDR-H3): H108-H138. For clarity, the numbering system by Honegger & Plückthun takes into account the length diversity found in naturally occurring antibodies in the various VH and VL subfamilies, both in particular the CDRs, and provides for gaps in the sequences, and therefore, in a given antibody variable domain, not all positions 1 to 149 are typically occupied by amino acid residues.
[0267] Preferably, the "antigen-binding region" comprises at least amino acid residues 4-138 of the variable light chain (VL) and amino acid residues 5-138 of the variable heavy chain (VH) (in each case according to Honegger & Pluichthun numbering), more preferably amino acid residues 3-144 of the VL and 4-144 of the VH, and particularly preferably the complete VL and VH chains (amino acid positions 1-149 of the VL and 1-149 of the VH). Antigen-binding portions can also be incorporated into single domain antibodies, maxibodies, minibodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs, and bis-scFvs (see, e.g., Holliger and Hudson, 2005, Nature Biotechnology, 23, 9, 1 Hel 1 36). Antigen-binding portions of antibodies can be grafted onto polypeptide-based scaffolds such as fibronectin type III (Fn3) (see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide monobodies). Antigen-binding portions can also be incorporated into single-chain molecules comprising a pair of tandem Fv segments (VH-CH1-VH-CH1) that, together with complementary light chain polypeptides, form a pair of antigen-binding regions (Zapata et al., 1995 Protein Eng. 8 (10): 1057-1062; and U.S. Pat. No. 5,641,870).
[0268] As used herein, the terms "domain" or "domain that specifically binds to X" or "binding domain," "antigen-binding fragment thereof," "antigen-binding portion," and the like of an antibody refer to one or more fragments of an intact whole antibody that retain the ability to specifically bind to a given antigen (e.g., IL-17A, TNFα, HSA, etc.). The antigen-binding function of an antibody is performed by fragments of the intact antibody. In some embodiments, the binding domain of a multispecific antibody of the disclosure is selected from the group consisting of: a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; a F(ab)2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CH1 domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a single-domain antibody (dAb) fragment consisting of the VH domain (Ward et al., 1989 Nature 102:101-102). 341:544-546); isolated complementarity determining regions (CDRs), dsFvs, scAbs, STABs, single domain antibodies (sdAbs or dAbs), single domain heavy chain antibodies, and single domain light chain antibodies, VHHs, VNARs, single domain antibodies based on shark VNAR structures, and binding domains based on alternative scaffolds, including, but not limited to, ankyrin-based domains, phinomers, avimers, anticalins, fibronectin, and binding sites incorporated into antibody constant regions (e.g., F-star's Modular Antibody Technology™). Suitably, the binding domain of the present disclosure is an Fv fragment (Fv). Suitably, the binding domain of the present disclosure is a single-chain Fv fragment (scFv). Suitably, the binding domain of the present disclosure is a Fab fragment.
[0269] Preferably, the "domain" or "domain that specifically binds to X" or "binding domain," "antigen-binding fragment thereof," or "antigen-binding portion" comprises at least amino acid residues 4 to 138 of the variable light chain (VL) and amino acid residues 5 to 138 of the variable heavy chain (VH) (in each case numbered according to Honegger & Plückthun), more preferably amino acid residues 3 to 144 of the VL and amino acid residues 4 to 144 of the VH, and particularly preferred are the complete VL and VH chains (amino acid positions 1 to 149 of the VL and amino acid positions 1 to 149 of the VH). Antigen-binding portions can also be incorporated into single-domain antibodies, maxibodies, minibodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs, and bis-scFvs (see, e.g., Holliger and Hudson, 2005, Nature Biotechnology, 23, 9, 1 Hel 1 36). Antigen-binding portions of antibodies can be grafted onto polypeptide-based scaffolds such as fibronectin type III (Fn3) (see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide monobodies). Antigen-binding portions can also be incorporated into single-chain molecules comprising a pair of tandem Fv segments (VH-CH1-VH-CH1) that, together with complementary light chain polypeptides, form a pair of antigen-binding regions (Zapata et al., 1995 Protein Eng. 8 (10): 1057-1062; and U.S. Pat. No. 5,641,870).
[0270] As used herein, the terms "binding specificity" or "specifically binds" refer to the ability of an individual antibody or antibody domain to react with one antigenic determinant but not with a different antigenic determinant. As used herein, the terms "specifically binds to" or "specific for" refer to a measurable and reproducible interaction, such as the binding of a target to an antibody or antibody domain, that determines the presence of the target in the presence of a heterogeneous population of molecules, including biomolecules. For example, an antibody or antibody domain that specifically binds to a target (which may be an epitope) is an antibody or antibody domain that binds to this target with higher affinity, avidity, more readily, and / or for a longer duration than it binds to other targets. In its most general form (and unless a defining reference is cited), "specific binding" refers to the ability of an antibody or antibody domain to distinguish between a target of interest and unrelated molecules, as determined, for example, according to specificity assay methods known in the art. Such methods include, but are not limited to, Western blot, ELISA, RIA, ECL, IRMA, SPR (surface plasmon resonance) testing, and peptide scanning. For example, a standard ELISA assay can be performed. Scoring can be performed using standard color development (e.g., secondary antibodies using horseradish peroxide and tetramethylbenzidine using hydrogen peroxide). Reactions in specific wells are scored, for example, by optical density at 450 nm. A typical background (=negative reaction) is approximately 0.1 OD. A typical positive reaction can be approximately 1 OD. This means that the ratio of positive scores to negative scores can be 10-fold or greater. In a further example, an SPR assay can be performed, and a difference of at least 10-fold, preferably at least 100-fold, between background and signal indicates specific binding. Typically, binding specificity is determined using a set of approximately 3-5 unrelated molecules, such as milk powder or transferrin, rather than a single reference molecule. Certain antibodies or antibody domains of the present disclosure have binding specificity for human IL-17A or human TNFα.
[0271] The multispecific antibodies of the present disclosure comprise a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, and thus have binding specificity for IL-17A and TNFα, and in particular for human IL-17A and human TNFα. In one embodiment, an antibody of the present disclosure has binding specificity for human IL-17A and cynomolgus monkey (Macaca fascicularis) (also known as Cynomolgus monkey or "Cynomolgus") IL-17A. In one embodiment, an antibody of the present disclosure has binding specificity for human TNFα and cynomolgus monkey (Macaca fascicularis) (also known as Cynomolgus monkey or "Cynomolgus") TNFα.
[0272] In another aspect, the disclosure relates to antibodies or antibody domains with binding specificity for human IL-17A and cynomolgus monkey (Macaca fascicularis) (also known as Cynomolgus monkey or "Cynomolgus") IL-17A.
[0273] Suitably, the anti-IL-17A antibodies of the present disclosure are isolated antibodies.
[0274] Suitably, the anti-IL-17A antibodies of the present disclosure are monoclonal antibodies.
[0275] The anti-IL-17A antibodies of the present disclosure include, but are not limited to, chimeric antibodies and humanized antibodies.
[0276] Suitably, the anti-IL-17A antibodies of the present disclosure are humanized. Suitably, the anti-IL-17A antibodies of the present disclosure are humanized and comprise CDRs from rabbit.
[0277] Antibodies of the present disclosure include, but are not limited to, the isolated humanized monoclonal antibodies described herein, including those in the Examples. Examples of such anti-human IL-17A antibodies are those whose sequences are set forth in Table 1. Additional details regarding the generation and characterization of the antibodies described herein are provided in the Examples.
[0278] The isolated antibody of the present disclosure having binding specificity for human IL-17A comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein (a) the VH comprises, in order, three complementarity-determining regions: HCDR1, HCDR2, and HCDR3, and (b) the VL comprises, in order, three complementarity-determining regions: LDCR1, LDCR2, and LDCR3.
[0279] The present disclosure provides antibodies that specifically bind to IL-17A protein, wherein the antibodies comprise a VH CDR having the amino acid sequence of any one of the VH CDRs listed in Table 1. In particular, the present disclosure provides antibodies that specifically bind to IL-17A protein, wherein the antibodies comprise one, two, three, or more VH CDRs having the amino acid sequence of any of the VH CDRs listed in Table 1.
[0280] The present disclosure provides an antibody having binding specificity to human IL-17A comprising a heavy chain variable region (VH), wherein the VH comprises, in order: (i) three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein the HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 1, 4, and 7; the HCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 2, 5, and 8; and the HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 3, 6, and 9. In particular, the present disclosure provides antibodies that have binding specificity for human IL-17A and that comprise the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively; or (ii) three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein said HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45, said HCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46, and said HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 41, 44, and 47. In particular, the present disclosure provides antibodies that have binding specificity for human IL-17A and that comprise the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively.
[0281] The present disclosure also provides antibodies that specifically bind to IL-17A protein, wherein the antibodies comprise a VL CDR having the amino acid sequence of any one of the VL CDRs listed in Table 1. In particular, the present disclosure provides antibodies that specifically bind to IL-17A protein, wherein the antibodies comprise one, two, three, or more VL CDRs having the amino acid sequence of any of the VL CDRs listed in Table 1.
[0282] The present disclosure provides an antibody having binding specificity to human IL-17A, comprising a light chain variable region (VL), wherein the VL comprises, in order: (i) three complementarity determining regions LDCR1, LDCR2, and LDCR3, wherein the LDCR1 has an amino acid sequence selected from any one of SEQ ID NOs: 12, 15, and 18; the LCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 13, 16, and 19; and the LCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 14, 17, and 20. In particular, the present disclosure provides antibodies having binding specificity for human IL-17A and comprising the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively; or (ii) three complementarity determining regions, LCDR1, LCDR2, and LCDR3, wherein the LCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 50, 53, and 56, the LCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 51, 54, and 57, and the LDCR3 has an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58. In particular, the present disclosure provides antibodies having binding specificity for human IL-17A and comprising the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively.
[0283] Suitably, the disclosure provides an antibody having binding specificity for human IL-17A, comprising a heavy chain variable region (VH) and a light chain variable region (VL),
[0284] (i) where (a) the VH comprises, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein the HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 1, 4, and 7, the HCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 2, 5, and 8, and the HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 3, 6, and 9; and (b) the VL comprises, in order, three complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein the LCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 12, 15, and 18, the LCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 13, 16, and 19, and the LCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 14, 17, and 20; or
[0285] (ii) where (a) the VH comprises, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein the HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45, the HCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46, and the HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 41, 44, and 47; and (b) The VL comprises, in order, three complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein the LCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 50, 53, and 56, the LCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 51, 54, and 57, and the LCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58.
[0286] In particular, the present disclosure provides antibodies that have binding specificity for human IL-17A and comprise (i) (a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and (b) the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively; or (ii) (a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and (b) the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively.
[0287] Other antibodies of the disclosure have been mutated but comprise amino acids in their CDR regions that have at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the CDR regions shown in the sequences set forth in Table 1. Suitably, other antibodies of the disclosure comprise mutated amino acid sequences in which no more than 1, 2, 3, 4, 5, or 10 amino acids have been mutated by amino acid deletion, insertion, or substitution in the CDR regions when compared to the CDR regions shown in the sequences set forth in Table 1. The mutations, e.g., substitutions, may be made at any residue within the set of CDRs and may be within CDR1, CDR2, and / or CDR3.
[0288] Suitably, an antibody of the present disclosure comprising a variant amino acid sequence is capable of inhibiting the activity of 1 ng of human IL-17A by 50% at a concentration of 50 ng / ml, preferably 20 ng / ml, preferably 10 ng / ml, preferably 5 ng / ml, more preferably 1 ng / ml, more preferably 0.5 ng / ml, and even more preferably 0.2 ng / ml or less, wherein said inhibitory activity is determined by measuring GRO-α secretion induced by human IL-17A in an HT-29 assay in the presence of 50 pg / ml of TNFα.
[0289] Suitably, the isolated antibody of the disclosure that has binding specificity for human IL-17A comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:
[0290] (i) (a) the VH comprises three complementarity determining regions HCDR1, HCDR2, and HCDR3, in order; the HCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 1, 4, and 7, preferably SEQ ID NO: 1; the HCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 2, 5, and 8, preferably SEQ ID NO: 2; the HCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 3, 6, and 9, preferably SEQ ID NO: 3; and / or (b) the VL comprises three complementarity-determining regions LCDR1, LCDR2, and LCDR3, in order; the LCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 12, 15, and 18, preferably SEQ ID NO: 12; the LCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 13, 16, and 19, preferably SEQ ID NO: 13; the LCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 14, 17, and 20, preferably SEQ ID NO: 14; or
[0291] (ii) (a) the VH comprises three complementarity determining regions HCDR1, HCDR2, and HCDR3, in order; the HCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 39, 42, and 45, preferably SEQ ID NO: 39; the HCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 40, 43, and 46, preferably SEQ ID NO: 40; the HCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 41, 44, and 47, preferably SEQ ID NO: 41; and / or (b) the VL comprises three complementarity-determining regions LCDR1, LCDR2, and LCDR3, in order; the LCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 50, 53, and 56, preferably SEQ ID NO: 50; the LCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 51, 54, and 57, preferably SEQ ID NO: 51; The LCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 52, 55, and 58, preferably SEQ ID NO: 52.
[0292] Suitably, the isolated antibodies of the present disclosure that have binding specificity for human IL-17A comprise: (i) HCDR1, HCDR2, and HCDR3 that have at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the sequences of SEQ ID NOs: 1, 2, and 3, respectively, and / or have at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the sequences of SEQ ID NOs: 12, 13, and 14, respectively; LCDR1, LCDR2, and LCDR3; or (ii) HCDR1, HCDR2, and HCDR3 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the sequences of SEQ ID NOs: 39, 40, and 41, respectively, and / or LCDR1, LCDR2, and LCDR3 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the sequences of SEQ ID NOs: 50, 51, and 52, respectively.
[0293] In a further embodiment, the present disclosure provides an antibody that specifically binds to human IL-17A, wherein said antibody comprises a VH domain and a VL domain.
[0294] Suitably, the present disclosure provides an antibody that specifically binds to human IL-17A, wherein the antibody comprises a VH1A, VH1B, VH3, or VH4 domain. In one embodiment, the isolated antibody of the present disclosure comprises a VH4 domain. In a preferred embodiment, the isolated antibody of the present disclosure comprises a VH3 domain.
[0295] Suitably, the present disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein the antibody comprises Vκ framework FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 framework FR1-FR3, and framework FR4, wherein the framework FR4 is selected from Vκ FR4, particularly Vκ1 FR4, Vκ3 FR4, and Vλ FR4. Suitable Vλ FR4s are those set forth in SEQ ID NOs: 26 to 32. In one embodiment, the present disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein the antibody comprises a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any of SEQ ID NOs: 26 to 32, preferably SEQ ID NO: 26 or SEQ ID NO: 27, more preferably SEQ ID NO: 27. Suitably, the present disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein the antibody comprises a Vλ FR4 comprising an amino acid sequence selected from any of SEQ ID NOs: 26 to 32, preferably the Vλ FR4 set forth in SEQ ID NO: 26 or SEQ ID NO: 27, more preferably the Vλ FR4 set forth in SEQ ID NO: 27.
[0296] Thus, in one embodiment, the present disclosure provides an antibody comprising:
[0297] (i)(a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively; or (i)(b) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively; (ii) a VH3 or VH4 domain, preferably a VH3 domain; and (iii) A VL domain comprising a VL framework comprising Vκ frameworks FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 FR1-FR3, and framework FR4, wherein the framework FR4 is selected from Vκ FR4, particularly Vκ1 FR4, Vκ3 FR4, and Vλ FR4, particularly a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 set forth in an amino acid sequence selected from any of SEQ ID NOs: 26 to 32, more preferably a Vλ FR4 set forth in SEQ ID NO: 27.
[0298] Suitably, the disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein said antibody comprises a VH domain set forth in Table 1.
[0299] Suitably, the present disclosure also provides an isolated antibody that specifically binds to human IL-17A, wherein the antibody comprises a VH amino acid sequence set forth in Table 1, wherein no more than about 10 amino acids in the framework sequence (e.g., a sequence that is not a CDR) have been mutated (mutations are additions, substitutions, or deletions, as various non-limiting examples).
[0300] Suitably, the present disclosure also provides an isolated antibody that specifically binds to human IL-17A, wherein the antibody comprises a VH amino acid sequence set forth in Table 1, wherein no more than about 20 amino acids in the framework sequence (e.g., a sequence that is not a CDR) have been mutated (mutations are additions, substitutions, or deletions, as various non-limiting examples).
[0301] Other antibodies of the disclosure are mutated but contain amino acids in the VH region that are at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to the VH regions shown in the sequences set forth in Table 1.
[0302] Suitably, the disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein said antibody comprises a VL domain set forth in Table 1.
[0303] Suitably, the present disclosure also provides an isolated antibody that specifically binds to human IL-17A, wherein the antibody comprises a VL amino acid sequence set forth in Table 1, wherein no more than about 10 amino acids in the framework sequence (e.g., a sequence that is not a CDR) have been mutated (mutations are additions, substitutions, or deletions, as various non-limiting examples).
[0304] Suitably, the present disclosure also provides an isolated antibody that specifically binds to human IL-17A, wherein the antibody comprises a VL amino acid sequence set forth in Table 1, wherein no more than about 20 amino acids in the framework sequence (e.g., a sequence that is not a CDR) have been mutated (mutations are additions, substitutions, or deletions, as various non-limiting examples).
[0305] Other antibodies of the disclosure include mutated amino acids in the VL region that are at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to the VL regions shown in the sequences set forth in Table 1.
[0306] In one embodiment, the disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein said antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to amino acid sequence SEQ ID NO: 10 or SEQ ID NO: 11, preferably SEQ ID NO: 10, and in particular said antibody comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively. In a further embodiment, the disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein said antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 90% identical to amino acid sequence SEQ ID NO: 11, and wherein said heavy chain variable region comprises Q14K, G16E, and G56A (AHo numbering).
[0307] In another embodiment, the disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein said antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:48 or SEQ ID NO:49, preferably SEQ ID NO:48, and in particular said antibody comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs:39, 40, and 41, respectively. In a further embodiment, the disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein said antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO:49, and wherein said heavy chain variable region comprises R20T and Q141P (AHo numbering).
[0308] In another embodiment, the present disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein the antibody (i) comprises a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to amino acid sequence SEQ ID NO:21 or SEQ ID NO:22, preferably SEQ ID NO:21; particularly the antibody comprises a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to amino acid sequence SEQ ID NO:12, 13, and 14, respectively. or (ii) a light chain variable region comprising an amino acid sequence which is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:59 or SEQ ID NO:60, preferably SEQ ID NO:59, in particular the antibody comprises the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs:50, 51, and 52, respectively.
[0309] In a further embodiment, the present disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein said antibody comprises a light chain variable region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 22, wherein said light chain variable region comprises A51P (AHo numbering).
[0310] In a further embodiment, the present disclosure provides an antibody that specifically binds to human IL-17A, wherein (i) the antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 10, and a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 21. or (ii) the antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:48, and a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:59.
[0311] Accordingly, the present disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein: (i) the antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 10, and a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 21. regions, wherein the antibody comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and / or the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively; in particular, the antibody comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively; or (ii) the antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:48, and a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:59. and / or LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively; particularly, the antibody comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively.
[0312] In a further embodiment, the present disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein said antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to amino acid sequence SEQ ID NO:49; and a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to amino acid sequence SEQ ID NO:60, particularly wherein said heavy chain variable region comprises R20T and Q141P (AHo numbering).
[0313] Accordingly, the present disclosure provides an isolated antibody that specifically binds to human IL-17A, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:49, and a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:60. and / or LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively, particularly wherein the antibody comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively, particularly wherein the antibody comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively.
[0314] In certain embodiments, the present disclosure provides an isolated antibody that specifically binds to human IL-17A, and comprises (i) a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 11, and / or a VL thereof comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 21 and 22; or (ii) a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 48 and 49, and / or a VL thereof comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 59 and 60. In certain embodiments, the antibody of the disclosure comprises (i) the VH sequence of SEQ ID NO: 10 and the VL sequence of SEQ ID NO: 21; or (ii) the VH sequence of SEQ ID NO: 48 and the VL sequence of SEQ ID NO: 59. In yet another specific embodiment, the antibody of the disclosure comprises (i) the VH sequence of SEQ ID NO: 11 and the VL sequence of SEQ ID NO: 22; or (ii) the VH sequence of SEQ ID NO: 49 and the VL sequence of SEQ ID NO: 60.
[0315] In one embodiment, the antibody that specifically binds to human IL-17A is an antibody described in Table 1. In one embodiment, the antibody that specifically binds to human IL-17A comprises an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to an amino acid sequence selected from the group consisting of: (i) SEQ ID NOs: 24 and 25, preferably SEQ ID NO: 24, or (ii) SEQ ID NOs: 61 and 62, preferably SEQ ID NO: 61. In one embodiment, the antibody that specifically binds to human IL-17A is one set forth in (i) SEQ ID NO: 24 or SEQ ID NO: 25, preferably SEQ ID NO: 24, or (ii) SEQ ID NO: 61 or SEQ ID NO: 62, preferably SEQ ID NO: 61.
[0316] Other antibodies of the disclosure with binding specificity for human IL-17A include those in which the amino acids or nucleic acids encoding the amino acids have been mutated, but which have at least 60, 70, 80, 90, or 95% identity to the sequences set forth in Table 1. In one embodiment, this includes variant amino acid sequences in which no more than 1, 2, 3, 4, or 5 amino acids have been mutated in the variable regions when compared to the variable regions set forth in the sequences set forth in Table 1, yet retain substantially the same activity. As used herein, the term "substantially the same activity" refers to activity that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 100%, or at least 110%, or at least 120%, or at least 130%, or at least 140%, or at least 150%, or at least 160%, or at least 170%, or at least 180%, or at least 190%, e.g., up to 200%, of the activity determined for a parent antibody, e.g., an antibody of the disclosure, particularly an antibody of the disclosure listed in Table 1.
[0317] In yet another embodiment, the present disclosure provides an antibody comprising an amino acid sequence homologous to a sequence set forth in Table 1, wherein the antibody binds to human IL-17A and retains the desired functional properties of the antibodies set forth in Table 1.
[0318] In one embodiment, an antibody of the present disclosure has a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein one or more of these CDR sequences have a specific amino acid sequence based on an antibody described herein or a conservative modification thereof, and the antibody retains the desired functional properties of the antibody of the present disclosure.
[0319] Accordingly, the present disclosure provides a monoclonal antibody comprising: (i) a heavy chain variable region (VH) comprising, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the amino acid sequence SEQ ID NO: 1 or a conservative variant thereof, HCDR2 has the amino acid sequence SEQ ID NO: 2 or a conservative variant thereof, and HCDR3 has the amino acid sequence selected from any one of SEQ ID NO: 3 or a conservative variant thereof; and a light chain variable region (VL) comprising, in order, three complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein said LCDR1 has the amino acid sequence SEQ ID NO: 12 or a conservative variant thereof, said LCDR2 has the amino acid sequence SEQ ID NO: 13 or a conservative variant thereof, and said LCDR3 has the amino acid sequence SEQ ID NO: 14 or a conservative variant thereof; or (ii) a heavy chain variable region (VH) comprising, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein HCDR1 is the amino acid sequence SEQ ID NO: 39 or a conservative variant thereof, HCDR2 is the amino acid sequence SEQ ID NO: 40 or a conservative variant thereof, and HCDR3 is the amino acid sequence selected from any one of SEQ ID NO: 41 or a conservative variant thereof; and a light chain variable region (VL) comprising, in order, three complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein said LCDR1 has the amino acid sequence SEQ ID NO: 50 or a conservative variant thereof, said LCDR2 has the amino acid sequence SEQ ID NO: 51 or a conservative variant thereof, and said LCDR3 has the amino acid sequence SEQ ID NO: 52 or a conservative variant thereof; wherein the antibody specifically binds to and / or neutralizes human IL-17A.
[0320] In one embodiment, the antibody of the present disclosure is optimized for expression in mammalian cells and comprises a heavy chain variable region and a light chain variable region, wherein one or more of these sequences have a specific amino acid sequence of or based on an antibody described herein, and wherein the antibody retains the desired functional properties of the antibody of the present disclosure. Accordingly, the present disclosure provides a monoclonal antibody optimized for expression in mammalian cells and comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from (i) any of SEQ ID NOs: 10 and 11, and conservative modifications thereof, or (ii) any of SEQ ID NOs: 48 and 49, and conservative modifications thereof; the light chain variable region comprises an amino acid sequence selected from (i) any of SEQ ID NOs: 21 and 22, and conservative modifications thereof, or (ii) any of SEQ ID NOs: 59 and 60, and conservative modifications thereof; wherein the antibody specifically binds to and / or neutralizes human IL-17A.
[0321] In one embodiment, an antibody of the disclosure is optimized for expression in mammalian cells and has a full-length heavy chain sequence and a full-length light chain sequence, one or more of which have a specific amino acid sequence based on an antibody described herein or a conservative modification thereof, wherein the antibody retains the desired functional properties of the antibodies of the disclosure.
[0322] As used herein, the term "optimized" means that a nucleotide sequence has been altered to encode an amino acid sequence using codons that are preferred in a production cell or organism, typically a eukaryotic cell, such as a Pichia cell, a Chinese hamster ovary cell (CHO), or a human cell. An optimized nucleotide sequence is engineered to retain, completely or as much as possible, the amino acid sequence originally encoded by the starting nucleotide sequence, also known as the "parent" sequence. The optimized sequences herein are engineered to have codons that are preferred in mammalian cells. However, optimized expression of these sequences in other eukaryotic or prokaryotic cells is also contemplated herein. The amino acid sequence encoded by an optimized nucleotide sequence is also said to be optimized.
[0323] Another type of variable region modification is to mutate amino acid residues within the VH and / or VL CDR1, CDR2, and / or CDR3 regions to thereby improve one or more binding characteristics (e.g., affinity) of the antibody of interest, a process known as "affinity maturation." Site-directed mutagenesis or PCR-mediated mutagenesis can be performed to introduce the mutations, and their effect on antibody binding, or other functional properties of interest, can be assessed in in vitro or in vivo assays such as those described herein and provided in the Examples. Conservative modifications can be introduced (as explained above). Mutations can be amino acid substitutions, additions, or deletions. More typically, no more than one, two, three, four, or five residues within the CDR regions are altered.
[0324] An "affinity matured" antibody is one that contains one or more alterations in one or more variable domains that result in improved affinity of the antibody for an antigen, compared to a parent antibody that does not possess those alterations. In one embodiment, the affinity matured antibody has nanomolar or even picomolar affinity for the target antigen. Affinity matured antibodies are produced by procedures known in the art. For example, Marks et al., Bio / Technology 10:779-783 (1992) describe affinity maturation by shuffling VH and VL domains. Random mutagenesis of HVR and / or framework residues is described, for example, in Barbas et al. Proc Nat. Acad. Sci USA 91:3809-3813 (1994); Schier et al. Gene 169:147-155 (1995); Jackson et al., J. Immunol. 154(7):3310-9 (1995); and Hawkins et al., J. Mol. Biol. 226:889-896 (1992). Accordingly, the present disclosure provides affinity matured antibodies.
[0325] Antibodies of the disclosure can also be prepared using antibodies having one or more of the VH and / or VL sequences set forth herein as starting materials for engineering modified antibodies, which may have altered properties from the starting antibody. Antibodies can be engineered by modifying one or more residues in one or both variable regions (i.e., VH and / or VL), e.g., in one or more CDR regions and / or in one or more framework regions. Additionally or alternatively, antibodies can be engineered by modifying residues in the constant regions, e.g., to alter the effector function of the antibody.
[0326] One type of variable region engineering that can be performed is CDR grafting. Antibodies interact with target antigens primarily through amino acid residues located in the six heavy and light chain complementarity determining regions (CDRs). For this reason, the amino acid sequences within the CDRs are more diverse between individual antibodies than sequences outside the CDRs. Because CDR sequences are involved in most antibody-antigen interactions, recombinant antibodies that mimic the properties of a particular natural antibody can be expressed by constructing expression vectors containing the CDR sequences of that particular natural antibody grafted onto the framework sequences of a different antibody with different properties (see, e.g., Riechmann, L. et al., 1998 Nature 332:323-327; Jones, P. et al., 1986 Nature 321:522-525; Queen, C. et al., 1989 Proc. Natl. Acad. Sci. USA 86: 10029-10033; Winter, U.S. Pat. No. 5,225,539, and Queen et al., U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).
[0327] Such framework sequences can be obtained from public DNA databases or published references that contain germline antibody gene sequences or rearranged antibody sequences. For example, germline DNA sequences for human heavy and light chain variable region genes can be found in the "VBase" human germline sequence database (available on the Internet at www.mrc-cpe.cam.ac.uk / vbase), as well as in Kabat, EA, et al., 1991 Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242; Tomlinson, IM, et al., 1992 J. fol. Biol. 227:776-798; and Cox, JPL et al., 1994 Eur. J Immunol. 24:827-836, the contents of each of which are expressly incorporated herein by reference. For example, germline DNA sequences of human heavy and light chain variable region genes, and rearranged antibody sequences, are found in the "IMGT" database (available on the Internet at www.imgt.org; see Lefranc, MP et al., 1999 Nucleic Acids Res. 27:209-212; the contents of each of which are expressly incorporated herein by reference).
[0328] Exemplary framework sequences for use in the antibodies of the present disclosure are those structurally similar to the framework sequences used by selected antibodies of the present disclosure, e.g., the consensus sequences and / or framework sequences used by the monoclonal antibodies of the present disclosure. The VH CDR1, 2, and 3 sequences and the VL CDR1, 2, and 3 sequences can be grafted into framework regions having sequences identical to those found in the germline immunoglobulin gene from which the framework sequences are derived, or the CDR sequences can be grafted into framework regions containing one or more mutations compared to the germline sequences. For example, in certain instances, it has been found beneficial to mutate residues within the framework regions to maintain or enhance the antigen-binding ability of an antibody (see, e.g., U.S. Patent Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370 to Queen et al.).
[0329] A wide variety of antibody / immunoglobulin frameworks or scaffolds can be used, so long as the resulting polypeptide contains at least one binding region that specifically binds to IL-17A. Such frameworks or scaffolds include the five major idiotypes of human immunoglobulins, antigen-binding fragments thereof, and immunoglobulins of other animal species, preferably with humanized versions.
[0330] In one aspect, the present disclosure relates to methods for generating non-immunoglobulin-based antibodies using non-immunoglobulin scaffolds onto which the CDRs of the present disclosure can be grafted. Known or future non-immunoglobulin frameworks and scaffolds can be used as long as they contain binding regions specific for the target IL-17A protein. Known non-immunoglobulin frameworks or scaffolds include, but are not limited to, fibronectin (Compound Therapeutics, Inc., Waltham, Mass.), ankyrin (Molecular Partners AG, Zurich, Switzerland), domain antibodies (Domantis, Ltd., Cambridge, Mass., and Ablynx nv, Zwijnaarde, Belgium), lipocalins (Pieris Proteolab AG, Freising, Germany), small modular immunopharmaceuticals (Trubion Pharmaceuticals Inc., Seattle, Wash.), maxybodies (Avidia, Inc., Mountain View, Calif.), protein A (Affibody AG, Sweden), and affilin (gamma-crystallin or ubiquitin) (Scil Proteins GmbH, Halle, Germany).
[0331] Antibodies according to the present disclosure have valuable properties that are predicted to be beneficial to human patients in need of human IL-17A targeted therapy. Antibodies according to the present disclosure are characterized by one or more of the following properties (as determined in Examples 1 and 2):
[0332] The antibody specifically binds to human IL-17A and: (a) having binding specificity for cynomolgus monkey IL-17A; (b) selectively binds to human IL-17A over human IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F as measured by ELISA; (c) inhibiting or blocking the binding between IL-17A and its receptor (IL-17RA); (d) reducing or neutralizing IL-17A activity; (e) capable of inhibiting GRO-α secretion as assessed in vitro in the HT-29 assay;
[0333] (f) having the ability to block the interaction of IL-17A and IL-17RA with a potency (relative potency) of greater than 5, particularly greater than 10, greater than 15, and more particularly greater than 20 compared to the potency of secukinumab as determined by ELISA assay, wherein said relative potency is greater than or equal to the IC50 of secukinumab as determined by ELISA. 50 values (ng / mL) and IC of said antibodies in scFv format determined by ELISA 50 The ratio of the value (ng / mL) to
[0334] (g) has the ability to neutralize IL-17A with a potency (relative potency) greater than 50, particularly greater than 100, and more particularly greater than 150 compared to a potency (relative potency) relative to secukinumab as determined by measuring GRO-α secretion in an HT-29 assay, wherein said relative potency is the IC50 of secukinumab as measured by the HT-29 assay. 50 Values (ng / mL) and IC of antibodies of the invention in scFv format measured by HT-29 assay 50 The ratio of the value (ng / mL) to
[0335] (h) capable of inhibiting the activity of 1 ng of human IL-17A by 50% at a concentration of 1 ng / mL or less, particularly 0.5 ng / mL or less, and more particularly 0.2 ng / mL or less, wherein the inhibitory activity is determined by measuring GRO-α secretion induced by human IL-17A in an HT-29 assay in the presence of 50 pg / mL of TNFα;
[0336] (i) a dissociation constant (K) of less than 5 nM, particularly less than 1 nM, less than 0.5 nM, less than 0.2 nM, particularly less than 100 pM, and more particularly less than 50 pM, as measured by surface plasmon resonance, preferably in a direct setting. D ) and binds to human IL-17A.
[0337] (j) a K of less than 10 nM, e.g., less than 7 nM, less than 5 nM, less than 2 nM, less than 1 nM, particularly less than 0.5 nM, as measured by surface plasmon resonance, particularly as measured by surface plasmon resonance in a capture setting. D and binds to cynomolgus monkey IL-17A.
[0338] (k) when in scFv format, the melting temperature (Tm) as determined by differential scanning fluorimetry is at least 60°C, particularly at least 62°C, more particularly at least 65°C, and even more particularly at least 70°C, particularly wherein the antibody is in phosphate-citrate buffer, pH 6.4, 150 mM NaCl;
[0339] (l) when in scFv format, there is a loss of less than 5%, particularly less than 3%, and more particularly less than 1% of the monomer content of the antibody of the invention when the starting concentration is 10 mg / ml after 5 successive freeze-thaw cycles, particularly where the antibody is in phosphate buffered saline (PBS) at pH 7.4; and / or
[0340] (m) if in scFv format, after storage at 4°C for at least 2 weeks, particularly at least 4 weeks, the loss of monomer content of the antibody of the disclosure at a starting concentration of 10 mg / ml is 5% or less, particularly less than 4%, 3%, 2%, particularly less than 1%, particularly where the antibody is in phosphate buffered saline (PBS), pH 7.4; and / or (n) When the antibody of the present disclosure has a starting concentration of 10 mg / ml, there is less than 5% loss of monomer content after storage at 37°C for at least 2 weeks, particularly at least 4 weeks.
[0341] In one embodiment, an antibody of the disclosure selectively binds to human IL-17A over human IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F as measured by ELISA. As used herein, the term "selectively binds" is intended to mean that the antibody, composition, formulation, etc. does not significantly bind to IL-17B / C / D / E / F, but binds to IL-17A. Selective binding typically exhibits a moderate to high IC 50 High affinity (or low K) binding, as distinguished from nonspecific binding, has low affinity. D ) and low to medium IC 50 Typically, antibodies are characterized by -7 K less than M D Binding is considered selective if the antibody binds with a higher affinity, i.e., a lower K, as measured by SPR, to human IL-17B, IL-17C, IL-17D, IL-17E, IL-17F. Suitably, the antibody of the disclosure binds with a higher affinity, i.e., a lower K, as measured by SPR. D Suitably, the antibodies of the disclosure bind to human IL-17A at IC 16.1 or higher for IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F, and IC 16.1 or higher for IL-17A, as measured by ELISA. 50 at least 100 times larger, in particular at least 200 times, at least 300 times, or at least 400 times larger than IC 50 It has a value.
[0342] The antibodies of the present disclosure specifically bind to IL-17A, where binding to IL-17A (a) inhibits or blocks the binding of IL-17A to its receptor (IL-17RA), and (b) reduces or neutralizes IL-17A activity.
[0343] The term "neutralizing antibody," as used herein, describes an antibody that can neutralize the biological signaling activity of IL-17A, for example, by blocking the binding of IL-17A to one or more of its receptors, particularly by blocking the binding of IL-17A to IL-17RA. The antibodies of the present disclosure are IL-17A neutralizing antibodies. It will be understood that the term "neutralizing," as used herein, refers to a reduction in biological signaling activity, which may be partial or complete. Neutralization of IL-17A can be determined by various assays, examples of which are described elsewhere herein.
[0344] Thus, antibodies of the disclosure are capable of inhibiting GRO-α secretion in vitro as assessed in an HT-29 assay (described in Examples 1 and 2). In one embodiment, an antibody of the disclosure has the ability to neutralize IL-17A with a potency (relative potency) of greater than 50, preferably greater than 100, and more preferably greater than 150, compared to the potency of secukinumab as determined by measuring GRO-α secretion in an HT-29 assay, wherein the relative potency is the IC of secukinumab as determined by the HT-29 assay. 50 Values (ng / mL) and IC of antibodies of the present disclosure in scFv format as determined by HT-29 assay 50 In a further embodiment, the antibody of the present disclosure is capable of inhibiting the activity of 1 ng of human IL-17A by 50% at a concentration of 1 ng / mL or less, preferably 0.5 ng / mL or less, and more preferably 0.2 ng / mL or less, wherein the inhibitory activity is determined by measuring GRO-α secretion induced by human IL-17A in an HT-29 assay in the presence of 50 pg / mL of TNFα.
[0345] In one embodiment, an antibody of the disclosure has the ability to block the interaction of IL-17A and IL-17RA with a potency (relative potency) of greater than 5, preferably greater than 10, greater than 15, more particularly greater than 20, compared to the potency of secukinumab as determined by ELISA assay, wherein said relative potency is the IC50 of secukinumab measured by ELISA. 50 values (ng / mL) and IC of antibodies of the present disclosure in scFv format measured by ELISA 50 The ratio is the value (ng / mL).
[0346] As used herein, the term "affinity" refers to the strength of antibody-antigen interaction at a single antigenic site. Within each antigenic site, the variable regions of the antibody "arms" interact with the antigen at multiple sites through weak non-covalent forces; the more interactions, the stronger the affinity.
[0347] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, "binding affinity," "binds," "binds to," or "bound to," as used herein, refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody fragment and an antigen). The affinity of a molecule X for a partner Y is generally determined by the dissociation constant (K D ) Affinity can be measured by common methods known in the art, including those described herein. In general, low-affinity antibodies bind antigens slowly and tend to dissociate easily, whereas high-affinity antibodies generally bind antigens quickly and tend to maintain binding for a long time. Various methods for measuring binding affinity are known in the art, any of which can be used for purposes of the present invention. Specific exemplary embodiments for measuring binding affinity, i.e., binding strength, are described below.
[0348] As used herein, "K" assoc ", "Ka" or "K on" is intended to refer to the association rate of a particular antibody-antigen interaction, while the term "K dis ", "Kd" or "K off " is intended to refer to the off-rate of a particular antibody-antigen interaction. In one embodiment, "K" as used herein D The term "K" is intended to refer to the dissociation constant, which is obtained from the ratio of K to K (i.e., K / K) and is expressed as a molar concentration (M). D " or "K D "KD" or "KD value" is measured in one embodiment using a T200 instrument (Biacore, GE Healthcare). To measure the affinity of humanized scFv for human IL-17A, biotinylated human IL-17A is captured using Biacore's Biotin-CAPture kit. After each analyte injection cycle, the CAP sensor chip is regenerated and new antigen is captured. The scFv is injected as the analyte using a dose-response multi-cycle kinetic assay at analyte concentrations ranging from 0.35 to 90 nM diluted in running buffer. The resulting sensorgrams are fitted using a 1:1 binding model. Alternatively or additionally, the affinity of the humanized scFv can be measured and analyzed using an alternative SPR assay setup: IL-17A is immobilized on a CM5 sensor chip (GE Healthcare) by amine coupling, and serial dilutions of the scFv from 0.35 to 90 nM are re-injected over the immobilized IL-17A.
[0349] Suitably, the affinity of the antibodies of the present disclosure for IL-17A may be higher than the affinity of IL-17A for IL-17RA. It is understood that the higher affinity of the antibodies of the present disclosure compared to the affinity of IL-17A for IL-17RA may be particularly useful for dissociating or neutralizing pre-formed IL-17RA / IL-17A complexes. In one embodiment, the antibodies of the present disclosure neutralize the IL-17RA / IL-17A interaction. In another embodiment, the antibodies of the present disclosure inhibit or block the binding of IL-17A to its receptor (IL-17RA). In one embodiment, the antibodies of the present disclosure neutralize IL-17A activity.
[0350] Suitably, the affinity of the antibodies of the present disclosure for IL-17A may be comparable to or greater, preferably greater, than the affinity of secukinumab for IL-17A. In one embodiment, the antibodies of the present disclosure neutralize IL-17A activity with comparable or greater, preferably greater, potency than secukinumab. In a further embodiment, the antibodies of the present disclosure neutralize IL-17RA / IL-17A interaction with comparable or greater, preferably greater, potency than secukinumab.
[0351] The binding affinity of an antibody can be determined, for example, by the dissociation constant (K D ) can be determined by the K D where weaker affinity is represented by a higher K D is expressed by
[0352] Thus, in suitable embodiments, the antibodies of the present disclosure have a K of 1 to 10,000 pM, 1 to 7,000 pM, 1 to 5,000 pM, 1 to 2,500 pM, 1 to 2,000 pM, 1 to 1,000 pM, 1 to 750 pM, 1 to 500 pM, 1 to 400 pM, 1 to 300 pM, 1 to 200 pM, 1 to 100 pM, or 1 to 50 pM, preferably as measured by surface plasmon, and more preferably as measured by surface plasmon resonance in a direct setting. DIn suitable embodiments, the antibodies of the disclosure may have a K of 1 to 200 pM, particularly 1 to 100 pM, as measured by surface plasmon resonance in a direct setting. D In certain embodiments, the antibodies of the disclosure have a K of 1 to 50 pM as measured by surface plasmon resonance in a direct setting. D In suitable embodiments, the antibodies of the disclosure have a K of less than 5 nM, less than 4 nM, less than 3 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.25 nM, less than 0.2 nM, less than 150 pM, less than 100 pM, or less than 50 pM, preferably as measured by surface plasmon, more preferably as measured by surface plasmon resonance in a direct setting. D Suitably, the antibodies of the disclosure may have a K of less than 1 nM, particularly less than 100 pM. D Suitably, the antibodies of the disclosure have a K of less than 0.5 nM, particularly less than 50 pM. D More suitably, the antibodies of the disclosure have a K of less than 0.2 nM, particularly less than 50 pM, as measured by surface plasmon resonance in a direct setting. D It has.
[0353] In further embodiments, the antibodies of the disclosure have a K of less than 10 nM, e.g., less than 7 nM, less than 5 nM, less than 2 nM, less than 1 nM, particularly less than 0.5 nM, for cynomolgus IL-17A as measured by surface plasmon resonance (SPR) in a capture setting. D Combine with.
[0354] Suitably, the antibodies of the disclosure have a molecular weight of at least 10 when measured by surface plasmon resonance (SPR), preferably when measured by surface plasmon resonance in a direct setting. 3 M -1 s -1 or more, at least 10 4 M -1 s -1 or more, at least 5×10 4 M -1 s -1 or more, at least 10 5 M -1 s-1 or more, at least 5×10 5 M -1 s -1 or more, at least 10 6 M -1 s -1 More than K on Preferably, the antibodies of the disclosure bind to human IL-17A with a rate of at least 10 as measured by SPR, preferably as measured in a direct setting by surface plasmon resonance. 5 M -1 s -1 That's it, at least 5x10 in detail 5 M -1 s -1 More specifically, at least 10 6 M -1 s -1 More than K on Has speed.
[0355] Suitably, the antibodies of the disclosure bind to human IL-17A with a binding affinity of 5×10 to IL-17A as measured by surface plasmon resonance (SPR), preferably as measured by surface plasmon resonance in a direct setting. -3 s -1 Below, 3 x 10 -3 s -1 Below, 10 -3 s -1 Below, 5 x 10 -4 s -1 Below, 3 x 10 -4 s -1 Below, 10 -4 s -1 Below, 5 x 10 -5 s -1 The following K off Preferably, the antibodies of the present disclosure bind at a rate of 10 as measured by SPR, preferably in a direct setting by surface plasmon resonance. -4 s -1 Below, for details, 5x10 -5 s -1 The following K off Has speed.
[0356] Suitably, the antibodies of the present disclosure have beneficial biophysical properties.
[0357] Suitably, the antibodies of the disclosure have a melting temperature (Tm) when expressed in an scFv (single chain variable fragment) antibody format of at least 60°C, preferably at least 62°C, more preferably at least 65°C, and even more preferably at least 70°C, as determined by differential scanning fluorimetry (DSF) as previously described (Egan, et al., MAbs, 9(1) (2017), 68-84; Niesen, et al., Nature Protocols, 2(9) (2007) 2212-2221). The midpoint of the thermal unfolding transition of the scFv construct is determined by differential scanning fluorimetry using the fluorescent dye SYPRO® Orange (see Wong & Raleigh, Protein Science 25 (2016) 1834-1840). Samples were prepared in pH 6.4 phosphate-citrate buffer at a final protein concentration of 50 μg / mL, containing a final concentration of 5x SYPRO® Orange in a total volume of 100 μl. 25 μl of the prepared sample was added to a white-walled AB gene PCR plate in triplicate. The assay was performed on a qPCR instrument used as a thermal cycler, and fluorescence emission was detected using a custom dye calibration routine in the software. The PCR plate containing the test samples was subjected to a temperature ramp from 25°C to 96°C in 1°C increments, with a 30-second pause after each temperature increase. The total assay time was approximately 2 hours. Tm was calculated using the GraphPad Prism software using the mathematical second derivative method to calculate the inflection point of the curve. The reported Tm is the average of three measurements.
[0358] The antibodies of the present disclosure, particularly when expressed in an scFv (single chain variable fragment) antibody format, are characterized by a loss of less than 5%, particularly less than 3%, and more particularly less than 1% of monomer content after five consecutive freeze-thaw cycles, particularly when the starting concentration of the antibodies of the present disclosure is 10 mg / ml.
[0359] After storage for at least two weeks, particularly at least four weeks at 4°C, the antibodies of the present disclosure, particularly when expressed in scFv (single-chain variable fragment) antibody format, are characterized by a loss of 5% or less, particularly less than 4%, 3%, 2%, and preferably less than 1%, of monomer content when the starting concentration of the antibody of the present disclosure is 10 mg / ml. The loss of monomer content is determined by calculating the area under the curve of the SE-HPLC chromatogram. SE-HPLC, as outlined in USP Chapter 621, is a separation technique based on a solid stationary phase and a liquid mobile phase. This method utilizes a hydrophobic stationary phase and an aqueous mobile phase to separate molecules based on size and shape. Molecular separation occurs between the void volume (V0) and total permeation volume (VT) of a particular column. SE-HPLC measurements are performed on a Chromaster HPLC system (Hitachi High-Technologies Corporation) equipped with automatic sample injection and a UV detector set at a detection wavelength of 280 nm. The instrument is controlled by EZChrom Elite software (Agilent Technologies, version 3.3.2 SP2), which also supports the analysis of the resulting chromatograms. Protein samples are clarified by centrifugation and kept at 4–6 °C in the autosampler before injection. For the analysis of scFv samples, a Shodex KW403-4F column (Showa Denko Inc., #F6989202) is used with a standardized buffered saline mobile phase (50 mM sodium phosphate pH 6.5, 300 mM sodium chloride) at a recommended flow rate of 0.35 mL / min. The target sample load per injection was 5 μg. Samples are detected with a UV detector at a wavelength of 280 nm, and data are recorded using the appropriate software suite. The resulting chromatograms are analyzed from V0 to VT, thereby excluding matrix-related peaks with elution times greater than 10 min.
[0360] Suitably, the isolated antibody of the present disclosure is selected from the group consisting of monoclonal antibodies, chimeric antibodies, Fabs, Fvs, scFvs, dsFvs, scAbs, STABs, single domain antibodies (sdAbs or dAbs), single domain heavy chain antibodies, and single domain light chain antibodies, VHHs, VNARs, single domain antibodies based on shark VNAR structures, and binding domains based on alternative scaffolds including, but not limited to, ankyrin-based domains, phinomers, avimers, anticalins, fibronectin, and binding sites incorporated into the constant region of an antibody (e.g., F-star's Modular Antibody Technology™), preferably scFvs.
[0361] Suitably, the antibody of the present disclosure is an Fv. Suitably, the antibody of the present disclosure is an scFv antibody fragment. "Single-chain Fv" or "scFv" or "sFv" antibody fragments comprise the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains, which enables the sFv to form the desired structure for target binding. "Single-chain Fv" or "scFv" antibody fragments comprise the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains, which enables the scFv to form the desired structure for antigen binding (see, e.g., Pluckthun, The pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York, 1994), pp. 269-315). In a specific embodiment, the functional fragment is in the form of an scFv comprising a linker according to SEQ ID NO: 23. In one embodiment, the antibody that specifically binds to human IL-17A is an antibody described in Table 1. In one embodiment, an antibody that specifically binds to human IL-17A comprises an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to an amino acid sequence selected from the group consisting of: (i) SEQ ID NO: 24 and SEQ ID NO: 25; or (ii) SEQ ID NO: 61 and SEQ ID NO: 62. In a further embodiment, the antibody of the disclosure is a single-chain variable fragment (scFv), such as (i) set forth in SEQ ID NO: 24 or SEQ ID NO: 25, or (ii) set forth in SEQ ID NO: 61 or SEQ ID NO: 62.
[0362] Suitably, the antibody of the disclosure is an IgG antibody. In one embodiment, the antibody of the disclosure is an IgG selected from the group consisting of IgG1, IgG2, IgG3, and IgG4, preferably IgG1.
[0363] Exemplary Domains That Specifically Bind TNFα The multispecific antibodies of the present disclosure comprise a second domain that specifically binds to TNFα, said domain comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein (a) the VH comprises, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, and (b) the VL comprises, in order, three complementarity determining regions LDCR1, LDCR2, and LDCR3.
[0364] Suitable domains that specifically bind to TNFα for use in the multispecific antibodies of the present disclosure include, but are not limited to, the following: a humanized monoclonal antibody or binding domain thereof, the sequence of which is set out in Table 1 (described in WO2017 / 158101, which is hereby incorporated by reference in its entirety); Infliximab (Remicade®; U.S. Patent Nos. 6,277,969, 6,284,471, 6,790,444, and 6,835,823, all of which are incorporated herein by reference); Adalimumab / D2E7 (Humira®; described in U.S. Patent No. 6,090,382, which is incorporated herein by reference in its entirety); Certolizumab, PEGylated Fab fragment (Cimzia®; described in U.S. Patent Nos. 7,012,135 and 7,186,820, all of which are incorporated herein by reference); Golimumab (Simponi®; Published U.S. Application No. 2009 / 214528, incorporated herein by reference in its entirety).
[0365] Preferred domains that specifically bind TNFα for use in the multispecific antibodies of the present disclosure include, but are not limited to, the humanized monoclonal antibodies or binding domains thereof whose sequences are set forth in Table 1 (described in WO2017 / 158101, which is incorporated herein by reference in its entirety).
[0366] Accordingly, in one embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, wherein said second domain comprises a set of CDRs (HCDR1, HCDR2, HCDR3, LDCR1, LDCR2, and LDCR3), wherein said set of CDRs is a set of CDRs [wherein HCDR1′ is an amino acid sequence selected from any one of SEQ ID NOs: 25, 28, and 31, preferably SEQ ID NO: 25; HCDR2′ is an amino acid sequence selected from any one of SEQ ID NOs: 26, 29, and 32, preferably SEQ ID NO: 26; and HCDR3′ is an amino acid sequence selected from any one of SEQ ID NOs: 27, 30, and 33, preferably SEQ ID NO: 27]. LCDR1' is an amino acid sequence selected from any one of SEQ ID NOs: 38, 41, and 44, preferably SEQ ID NO: 38; LCDR2' is an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45, preferably SEQ ID NO: 39; and LCDR3' has an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46, preferably SEQ ID NO: 40], and has 10 or fewer amino acid substitutions, for example, 9 or fewer amino acid substitutions, 8 or fewer amino acid substitutions, 7 or fewer amino acid substitutions, 6 or fewer amino acid substitutions, 5 or fewer amino acid substitutions, 4 or fewer amino acid substitutions, 3 or fewer amino acid substitutions, 2 or fewer amino acid substitutions, 1 or 0 amino acid substitutions, preferably 0 amino acid substitutions.
[0367] In particular, the present disclosure provides multispecific antibodies comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises a VH CDR having the amino acid sequence of any one of the VH CDRs listed in Table 1. In particular, the second domain that specifically binds TNFα comprises (or consists of) one, two, three, or more VH CDRs having the amino acid sequence of any of the VH CDRs listed in Table 1.
[0368] Suitably, the present disclosure provides a second domain that specifically binds to TNFα, wherein said second domain comprises a heavy chain variable region (VH), said VH comprising, in order, three complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein said HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 25, 28 and 31, said HCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 26, 29 and 32, and said HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 27, 30 and 33. In particular, said second domain comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NOs: 25, 26 and 27, respectively.
[0369] The present disclosure also provides a multispecific antibody comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, wherein said second domain comprises a VL CDR having the amino acid sequence of any one of the VL CDRs listed in Table 1. In particular, said second domain that specifically binds to TNFα comprises (or consists of) one, two, three, or more VL CDRs having the amino acid sequence of any of the VL CDRs listed in Table 1.
[0370] Suitably, the second domain that specifically binds to TNFα comprises a light chain variable region (VL), wherein the VL comprises, in order, three complementarity determining regions LDCR1, LDCR2 and LDCR3, wherein the LDCR1 has an amino acid sequence selected from any one of SEQ ID NOs: 38, 41 and 44, the LCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 39, 42 and 45, and the LCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 40, 43 and 46. In particular, the second domain comprises the LDCR1, LDCR2 and LDCR3 sequences of SEQ ID NOs: 38, 39 and 40, respectively.
[0371] Suitably, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:
[0372] (a) the VH comprises, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein the HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 25, 28, and 31, the HCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 26, 29, and 32, and the HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 27, 30, and 33; and (b) The VL comprises three complementarity determining regions LCDR1, LCDR2, and LCDR3, in that order, wherein the LCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 38, 41, and 44; the LCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 39, 42, and 45; and the LCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 40, 43, and 46.
[0373] In particular, the present disclosure provides multispecific antibodies comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises (a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 25, 26, and 27, respectively, and (b) the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 38, 39, and 40, respectively.
[0374] Other domains of the disclosure that specifically bind to TNFα have been mutated but comprise amino acids in their CDR regions that have at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the CDR regions shown in the sequences set forth in Table 1. Suitably, other domains of the disclosure that specifically bind to TNFα comprise mutated amino acid sequences in which no more than 1, 2, 3, 4, 5, or 10 amino acids have been mutated in the CDR regions by amino acid deletion, insertion, or substitution when compared to the CDR regions shown in the sequences set forth in Table 1. The mutations, e.g., substitutions, may be made at any residue within the set of CDRs and may be within CDR1, CDR2, and / or CDR3.
[0375] Suitably, the second domain that specifically binds to TNFα of the multispecific antibody of the present disclosure comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: (a) the VH comprises, in order, three complementarity determining regions, HCDR1, HCDR2, and HCDR3, wherein the HCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 25, 28, and 31; the HCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 26, 29, and 32; and the HCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 27, 30, and 33; and / or (b) the VL comprises three complementarity determining regions LCDR1, LCDR2, and LCDR3, in that order, wherein the LCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with any one of SEQ ID NOs: 38, 41, and 44; the LCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with any one of SEQ ID NOs: 39, 42, and 45; and the LCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with any one of SEQ ID NOs: 40, 43, and 46.
[0376] Suitably, the second domain that specifically binds to TNFα comprises HCDR1, HCDR2 and HCDR3 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity with the sequences of SEQ ID NOs: 25, 26 and 27, respectively, and / or LCDR1, LCDR2 and LCDR3 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity with the sequences of SEQ ID NOs: 38, 39 and 40, respectively.
[0377] In a further embodiment, said second domain that specifically binds to TNFα comprises a heavy chain variable region VHB and a light chain variable region VLB.
[0378] Suitably, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, wherein said second domain comprises a heavy chain variable region VHB, wherein said VHB is VH1A, VH1B, VH3, or VH4. In one embodiment, said second domain that specifically binds to TNFα of the present disclosure comprises a heavy chain variable region VHB, wherein said VHB is VH4. In a preferred embodiment, said second domain that specifically binds to TNFα of the present disclosure comprises a heavy chain variable region VHB, wherein said VHB is VH3.
[0379] Suitably, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, wherein the second domain comprises a light chain variable region VLB, wherein the VLB comprises Vκ framework FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 framework FR1-FR3, and framework FR4, wherein the framework FR4 is selected from Vκ FR4, particularly Vκ1 FR4, Vκ3 FR4, and Vλ FR4. Suitable Vλ FR4s are those set forth in SEQ ID NOs: 97 to 103. In one embodiment, the second domain that specifically binds to TNFα comprises a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any of SEQ ID NOs: 97 to 103, preferably SEQ ID NO: 97 or SEQ ID NO: 98, more preferably SEQ ID NO: 97. Suitably, the second domain that specifically binds to TNFα comprises a Vλ FR4 comprising an amino acid sequence selected from any of SEQ ID NOs: 97 to 103, preferably a Vλ FR4 set forth in SEQ ID NO: 97 or 98, more preferably a Vλ FR4 set forth in SEQ ID NO: 98.
[0380] Accordingly, in one embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds to IL-17A and a second domain that specifically binds to TNFα, wherein said second domain comprises: (a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 25, 26, and 27, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 38, 39, and 40, respectively; (b) a VHB, wherein the VHB is a VH3 or a VH4, preferably a VH3; and (c) A VLB comprising a VL framework comprising Vκ frameworks FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 FR1-FR3, and framework FR4, wherein the framework FR4 is a Vκ FR4, particularly a Vκ1 FR4, a Vκ3 FR4, and a Vλ FR4, particularly a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any of SEQ ID NOs: 97 to 103, preferably a Vλ FR4 set forth in any of SEQ ID NOs: 97 to 103, preferably a Vλ FR4 set forth in SEQ ID NO: 97 or 98, more preferably a Vλ FR4 set forth in SEQ ID NO: 98.
[0381] Suitably, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises a VH as set forth in Table 1. Suitably, the present disclosure also provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises (or consists of) a VH amino acid sequence as set forth in Table 1, wherein about 20 or fewer amino acids, preferably about 10 or fewer amino acids, in the framework sequences (e.g., sequences that are not CDRs) have been mutated (wherein the mutations are, by way of various non-limiting examples, additions, substitutions, or deletions). Other domains of the present disclosure that specifically bind TNFα have been mutated but comprise amino acids that have at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the VH region set forth in the sequences set forth in Table 1.
[0382] Suitably, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises a VL as set forth in Table 1. Suitably, the present disclosure also provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises (or consists of) a VL amino acid sequence as set forth in Table 1, wherein about 20 or fewer amino acids, preferably about 10 or fewer amino acids, in the framework sequences (e.g., sequences that are not CDRs) have been mutated (wherein the mutations are additions, substitutions, or deletions, as various non-limiting examples). Other domains of the present disclosure that specifically bind TNFα have been mutated but comprise amino acids that have at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the VL region shown in the sequences set forth in Table 1.
[0383] In one embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, and 37, preferably SEQ ID NO: 34; in particular, said domains comprise the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 25, 26, and 27, respectively. In a preferred embodiment, the second domain that specifically binds to TNFα comprises a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence SEQ ID NO: 34, wherein the heavy chain variable region comprises G56A, R82L, S85A, K86Q (AHo numbering), and in particular, the domain comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 25, 26, and 27, respectively. Suitably, the second domain that specifically binds to TNFα may comprise a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence SEQ ID NO: 36, wherein the heavy chain variable region comprises A24K, G56A, R82L (AHo numbering), and in particular, the domain comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 25, 26, and 27, respectively. Suitably, the second domain that specifically binds to TNFα may comprise a heavy chain variable region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 37, wherein the heavy chain variable region comprises G56A, R82L, S85A, K86Q (AHo numbering), and in particular the domain comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NOs: 25, 26 and 27, respectively.
[0384] In another embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises a light chain variable region comprising an amino acid sequence at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 48, 49, 50, and 51, preferably SEQ ID NO: 47; in particular, said domains comprise the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 38, 39, and 40, respectively.
[0385] In a preferred embodiment, the second domain that specifically binds to TNFα comprises a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence SEQ ID NO: 47, wherein the light chain variable region comprises T22N, A51R, F89Y (AHo numbering), and in particular, the domain comprises the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 38, 39, and 40, respectively. Suitably, the second domain that specifically binds to TNFα may comprise a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence SEQ ID NO: 49, wherein the light chain variable region comprises T22N, D88E, S95G, E99A (AHo numbering), and in particular, the domain comprises the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 38, 39, and 40, respectively. Suitably, the second domain that specifically binds to TNFα may comprise a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence SEQ ID NO: 50, wherein the light chain variable region comprises T22N, A51R, F89Y, S95G, G141T, L145V (AHo numbering), and in particular, the domain comprises the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 38, 39, and 40, respectively. Suitably, the second domain that specifically binds to TNFα may comprise a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence SEQ ID NO: 51, wherein the light chain variable region comprises T22N, K50Q, A51R, F89Y, G141T, L145V (AHo numbering), and in particular, the domain comprises the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 38, 39, and 40, respectively.
[0386] In a further embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 34; and a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 47.
[0387] Preferably, the second domain that specifically binds to TNFα comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:34, and a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO:47. and a chain variable region, wherein the domains comprise the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 25, 26, and 27, respectively, and / or the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 38, 39, and 40, respectively, preferably the domains comprise the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 25, 26, and 27, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 38, 39, and 40, respectively.
[0388] Suitably, the second domain that specifically binds to TNFα comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 37, and an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 50 or 51. and a light chain variable region, wherein the domains comprise the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 25, 26, and 27, respectively, and / or the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 38, 39, and 40, respectively, preferably the domains comprise the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 25, 26, and 27, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 38, 39, and 40, respectively.
[0389] In a specific embodiment, the present disclosure provides a multispecific antibody comprising said first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, and 37, and / or a VL comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 48, 49, 50, and 51. In a particular embodiment, the second domain that specifically binds TNFα comprises the VH sequence of SEQ ID NO: 34 and the VL sequence of SEQ ID NO: 47. In yet another particular embodiment, said second domain that specifically binds TNFα comprises the VH sequence of SEQ ID NO: 37 and the VL sequence of SEQ ID NO: 50 or SEQ ID NO: 51.
[0390] In one embodiment, the domain that specifically binds to human TNFα is a domain set forth in Table 1. Other domains of the present disclosure that have binding specificity for human TNFα include domains in which the amino acids or nucleic acids encoding the amino acids have been mutated, but which have at least 60, 70, 80, 90, or 95% identity to the sequences set forth in Table 1. In one embodiment, this includes variant amino acid sequences in which no more than 1, 2, 3, 4, or 5 amino acids have been mutated in the variable region when compared to the variable region set forth in the sequence set forth in Table 1, but which retain substantially the same activity.
[0391] In yet another embodiment, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises an amino acid sequence homologous to a sequence set forth in Table 1, and wherein said domain binds to human TNFα and retains desirable functional properties of the domain set forth in Table 1.
[0392] In one embodiment, a domain of the present disclosure that specifically binds to TNFα has a heavy chain variable region comprising HCDR1, HCDR2, and HCDR3 sequences, and a light chain variable region comprising LDCR1, LDCR2, and LDCR3 sequences, wherein one or more of these CDR sequences have a specific amino acid sequence based on the domains described herein or conservative modifications thereof, and the domain retains the desired functional properties of the antibodies of the present disclosure.
[0393] Accordingly, the present disclosure provides a multispecific antibody comprising a first domain that specifically binds IL-17A and a second domain that specifically binds TNFα, wherein said second domain comprises (or consists of): a heavy chain variable region (VH) comprising, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the amino acid sequence SEQ ID NO: 25 or a conservative variant thereof, HCDR2 has the amino acid sequence SEQ ID NO: 26 or a conservative variant thereof, and HCDR3 has the amino acid sequence selected from any one of SEQ ID NO: 27 or a conservative variant thereof; and a light chain variable region (VL) comprising, in order, three complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein said LCDR1 has the amino acid sequence SEQ ID NO: 38 or a conservative variant thereof, said LCDR2 has the amino acid sequence SEQ ID NO: 39 or a conservative variant thereof, and said LCDR3 has the amino acid sequence SEQ ID NO: 40 or a conservative variant thereof; wherein said domain specifically binds to and / or neutralizes human TNFα.
[0394] Exemplary domains that specifically bind to human serum albumin (HSA) The multispecific antibodies of the present disclosure comprise a third domain that specifically binds to human serum albumin, said domain comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein (a) the VH comprises, in order, three complementarity determining regions: HCDR1, HCDR2, and HCDR3, and (b) the VL comprises, in order, three complementarity determining regions: LDCR1, LDCR2, and LDCR3.
[0395] Suitably, the multispecific antibody of the present disclosure may comprise a third binding domain having a third specificity different from the specificities of the first and second domains. Suitably, the multispecific antibody of the present disclosure may comprise a third domain that specifically binds to human serum albumin (HSA). Thus, in one embodiment, the multispecific antibody of the present disclosure comprises a first domain that specifically binds to IL-17A, a second domain that specifically binds to TNFα, and a third domain that specifically binds to human serum albumin.
[0396] Suitable domains that specifically bind human serum albumin for use in the multispecific antibodies of the present disclosure include, but are not limited to, the humanized monoclonal antibodies or binding domains thereof whose sequences are set forth in Table 1.
[0397] In one embodiment, the domain that specifically binds to human serum albumin comprises a set of CDRs (HCDR1, HCDR2, HCDR3, LDCR1, LDCR2, and LDCR3), wherein the set of CDRs is a set of CDRs [wherein: (a) HCDR1' is set forth in SEQ ID NO: 52, HCDR2' is set forth in SEQ ID NO: 53, HCDR3' is set forth in SEQ ID NO: 54, LCDR1' is set forth in SEQ ID NO: 62, LCDR2' is set forth in SEQ ID NO: 63, and LCDR3' is set forth in SEQ ID NO: 64; or (b) HCDR1' is set forth in SEQ ID NO: 73, HCDR2' is set forth in SEQ ID NO: 74, HCDR3' is set forth in SEQ ID NO: 75, LCDR1' is set forth in SEQ ID NO: 83, LCDR2' is set forth in SEQ ID NO: 84, and LCDR3' is set forth in SEQ ID NO: 85], which has 10 or fewer amino acid substitutions, for example 9 or fewer amino acid substitutions, 8 or fewer amino acid substitutions, 7 or fewer amino acid substitutions, 6 or fewer amino acid substitutions, 5 or fewer amino acid substitutions, 4 or fewer amino acid substitutions, 3 or fewer amino acid substitutions, 2 or fewer amino acid substitutions, 1 or 0 amino acid substitutions, preferably 0 amino acid substitutions.
[0398] In particular, the domain that specifically binds to human serum albumin comprises a VH CDR having the amino acid sequence of any one of the VH CDRs listed in Table 1. In particular, the present disclosure provides multispecific antibodies comprising a third domain that specifically binds to HSA, wherein the domain comprises (or consists of) one, two, three, or more VH CDRs having the amino acid sequence of any of the VH CDRs listed in Table 1.
[0399] Suitably, the domain that specifically binds to human serum albumin comprises a heavy chain variable region (VH), wherein said VH comprises, in order, three complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein: (a) the HCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58, the HCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 53, 56, and 59, and the HCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 54, 57, and 60; or (b) the HCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 73, 76, and 79, the HCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 74, 77, and 80, and the HCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 75, 78, and 81.
[0400] In a preferred embodiment, the domain that specifically binds to human serum albumin comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 52, 53, and 54, respectively. In another embodiment, the domain that specifically binds to human serum albumin comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 73, 74, and 75, respectively.
[0401] Suitably, the domain that specifically binds to human serum albumin comprises a VL CDR having the amino acid sequence of any one of the VL CDRs set out in Table 1. In particular, the present disclosure provides multispecific antibodies comprising a third domain that specifically binds to HSA, wherein said domain comprises (or alternatively consists of) one, two, three or more VL CDRs having the amino acid sequence of any of the VL CDRs set out in Table 1.
[0402] Suitably, said domain that specifically binds to human serum albumin comprises a light chain variable region (VL), wherein said VL comprises, in order, three complementarity determining regions LDCR1, LDCR2 and LDCR3, wherein: (a) the LCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 62, 65, and 68, the LCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 63, 66, and 69, and the LCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 64, 67, and 70; or (b) the LCDR1 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 83, 86, and 89, the LCDR2 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 84, 87, and 90, and the LCDR3 is set forth in an amino acid sequence selected from any one of SEQ ID NOs: 85, 88, and 91.
[0403] In a preferred embodiment, the domain that specifically binds to human serum albumin comprises the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 62, 63, and 64, respectively. In another embodiment, the domain that specifically binds to human serum albumin comprises the LDCR1, LDCR2, and LDCR3 sequences of SEQ ID NOs: 83, 84, and 85, respectively.
[0404] Suitably, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: (a) the VH comprises, in order, three complementarity determining regions, HCDR1, HCDR2, and HCDR3, wherein the HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 52, 55, and 58, the HCDR2 has a sequence selected from any one of SEQ ID NOs: 53, 56, and 59, and the HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 54, 57, and 60; and the VL comprises, in order, three complementarity determining regions, LDCR1, LDCR2, and LDCR3, wherein the LSCR1 has an amino acid sequence selected from any one of SEQ ID NOs: 62, 65, and 68, the LDCR2 has an amino acid sequence selected from any one of SEQ ID NOs: 63, 66, and 69, and the LCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 64, 67, and 70; or (b) the VH comprises, in order, three complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein the HCDR1 has an amino acid sequence selected from any one of SEQ ID NOs: 73, 76, and 79, the HCDR2 has an amino acid sequence selected from any one of SEQ ID NOs: 74, 77, and 80, and the HCDR3 has an amino acid sequence selected from any one of SEQ ID NOs: 75, 78, and 81; and the VL comprises, in order, three complementarity determining regions LDCR1, LDCR2, and LDCR3, wherein the LSCR1 has an amino acid sequence selected from any one of SEQ ID NOs: 83, 86, and 89, the LDCR2 has an amino acid sequence selected from any one of SEQ ID NOs: 84, 87, and 90, and the LDCR3 has an amino acid sequence selected from any one of SEQ ID NOs: 85, 88, and 91.
[0405] In a preferred embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises (a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 52, 53, and 54, respectively, and (b) the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 62, 63, and 64, respectively. In another embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises (a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 73, 74, and 75, respectively, and (b) the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 83, 84, and 85, respectively.
[0406] Other domains of the present disclosure that specifically bind to HSA have been mutated but contain amino acids in their CDR regions that have at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the CDR regions shown in the sequences set forth in Table 1. Suitably, other domains of the present disclosure that specifically bind to HSA contain mutated amino acid sequences in which 1, 2, 3, 4, 5, or 10 or fewer amino acids in the CDR regions have been mutated by amino acid deletion, insertion, or substitution when compared to the CDR regions shown in the sequences set forth in Table 1. The mutations, e.g., substitutions, can be made at any residue within the set of CDRs and may be within CDR1, CDR2, and / or CDR3.
[0407] Suitably, the third domain that specifically binds to HSA of the multispecific antibody of the present disclosure comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: (a) the VH comprises, in order, three complementarity determining regions, HCDR1, HCDR2, and HCDR3, wherein the HCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 52, 55, and 58, the HCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 53, 56, and 59, and the HCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 54, 57, and 60; and / or (b) The VL comprises three complementarity determining regions, LCDR1, LCDR2, and LCDR3, in that order, wherein the LCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 62, 65, and 68; the LCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 63, 66, and 69; and the LCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 64, 67, and 70.
[0408] Suitably, the multispecific antibody comprises a third domain which specifically binds to HSA, wherein the third domain comprises HCDR1, HCDR2 and HCDR3 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity to the sequences of SEQ ID NOs: 52, 53 and 54, respectively, and / or comprises LCDR1, LCDR2 and LCDR3 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity to the sequences of SEQ ID NOs: 62, 63 and 64, respectively.
[0409] Suitably, the third domain that specifically binds to HSA of the multispecific antibody of the present disclosure comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: (a) the VH comprises, in order, three complementarity determining regions, HCDR1, HCDR2, and HCDR3, wherein the HCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 73, 76, and 79, the HCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 74, 77, and 80, and the HCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 75, 78, and 81; and / or (b) The VL comprises three complementarity determining regions LCDR1, LCDR2, and LCDR3, in that order, wherein the LCDR1 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 83, 86, and 89; the LCDR2 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 84, 87, and 90; and the LCDR3 has an amino acid sequence having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to any one of SEQ ID NOs: 85, 88, and 91.
[0410] Suitably, the multispecific antibody comprises a third domain which specifically binds to HSA, wherein the third domain comprises HCDR1, HCDR2 and HCDR3 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity to the sequences of SEQ ID NOs: 73, 74 and 75, respectively, and / or LCDR1, LCDR2 and LCDR3 having at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity to the sequences of SEQ ID NOs: 83, 84 and 85, respectively.
[0411] In a further embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a heavy chain variable region, VHC, and a light chain variable region, VLC.
[0412] Suitably, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein the third domain comprises a heavy chain variable region VHC, wherein the VHC is VH1A, VH1B, VH3, or VH4. In one embodiment, the third domain of the present disclosure that specifically binds to HSA comprises a heavy chain variable region VHC, wherein the VHC is VH4. In a preferred embodiment, the third domain of the present disclosure that specifically binds to HSA comprises a heavy chain variable region VHC, wherein the VHC is VH3.
[0413] Suitably, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein the third domain comprises a light chain variable region VLC, wherein the VLC comprises Vκ framework FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 framework FR1-FR3, and framework FR4, wherein the FR4 is selected from Vλ FR4, particularly Vκ1 FR4, Vκ3 FR4, and Vλ FR4. Suitable Vλ FR4s are those set forth in SEQ ID NOs: 97 to 103. In one embodiment, the third domain comprises a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any of SEQ ID NOs: 97 to 103, preferably SEQ ID NO: 97 or SEQ ID NO: 98, more preferably any of SEQ ID NO: 97. Suitably, the third domain comprises a Vλ FR4 comprising an amino acid sequence selected from any of SEQ ID NOs: 97 to 103, preferably a Vλ FR4 set forth in SEQ ID NO: 97 or 98, more preferably a Vλ FR4 set forth in SEQ ID NO: 98.
[0414] Thus, in a preferred embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises: (a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 52, 53, and 54, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 62, 63, and 64, respectively; (b) a VHC, wherein the VHC is a VH3 or a VH4, preferably a VH3; and (c) A VLC comprising a VL framework comprising Vκ frameworks FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 FR1-FR3, and framework FR4, wherein the framework FR4 is selected from a Vκ FR4, particularly a Vκ1 FR4, a Vκ3 FR4, and a Vλ FR4, particularly a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any one of SEQ ID NOs: 97 to 103, preferably a Vλ FR4 set forth in an amino acid sequence selected from any one of SEQ ID NOs: 97 to 103, preferably a Vλ FR4 set forth in SEQ ID NO: 97 or 98, more preferably a Vλ FR4 set forth in SEQ ID NO: 98.
[0415] In a further embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises: (i) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 73, 74, and 75, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 83, 84, and 85, respectively; (ii) a VHC, wherein the VHC is a VH3 or a VH4, preferably a VH3; and (iii) A VLC comprising a VL framework comprising Vκ frameworks FR1, FR2, and FR3, particularly Vκ1 or Vκ3 FR1-FR3, preferably Vκ1 FR1-FR3, and a framework FR4, wherein the framework FR4 is selected from a Vκ FR4, particularly a Vκ1 FR4, a Vκ3 FR4, and a Vλ FR4, particularly a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, or 90% identity to an amino acid sequence selected from any one of SEQ ID NOs: 97 to 103, preferably a Vλ FR4 set forth in an amino acid sequence selected from any one of SEQ ID NOs: 97 to 103, preferably a Vλ FR4 of SEQ ID NO: 97 or 98, more preferably a Vλ FR4 set forth in SEQ ID NO: 98.
[0416] Suitably, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein the third domain comprises a VH as set forth in Table 1. Suitably, the present disclosure also provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein the third domain comprises (or alternatively consists of) a VH amino acid sequence as set forth in Table 1, wherein about 20 or fewer amino acids, preferably about 10 or fewer amino acids, have been mutated in the framework sequence (e.g., a sequence that is not a CDR) (mutations being, by way of various non-limiting examples, additions, substitutions, or deletions). Other domains of the present disclosure that specifically bind to HSA have been mutated, but comprise amino acids in the VH region that share at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the VH region set forth in the sequence set forth in Table 1.
[0417] Suitably, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein the third domain comprises a VL domain set forth in Table 1. Suitably, the present disclosure also provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein the third domain comprises (or alternatively consists of) a VL amino acid sequence set forth in Table 1, wherein about 20 or fewer amino acids, preferably about 10 or fewer amino acids, have been mutated in the framework sequence (e.g., a sequence that is not a CDR) (mutations being, by way of various non-limiting examples, additions, substitutions, or deletions). Other domains of the present disclosure that specifically bind to HSA have been mutated, but comprise amino acids in the VL region that share at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with the VL region set forth in the sequence set forth in Table 1.
[0418] In one embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 61, particularly wherein said domain comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 52, 53, and 54, respectively.
[0419] In another embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 71, and in particular wherein said domains comprise the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 62, 63, and 64, respectively.
[0420] In a further embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 61; and a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 71.
[0421] In a preferred embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 61; and and a light chain variable region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 52, 53, and 54, respectively, and / or the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NO: 62, 63, and 64, respectively, preferably the domains comprise the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NO: 52, 53, and 54, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NO: 62, 63, and 64, respectively.
[0422] In certain embodiments, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a VH comprising the amino acid sequence SEQ ID NO: 61, and / or a VL comprising the amino acid sequence SEQ ID NO: 71. In a preferred embodiment, the third domain that specifically binds to HSA comprises the VH sequence of SEQ ID NO: 61 and the VL sequence of SEQ ID NO: 71.
[0423] In yet another embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 82, and in particular said domain comprises the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 73, 74, and 75, respectively.
[0424] In another embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 92, particularly wherein said domains comprise the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 83, 84, and 85, respectively.
[0425] In a further embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 82, and a light chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 92.
[0426] In a preferred embodiment, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 82, and a heavy chain variable region comprising an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, preferably at least 90%, identical to the amino acid sequence SEQ ID NO: 92. and a light chain variable region comprising an amino acid sequence that is at least 90% identical to a sequence of SEQ ID NOs: 73, 74, and 75, respectively, and / or a LCDR1, LCDR2, and LCDR3 sequence of SEQ ID NOs: 83, 84, and 85, respectively, preferably a light chain variable region comprising the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 73, 74, and 75, respectively, and a LDCR1, LDCR2, and LDCR3 sequence of SEQ ID NOs: 83, 84, and 85, respectively.
[0427] In certain embodiments, the present disclosure provides a multispecific antibody comprising a third domain that specifically binds to HSA, wherein said third domain comprises a VH comprising the amino acid sequence SEQ ID NO: 82, and / or a VL thereof comprising the amino acid sequence SEQ ID NO: 92. In a preferred embodiment, said third domain that specifically binds to HSA comprises the VH sequence of SEQ ID NO: 82 and the VL sequence of SEQ ID NO: 92.
[0428] In one embodiment, the domain that specifically binds to human serum albumin is a domain set forth in Table 1. In one embodiment, the domain that specifically binds to HSA comprises an amino acid sequence that is at least 60, 70, 80, 90, 91, 92, 93, 94, 95, 96...
Claims
1. 1. An isolated multispecific antibody comprising a first domain that specifically binds to IL-17A, a second domain that specifically binds to TNFα, and optionally a third domain that specifically binds to human serum albumin (HSA), wherein: (a) the first domain comprises (i) a set of CDRs, i.e., the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively, or (ii) a set of CDRs, i.e., the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 39, 40, and 41, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 50, 51, and 52, respectively; and (b) the second domain comprises a set of CDRs, i.e., the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 63, 64, and 65, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 76, 77, and 78, respectively; and (c) the third domain, if present, comprises a set of CDRs, namely (i) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 90, 91, and 92, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 100, 101, and 102, respectively, or (ii) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 111, 112, and 113, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 121, 122, and 123, respectively.
2. 2. The multispecific antibody of claim 1, wherein the antibody comprises only one domain that specifically binds to IL-17A and / or only one domain that specifically binds to TNFα and / or optionally only one domain that specifically binds to human serum albumin.
3. 3. A multispecific antibody according to claim 1 or claim 2, wherein the domains are capable of binding simultaneously to their respective antigens or receptors.
4. A multispecific antibody according to any of the preceding claims, wherein the antibody has the following characteristics: (a) has the ability to neutralize IL-17A with a potency (relative potency) of greater than 2, e.g., greater than 5, greater than 10, greater than 15, greater than 20, greater than 25, greater than 30, greater than 35, greater than 40, greater than 45, preferably greater than 50, compared to the potency of secukinumab as determined by measuring Gro-α secretion in an HT-29 assay, wherein said relative potency is the IC of secukinumab measured by the HT-29 assay. 50 values (ng / mL) and IC of said multispecific antibodies measured by HT-29 assay 50 value (ng / mL); and (b) has the ability to neutralize TNFα with a potency (relative potency) of at least 1, e.g., greater than 1, greater than 1.5, greater than 2, greater than 2.5, greater than 3, greater than 3.5, preferably greater than 4, more preferably greater than 4.5, compared to the potency of the scDb of SEQ ID NO: 149 (A13) as determined by measuring Gro-α secretion in an HT-29 assay, wherein said relative potency is the IC of said scDb of SEQ ID NO: 149 (A13) as measured by an HT-29 assay. 50 Values (nM) and IC of said multispecific antibodies measured by HT-29 assay 50 value (nM); and (c) optionally, having the ability to block the interaction of IL-17A with IL-17RA with a potency (relative potency) of greater than 2, e.g., greater than 3, greater than 4, greater than 5, greater than 6, greater than 7, greater than 8, greater than 9, preferably greater than 10, compared to the potency of secukinumab determined by ELISA assay, wherein said relative potency is the IC of secukinumab measured by ELISA. 50 values (ng / mL) and IC of said multispecific antibodies measured by ELISA. 50 value (ng / mL); and (d) Optionally, it has the ability to neutralize TNFα with a potency (relative potency) of at least 0.4, such as at least 0.5, preferably at least 1, compared to the potency of the scDb of SEQ ID NO: 149 (A13) determined in an L929 assay, wherein said relative potency is the IC of said scDb of SEQ ID NO: 125 measured by the L929 assay. 50 Values (nM) and IC of said multispecific antibodies measured by L929 assay 50 and / or (e) a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, preferably less than 0.5 nM, as measured by surface plasmon resonance. D ) binds to human IL-17A, and optionally has a K of less than 5 nM, e.g., less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, preferably less than 0.5 nM, as measured by surface plasmon resonance. D and binds to cynomolgus IL-17A; and (f) a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, preferably less than 0.5 nM, more preferably less than 0.25 nM, as measured by surface plasmon resonance. D ) and binds to human TNFα; and (g) optionally, a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, preferably less than 2 nM, as measured by surface plasmon resonance; D ) binds to human serum albumin, optionally with a dissociation constant (K) of less than 5 nM, e.g., less than 4 nM, less than 3 nM, preferably less than 2 nM, as measured by surface plasmon resonance. D ) and binds to cynomolgus monkey serum albumin.
5. A multispecific antibody according to any of the preceding claims, wherein the antibody has the following characteristics: (a) has a melting temperature (Tm) in phosphate-citrate buffer, pH 6.4, 150 mM NaCl, of at least 55°C, preferably at least 58°C, and more preferably at least 60°C, as determined by differential scanning fluorimetry; (b) said multispecific antibody has a loss of monomer content of less than 5%, such as less than 4%, less than 3%, less than 2%, preferably 1% or less, after five successive freeze-thaw cycles at a starting concentration of 10 mg / ml in phosphate buffered saline (PBS), pH 7.4; (c) said multispecific antibody has a loss of monomer content of less than 10%, preferably less than 5%, after storage at 4° C. for at least 2 weeks, in particular at least 4 weeks, when at a starting concentration of 10 mg / ml in phosphate buffered saline (PBS), pH 7.4; and / or (d) said multispecific antibody has a loss of monomer content of less than 20%, preferably less than 15%, after storage at 37° C. for at least 2 weeks, in particular at least 4 weeks, when at a starting concentration of 10 mg / ml in phosphate buffered saline (PBS), pH 7.
4.
6. 10. The multispecific antibody according to any one of the preceding claims, wherein said first domain, and / or said second domain, and / or optionally said third domain comprise a heavy chain variable region VH, wherein said VH is VH3 or VH4, preferably VH3.
7. 20. The multispecific antibody according to any one of the preceding claims, wherein said first domain and / or said second domain and / or optionally said third domain comprises a light chain variable region VL, wherein said VL comprises a VK framework FR1, FR2 and FR3, in particular a VK1 or VK3 FR1-FR3, preferably a VK1 FR1-FR3, and a framework FR4, wherein said framework FR4 is selected from a VK FR4, in particular a VK1 FR4, a VK3 FR4 and a Vλ FR4, in particular a Vλ FR4 comprising an amino acid sequence having at least 60, 70, 80, 90% identity with an amino acid sequence selected from any of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 according to any of SEQ ID NOs: 26 to 32, preferably a Vλ FR4 according to SEQ ID NO: 26 or 27, more preferably a Vλ FR4 according to SEQ ID NO:
27.
8. 8. The multispecific antibody according to any one of claims 6 to 7, wherein the VH of the first domain comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 10 and / or the VL of the first domain comprises an amino acid sequence that is at least 90% identical to the amino acid sequence SEQ ID NO: 21, Preferably, the VH of the first domain comprises an amino acid sequence selected from the group consisting of the amino acid sequences SEQ ID NOs: 10 and 11, and / or the VL of the first domain comprises an amino acid sequence selected from the group consisting of the amino acid sequences SEQ ID NOs: 21 and 22, More preferably, said multispecific antibody, wherein the VH of said first domain is as set forth in SEQ ID NO: 10 and / or the VL of said first domain is as set forth in SEQ ID NO:
21.
9. 9. The multispecific antibody according to any one of claims 6 to 8, wherein the VH of said second domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 73, 74 and 75, preferably an amino acid sequence that is at least 90% identical to SEQ ID NO: 72, and / or the VL of said second domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 85, 86, 87, 88 and 89, preferably an amino acid sequence that is at least 90% identical to SEQ ID NO: 85, preferably wherein the VH of said second domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 73, 74 and 75, and / or wherein the VL of said second domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 85, 86, 87, 88 and 89, more preferably wherein the VH of said second domain is as set forth in SEQ ID NO: 72 and / or the VL of said second domain is as set forth in SEQ ID NO:
85.
10. 10. The multispecific antibody according to any one of claims 6 to 9, wherein the third domain is present, and (i) the VH of said third domain comprises an amino acid sequence which is at least 90% identical to the amino acid sequence SEQ ID NO:99, and / or the VL of said third domain comprises an amino acid sequence which is at least 90% identical to the amino acid sequence SEQ ID NO:108, preferably wherein the VH of said third domain is set forth in SEQ ID NO:99, and / or the VL of said third domain is set forth in SEQ ID NO:108; or (ii) the multispecific antibody, wherein the VH of said third domain comprises an amino acid sequence which is at least 90% identical to the amino acid sequence SEQ ID NO: 120 and / or the VL of said third domain comprises an amino acid sequence which is at least 90% identical to the amino acid sequence SEQ ID NO: 130, preferably wherein the VH of said third domain is as set forth in SEQ ID NO: 120 and / or the VL of said third domain is as set forth in SEQ ID NO:
130.
11. 2. The multispecific antibody according to any one of the preceding claims, which is selected from the group consisting of single chain diabodies (scDb), tandem scDb (Tandab), linear dimeric scDb (LD-scDb), cyclic dimeric scDb (CD-scDb), bispecific T cell engagers (BiTEs; tandem di-scFv), tandem tri-scFv, tribodies (Fab-(scFv) 2 ) or bibody (Fab-(scFv) 1 ), Fab, Fab-Fv 2 , Morrison (IgG CH3-scFv fusion (Morrison L) or IgG CL-scFv fusion (Morrison H)), triabody, scDb-scFv, bispecific Fab 2 , dimini antibody, tetrabody, scFv-Fc-scFv fusion, scFv-HSA-scFv fusion, didiabody, DVD-Ig, COVD, IgG-scFab, scFab-dsscFv, Fv 2 -Fc, IgG-scFv fusions, such as bsAb (scFv linked to the C-terminus of the light chain), Bs1Ab (scFv linked to the N-terminus of the light chain), Bs2Ab (scFv linked to the N-terminus of the heavy chain), Bs3Ab (scFv linked to the C-terminus of the heavy chain), Ts1Ab (scFv linked to the N-terminus of both the heavy and light chains), Ts2Ab (dsscFv linked to the C-terminus of the heavy chain), bispecific antibodies based on heterodimeric Fc domains, such as Knob-into-Hole antibodies (KiH); Fv, scFv, scDb, tandem-di-scFv, tandem tri-scFv, Fab-(scFv). 2 , Fab-(scFv) 1 , Fab, Fab-Fv 2 , a heterodimeric Fc domain or any other heterodimerization domain fused to the N-terminus and / or C-terminus of either chain of COVD, MATCH and duobody, preferably tribody or scDb-scFv.
12. 10. The multispecific antibody according to any one of the preceding claims, wherein the antibody comprises an amino acid sequence having at least 80% identity, preferably at least 90% identity, with a sequence selected from any of SEQ ID NOs: 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147 and 148, preferably 143, and wherein the antibody comprises (i) a first domain that specifically binds IL-17A, comprising the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 12, 13, and 14, respectively; and (ii) a second domain that specifically binds TNFα, comprising the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 63, 64, and 65, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 76, 77, and 78, respectively; and (iii) a third domain that specifically binds to HSA, comprising the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 90, 91, and 92, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 100, 101, and 102, respectively; Preferably, said antibody comprises an amino acid sequence selected from any of SEQ ID NOs: 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147 and 148, preferably 143.
13. A pharmaceutical composition comprising a multispecific antibody according to any one of the preceding claims and a pharma- ceutical acceptable carrier.
14. A multispecific antibody according to any one of claims 1 to 12 or a pharmaceutical composition according to claim 13 for use as a medicament.
15. A kit comprising the multispecific antibody according to any one of claims 1 to 13, or the pharmaceutical composition according to claim 14.
